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Autocrine production of human growth hormone (hGH) by human mammary carcinoma 
cells may direct human mammary carcinoma cell behavior to impact on the final clinical 
prognosis. One major mechanism by which GH affects cellular and somatic function is 
by regulating the level of specific mRNA species. To investigate the regulation of 
homeobox gene HOXA1 by autocrine production of hGH in human mammary carcinoma 
cells (MCF-7), which was identified by previous researchers using cDNA miroarray 
analyses, the present study used an in vitro model of MCF-7 cells stably transfected with 
the wild-type hGH gene (MCF7-hGH) and a control stably transfected with a translation-
deficient hGH gene (MCF7-MUT). The production of autocrine hGH increased HOXA1 
mRNA, protein, and transcriptional activity in human mammary carcinoma cells. Forced 
expression of HOXA1 in MCF-7 cells resulted in increased total cell number. HOXA1 
expression in MCF-7 cells prevented apoptotic cell death in a Bcl-2-dependent manner. 
HOXA1 expression in MCF-7 cells also protected against doxorubicin-induced apoptosis. 
Forced expression of HOXA1 in MCF-7 cells, in a Bcl-2-dependent manner, resulted in 
dramatic increase in anchorage-independent proliferation in suspension culture and 
colony formation in soft agar. HOXA1 overexpression was sufficient to oncogenically 
transform spontaneously immortalized human mammary epithelial cells (MCF-10A) with 
resultant colony formation in soft agar. When implanted into the mammary (axillary) fat 
pad of female severe combined immunodeficient mice (SCID mice), MCF-10A cells with 
overexpressed HOXA1 (MCF10A-HOXA1 cells) formed aggressive tumor in vivo. Thus, 





HOXA1 was found to have increased expression in MCF-7 cells at full confluence. This 
confluence-dependent expression of HOXA1 was abrogated by incubating the cell with 
EGTA which blocked the cell-cell adhesion or with an E-cadherin functional blocking 
antibody. To distinguish the E-cadherin-dependent regulation from the E-cadherin-
activated signaling regulation of HOXA1 expression, a functional E-cadherin ligand 
(hE/Fc) was utilized and this confluence-dependent expression of HOXA1 was confirmed 
to be direct downstream consequence of E-cadherin ligation. Furthermore, E-cadherin 
increased HOXA1 at full confluence through Rac1. Increased HOXA1 expression at full 
confluence had increased anti-apoptotic effect in human mammary carcinoma cells. 
These results indicated that a cross link may exist between E-cadherin and HOXA1 
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Chapter 1   Introduction 
 
Growth hormone (GH) is obligatory for normal pubertal mammary gland development in 
non-primates (Hull and Harvey, 2001). Specifically, GH acts on both the mammary 
stromal and epithelial components to result in ductal elongation and the differentiation of 
ductal epithelia into terminal end buds (Walden et al., 1998; Kleinberg, 1997). Expression 
of the human growth hormone (hGH) transgene in mice results in precocious 
development of the mammary gland (Bchini et al., 1991; Tornell et al., 1991) and the 
development of neoplasia (Tornell et al., 1991). Conversely, spontaneous or 
experimentally engineered functional deficiency of GH (Nagasawa et al., 1985; Swanson 
and Unterman, 2002; Stavrou and Kleinberg, 2001; Okada and Kopchick, 2001) results in 
severely impaired mammary gland development and virtual resistance to the spontaneous 
development of hyperplastic alveolar nodules (Nagasawa et al., 1985) and chemically 
induced mammary carcinogenesis (Swanson and Unterman, 2002; Okada and Kopchick, 
2001). Similarly, in a primate model, hGH administration results in marked hyperplasia 
of the mammary gland with an increased epithelial proliferation index (Ng et al., 1997). 
Thus, the somatotropic axis represents one potential and unutilized approach for novel 
therapeutic approaches to the treatment of mammary epithelial neoplasia.  
The hGH gene is also expressed in epithelial cells of the normal human mammary gland 
(Raccurt et al., 2002). Increased epithelial expression of the hGH gene is associated with 
the acquisition of pathological proliferation, and the highest level of hGH gene expression 
is observed in metastatic mammary carcinoma cells (Raccurt et al., 2002). Human growth 




throughout the process of neoplastic progression (Mertani et al., 1998), and therefore, 
alterations in the local concentration of ligand are likely to be pivotal in determining the 
effects of hGH on mammary epithelial cell behavior. We have recently generated a model 
system to study the role of autocrine-produced hGH in mammary carcinoma by stable 
transfection of either the hGH gene or a translation-deficient hGH gene into mammary 
carcinoma cells (Kaulsay et al., 1999). The autocrine production of hGH by mammary 
carcinoma cells results in a hyperproliferative state with marked synergism between 
trophic agents such as insulin-like growth factor-1 (Kaulsay et al., 1999). The increase in 
mammary carcinoma cell number as a consequence of autocrine production of hGH is a 
result of both increased mitogenesis and decreased apoptosis (Kaulsay et al., 2001). Thus, 
autocrine production of hGH by mammary carcinoma cells may direct mammary 
carcinoma cell behavior to impact on the final clinical prognosis, and therefore, 
systematic analysis of the relevant mechanistic features by which it exerts its cellular 
effects is required.  
One major mechanism by which GH affects cellular and somatic function is by regulating 
the level of specific mRNA species (Isaksson et al., 1985). The previous researchers 
utilized cDNA microarray analyses to identify genes regulated by autocrine production of 
hGH in human mammary carcinoma cells (MCF-7) (Mertani et al., 2001). One gene 
demonstrated to be upregulated by autocrine hGH in MCF-7 cells was the homeobox 
containing transcription factor HOXA1 (Mertani et al., 2001).  
Homeobox genes are a family of regulatory genes encoding specific nuclear proteins 




nucleotide sequence motif (the homeobox) encoding the roughly 61 amino acid 
homeodomain (HD). The Drosophila Antennapedia (Antp) HD defines a consensus 
sequence referred to as class I HD (Hox genes) (Akam, 1987). In mice (Hox genes) and 
human (HOX genes) there are at least 39 genes organized in four genomic clusters of 
approximately 100 kb in length, called Hox loci, each localized on a different 
chromosome (HOXA at 7p15.3, HOXB at 17p21.3, HOXC at 12q13.3, and HOXD at 
2q31) and comprising 9-11 genes each (Apiou et al., 1996; Scott, 1992). The Hox genes 
are arranged in the same order along the chromosomes as they are expressed along the 
anteroposterior axis of the embryo, i.e. the genes that are located 5’ in the clusters are 
expressed most posteriorly, whereas the more 3’ located genes are progressively 
expressed in more anterior regions (Mark et al., 1997).  
Homeobox genes play a key role in a variety of developmental processes including 
central nervous system and skeletal development, limb and digit specification, and 
organogenesis (Edelman et al., 1993). For example, HOXA1 has been demonstrated to be 
required for vertebrate hindbrain segmentation (Barrow et al., 2000). Several reports also 
suggest the involvement of homeobox-containing genes in the control of cell proliferation 
and, when dysregulated, in oncogenesis (Cillo et al., 1992; Abate-Shen, 2002). Gain of 
function of certain classes of homeobox genes has been demonstrated to promote the 
oncogenic phenotype. For example, it was shown that murine homeobox genes, Pax, can 
promote oncogenesis in tissue culture cells and in mice. Pax1, Pax2, Pax3, Pax6, and 
Pax8 proteins were able to induce transformation of cultured cells and tumor formation in 
mice (Maulbecker and Gruss, 1993). Moreover, alterations of HOX gene expression have 




et al., 1993), including those of the mammary gland (Care et al., 1998; Raman et al., 
2000). Accordingly, Hoxa1 has been detected in carcinoma of the mammary gland in the 
mouse but not in normal mammary tissue (Friedmann et al., 1994), and HOXA1 
expression has also been detected in neoplastic lesions of the human mammary gland 
(Chariot and Castronovo, 1996). Therefore, HOXA1 may be involved in mammary gland 
neoplastic progression. 
 
To date, no effect of HOXA1 on the human mammary gland tumorigenesis has been 
reported. The work presented here sought, therefore, to determine the role of hGH-
regulated HOXA1 in human mammary gland neoplasia in vitro and in vivo.         
Autocrine hGH production by human mammary carcinoma cells increased the expression 
and transcriptional activity of HOXA1. Forced expression of HOXA1 in human 
mammary carcinoma cells increased total cell number primarily by prevention of 
apoptotic cell death in a Bcl-2-dependent manner. Forced expression of HOXA1 was 
sufficient to result in the oncogenic transformation of immortalized human mammary 
epithelial cells with resultant anchorage-independent growth and tumor formation in vivo. 
In addition, HOXA1 was found to have increased expression at full confluence in human 
mammary carcinoma cells, MCF-7. HOXA1 confluence-dependent expression was 
directed by E-cadherin signaling through Rac1. Increased HOXA1 expression at full 
confluence had increased anti-apoptotic effect in human mammary carcinoma cells.  
 





1.           To confirm that HOXA1 is up-regulated by human autocrine GH. 
2.           To investigate the role of HOXA1 in human mammary gland neoplasia in vitro  
              and in vivo. 















































2.1      Growth hormone 
 
2.1.1 Growth hormone structure 
 
The pituitary gland was first recognized to have growth-promoting activity in 1921 
(Evans and Long, 1921). Later, growth was believed to be regulated by a growth factor. 
In 1945, Li et al. isolated growth hormone (GH) from bovine pituitary glands (Li et al., 
1945). Growth hormone belongs to a large family of evolutionarily related protein 
hormones that includes prolactin (PRL), mouse proliferin (mPLF), mouse proliferin-
related protein (mPRP), rat decidual PRL-like protein (rdecPRP), and somatolactin (Roby 
et al., 1993; Ono et al., 1990; Linzer et al., 1985; Linzer and Nathans, 1984; Duckworth 
et al., 1986). The human GH (hGH) gene is approximately 2.6 kb in length and is located 
on the long arm of chromosome 17, q22-24 (Miller and Eberhardt, 1983; Kopchick and 
Andry, 2000). The hGH gene is a part of a gene cluster of five related genes (Figure 1). 
They are GH-N (growth hormone-normal gene), chorionic somatomammotropin-like 
(CS-L) gene, chorionic somatomammotropin-A (CS-A), GH-V (growth hormone-
variant), and the chorionic somatomammotropin-B (CS-B) gene (Hirt et al., 1987). In 
humans, the five genes have more than 92% nucleotide sequence identity in their coding 
and flanking regions (Miller and Eberhardt, 1983). Human GH-N is expressed only in the 
pituitary gland and encodes two hGH proteins: a 22-kD and a 20-kD protein. The latter is 
encoded by an alternative spliced product of the primary hGH-N gene transcript (Cooke 






Figure 1. Schematic representation of the human GH gene cluster. The gene cluster 
spans over 50 kb and consists of GH-N, CS-L, CS-A, GH-V, and CS-B. The hGH gene, 
approximately 2.6 kb in length, consists of five exons (I–V) and four introns (a–d) 
(modified from Hirt et al., 1987). 
 
In 1987, the three-dimensional structure of porcine GH was first determined (Abdel-
Meguid et al., 1987).  In 1992, the crystal structure of hGH was also determined (De Vos 
et al., 1992). Human GH is a 191 amino acid single chain polypeptide with a molecular 
weight of 22 kDa. Human GH has four helices in the core. The NH2- and COOH-terminal 
helices (helices 1 and 4) are longer than the other two. The helices are oriented up-up-
down-down. Helix 1 and helix 2 are linked by a connection including residues 35 to 71 
and a connection consisting of residues 129 to 154 links helix 3 and helix 4. Helix 2 is 
linked to helix 3 by a short segment (residues 93 to 105). In addition to the four helices in 
the core, there are three much shorter helices in the connecting loops. One is located at 
the beginning and another is at the end of the connection between helices 1 and 2. The 
third one is located in the connection between helices 2 and 3. Human GH has two 
disulfide bonds at Cys53-Cys165 and Cys182-Cys189 (De Vos et al., 1992). These four 
I II III IV V 
GS-L GH-V GS-B 
2.5kb 0kb  
GH-N GS-A 




Cys residues are conserved between GH, prolactins (PRL) and placental lactogens (PL) 
(Nicoll et al., 1986). The core of hGH is made up of mostly hydrophobic residues and 
there are other hydrophobic clusters between the four-helix core and the connections (De 
Vos et al., 1992).  
 
2.1.2  Growth hormone biological effects 
 
 
The biological effects of GH are pleiotropic and involve multiple organs and 
physiological systems. The major biological effect of GH is to stimulate postnatal 
longitudinal growth. It has been known to promote general body growth, including both 
organ size and longitudinal bone growth (Isaksson et al., 1985). Hypersecretion of the 
hormone can lead to gigantism, or acomegaly, in adults, resulting in enlarged bones, 
especially in the face, as well as oversized organs (Calao et al., 1997). Transgenic rabbits 
that overexpress GH have also been found to develop acromegaly (Costa et al., 1998). On 
the other hand, hyposecretion of GH can lead to dwarfism. Growth hormone-deficient 
children grow taller when treated with GH (Blethen et al., 1997).  
 
In addition to growth effects, GH exerts many metabolic effects that persist throughout 
life (Le Roith et al., 1992). Through interaction with the GH receptor (GHR), GH is 
known to regulate lipid, and carbohydrate metabolism (Casanueva, 1992; Kelly et al., 
1994). Growth hormone also promotes nitrogen retention, mineral metabolism, and 
electrolyte balance (Strobl and Thomas, 1994). Growth hormone has been shown to 
stimulate the conversion of preadipose 3T3 cell lines to adipocytes (Morikawa et al., 




triglyceride accumulation via inhibition of lipoprotein lipase activity (Richelsen et al., 
1994; Johannsson et al., 1997; Lobie et al., 2000). Growth hormone has been shown to 
reduce fat mass, especially in individuals who have accumulated excess fat mass during 
prolonged periods of GH deficiency (Russell-Jones et al., 1993). Growth hormone 
deficiency children are usually mildly obese and GH replacement therapy leads to a 
reduction in body fat (Wabitsch et al., 1995). The anabolic effect of GH induces protein 
synthesis in muscle resulting in increased lean muscle mass (Corpas et al., 1993). Muscle 
size is increased in GH-deficient individuals undergoing replacement therapy with 
recombinant human GH (hGH) at all ages (Manson and Wilmore, 1986; Rudman et al., 
1990). It was demonstrated that GH therapy actually increases whole body protein 
synthesis (Wolf et al., 1992; Le Roith et al., 2001).  
 
Growth hormone has also several immunomodulatory functions including the 
proliferation of B and T cells (Postel-Vinay et al., 1997), stimulation of cytokine 
(Malarkey et al., 2002) and immunoglobulin production (Kimata and Yoshida, 1994) and 
regulation of the activity of neutrophils, macrophages and natural killer cells 
(Auernhammer and Strasburger, 1995). 
 
2.1.3      Cellular mechanisms of GH signal transduction 
 
The actions of GH are mediated by the binding of GH to the extracellular region of the 
transmembrane GH receptor (GHR) (Zhu et al., 2001). Growth hormone receptor is a 




superfamily (Kopchick and Andry, 2000). Site 1 of GH binds to one receptor molecule, 
after which a second receptor molecule binds to site 2 on the hormone. Thus a GH-GHR 
complex is formed consisting of one molecule of GH and two molecules of GHR 
(homodimer of GHR). Upon GH receptor dimerization (or conformational change as a 
result of ligand binding to a preformed dimmer), the tyrosine kinase JAK2 becomes 
rapidly phosphorylated and activated (Argetsinger et al., 1993). Studies using mutated 
and truncated GHRs have indicated that the cytoplasmic proline-rich box 1 region of 
GHR is required for GHR-JAK2 interaction and for tyrosyl phosphorylation of JAK2 
(Frank et al., 1994; Sotiropoulos et al., 1994). The GHR itself has no intrinsic tyrosine 
kinase activity and each JAK2 is thought to transphosphorylate one or more tyrosine 
residues in the kinase domain of the other JAK2, thereby activating both JAK2 molecules 
(Argetsinger and Carter-Su, 1996). Once activated, JAK2 then phosphorylates the GHR 
on multiple intracellular tyrosine residues providing docking sites for other signaling 
molecules that contain SH2 or other phosphotyrosine-binding motifs (Wang et al., 1996).  
 
Activation of JAK2 leads to the phosphorylation of and activation of a number of 
cytoplasmic signaling molecules including signal transducer and activator of 
transcription-1 (STAT1), -3 and -5, the mitogen-activated protein kinase (MAP kinase), 
extracellular signal-regulated kinase-1 and -2 (Erk1 and 2 or also named p44/p42 MAP 
kinase), insulin receptor substrate-1 (IRS-1), -2 and -3 and PI-3 kinase, protein kinase C 
(PKC), focal adhesion kinase (FAK), p38 and c-Jun amino (N)-terminal kinase (JNK) 
(Carter-Su et al., 1996; Moutoussamy et al., 1998; Yamauchi et al., 1998; Kopchick and 

















































Figure 2. Diagram illustrating the three major signaling pathways of GH: 1) The 
JAK/STAT pathway; 2) The MAP kinase pathway; 3) The IRS/PI-3 kinase pathway 
(modified from Carter-Su et al., 1996).  
 
 






The Janus family of tyrosine kinases is thought to be the predominant nonreceptor 
tyrosine kinases required for the initiation of GH signal transduction upon ligand binding 
to the receptor (Argetsinger et al., 1993; Foster et al., 1988; Silva et al., 1993). The JAK 
family includes JAK1, JAK2, JAK3, and Tyk2 (Argetsinger and Carter-Su, 1996). JAK2 
is the tyrosine kinase that is predominantly utilized by the GH receptor (Argetsinger et 
al., 1993; Zhu et al., 2001). Tyrosine phosphorylation of JAK1 and JAK3 can also be 
stimulated by GH, but the level of activation is much smaller than that of JAK2 (Carter-
Su et al., 1996).  
 
The main pathway by which GH and many other cytokines activates the JAK kinases and 
regulates gene transcription involves the STAT proteins. The STATs gene family consists 
of seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 
(Copeland et al., 1995). STAT proteins are recruited to the proximity of the activated 
JAKs by binding, through their SH2 domains, to phosphotyrosine-containing motifs on 
the cytoplasmic part of the receptor (Zhu et al., 2001). Activated STAT molecules 
dissociate from the receptor and translocate to the nucleus, bind to their appropriate DNA 
response elements and stimulate transcription. STAT5 is the predominant STAT utilized 
by GH.  
 
2)        The mitogen-activated protein kinase (MAPK) pathway 
The MAPK superfamily consists of serine-threonine protein kinases that have important 
functions in the regulation of gene expression, cellular proliferation and prevention of 




2001). To date, nearly 20 mammalian MAP kinase family members have been identified 
and more are anticipated (Pearson et al., 2001). Among them, the p44/42 MAPK (also 
named ERKs), the c-jun N-terminal kinases (also named JNK) and the p38 MAPK have 
been relatively well characterized (Zhu et al., 2001). Growth hormone has been reported 
to activate p44/42 MAPK, JNK and p38 MAPK (Campbell et al., 1992; Moller et al., 
1992; Winston and Bertics, 1992; Zhu et al., 1998; Zhu and Lobie, 2000). One common 
pathway by which the membrane receptor tyrosine kinases activate p42/p44 MAP kinase 
involves a signal transduction cascade through the Ras-Raf pathway consisting of 
molecules like Shc, Grb2, Son-of-sevenless (Sos), Ras and Raf (Crews and Erikson, 
1993; Pearson et al., 2001). Growth hormone has also been demonstrated to utilize this 
cascade (Winston and Hunter, 1995; Vanderkuur et al., 1997).  p44/p42 MAPK has been 
reported to phosphorylate and/or activate a variety of proteins including phospholipase 
A2, protein kinases c-Raf-1 and the S6 kinases p70rsk and p90rsk, cytoskeletal proteins, 
the transcription factors c-jun and p62TCF/Elk1 (ternary complex factor) (Davis, 1993; 
Pearson et al., 2001), and the STAT proteins (Davis, 1993; David et al., 1995; Treisman, 
1996; Pearson et al., 2001). Growth hormone has been demonstrated to involve all of 
these downstream proteins in its signal transduction pathways (Finidori, 2000; Thomas, 
1998; Argetsinger and Carter-Su, 1996).  
 
The activation of JNK is another pathway by which GH may affect cellular function. 
JNK is involved in many cellular processes including transcriptional regulation and 
apoptosis and it is likely that GH utilizes JNK for some of these purposes (Herdegen et 




activates p38 MAPK in a JAK2-dependent manner (Zhu and Lobie, 2000). p38 MAPK is 
demonstrated to be required for GH stimulation of ATF-2 and CHOP-mediated 
transcription, for GH-stimulated reorganization of the actin cytoskeleton and also for GH-
stimulated mitogenesis (Zhu and Lobie, 2000).  
 
3)        The PI-3 kinase pathway 
Growth hormone–stimulated PI-3 kinase activity is associated with either IRS-1 or IRS-2 
in a variety of cell types in vitro and in vivo (Yenush and White, 1997; White and 
Yenush, 1998). PI-3 kinase phosphorylates inositol lipids at the 3’ position of the inositol 
ring to generate the polyphosphoinositides PtdIns-3-P, PtdIns-3,4-P2 and PtdIns-3,4,5-P3. 
These lipids then function in signal transduction and membrane trafficking by interaction 
with 3-phosphoinositide-binding modules in a broad variety of proteins (Leevers et al., 
1999). PI-3 kinase is pivotal in many cellular processes including cell proliferation and 
survival, cytoskeletal reorganization and cellular metabolism (Yenush and White, 1997; 
White and Yenush, 1998). Growth hormone has been reported to activate in a PI-3 
kinase-dependent manner the serine/threonine kinase Akt/PKB to deliver an anti-
apoptotic signal (Costoya et al., 1999; Liang et al., 2000). Several substrates of Akt have 
been identified, including glucose synthase kinase 3 (GSK-3), 6-phospho-fructo-kinase 
(PFK2), GLUT4 and p70S6K and GH may utilize these molecules for its cellular effects.   
PI-3 kinase has also been demonstrated to play a role in GH-stimulated actin cytoskeletal 
reorganization (Goh et al., 1997). Another PI-3 kinase-dependent cellular effect described 





2.2      Growth hormone and mammary gland development and neoplasia 
 
2.2.1   Mammary gland development 
 
 
The mammary gland epithelium is an ectodermal derivative. The differentiation of 
mammary epithelium occurs in two major stages (Lewis, 2000). In the first stage (about 
day 10 of gestation), the mammary streaks are established and these streaks represent the 
first morphological evidence of mammary pattern formation and differentiation. The 
second stage occurs around day 11 of gestation with the definition of the nipple region. 
The mammary epithelium continues to grow and invades the underlying mammary 
mesenchyme. As the mammary bud elongates into a mammary sprout, it reaches a second 
mesenchyme, the fat pad precursor mesenchyme and forms the rudimentary branched 
tubular gland of the neonate. The gland remains rudimentary and relatively growth 
quiescent from birth to puberty. At puberty, ovarian hormones stimulate rapid ductal 
elongation. Ducts grow, divide, and form club-shaped terminal end buds. Breast size is 
increased by fat deposition and connective tissue development. Upon reaching the limits 
of the fat pad at ductal maturity, ductal elongation ceases and terminal end buds regress 
to leave a branched system of differentiated ducts. These ducts remain relatively 
quiescent until pregnancy. During pregnancy, hormonal changes initiate a transition from 
a predominantly ductal to a predominantly lobuloalveolar gland morphology. Near 
midpregnancy, the gland acquires the ability to produce milk proteins and at partition, the 
gland begins to secrete milk. Upon weaning, milk secretion ceases and the gland 





2.2.2  Growth hormone regulation of mammary gland development 
 
In addition to estrogen, GH is obligatory for normal pubertal mammary gland 
development, especially in non-primates (Hull and Harvey, 2001). Mammary 
development at puberty occurs because of synergy between estrogen and GH on 
formation of terminal end buds (Kleinberg, 1998). Pubertal mammary gland development 
cannot take place in the absence of the pituitary gland GH in the rat (Kleinberg et al., 
1990; Feldman et al., 1993; Walden et al., 1998). Non-lactogenic and lactogenic growth 
hormones have been shown to be potent stimulators of mammary development while 
GHR has been shown to mediate the action of GH within the mammary gland (Kleinberg, 
1998). Specifically, GH acts on both the mammary stromal and epithelial components to 
result in ductal elongation and the differentiation of ductal epithelia into terminal end 
buds (Walden et al., 1998; Kleinberg, 1997).  
 
Local implantation of bovine (b) or mouse (m) GH in the mammary gland stimulated end 
bud formation in female mice (Bradley and Towle, 1992). Feldman et al. have reported 
that treatment of hypophysectomized and ovariectomized rats with rat GH and estrogens 
can stimulate mammary gland development as judged by increased numbers of terminal 
end buds or alveolar structures (Feldman et al., 1993). In addition, in vivo administration 
of recombinant hGH to hypophysectomized and gonadectomized rats have both been 
demonstrated to be approximately 10-20 times more potent than hPRL in stimulating 
mammary development (Kleinberg et al., 1990). Growth hormone administration to peri-




et al., 1986; Sandles et al., 1987; Purup et al., 1993; McFadden et al., 1990). Treatment of 
aged female rhesus monkeys with GH resulted in a 3 to 4-fold mitogenic increase in 
mammary glandular size and epithelial proliferation index, although whether this result 
from direct effects of GH or induction of local production of IGF-I is unknown (Ng et al., 
1997). 
 
Expression of the hGH transgene in mice results in precocious development of the 
mammary gland and milk synthesis (Bchini et al., 1992; Tornell et al., 1991). Conversely, 
spontaneous or experimentally engineered functional deficiency of GH results in severely 
impaired mammary gland development and virtual resistance to the spontaneous 
development of hyperplastic alveolar nodules (Nafasawa et al., 1985; Swanson and 
Unterman, 2002; Stavrou and Kleinberg, 2001; Okada and Kopchick, 2002). In GH 
receptor knock out mice, litter size is markedly reduced and ductal outgrowth is greatly 
retarded (Zhou et al., 1997; Kelly et al., 2002).  
 
2.2.3  GH and mammary gland neoplasia 
 
Many findings have shown that the growth hormone (GH)/insulin-like growth factor I 
axis plays an important role in mammary gland neoplasia.  
 





Growth hormone was shown to have growth-promoting effects on human mammary 
cancer cells in vitro (Benlot et al., 1997). Antagonists of growth hormone-releasing 
hormone were effective at inhibiting the growth of estrogen-independent human breast 
cancer cells (Kahan et al., 2000).   
 
2.2.3.2. In vivo animal studies 
 
It was demonstrated in monkeys that hGH treatment induced mammary gland 
hyperplasia in aging animals (Ng et al., 1997). Transgenic mice that overexpress genes 
encoding GH agonists exhibit both mammary gland epithelial cell hyperplasia and an 
increased frequency of mammary tumors (Tornell et al., 1992). Conversely, it was 
demonstrated that mammary gland carcinogenesis was reduced in transgenic mice 
expressing a growth hormone antagonist (Pollak et al., 2001). In addition, the growth 
hormone receptor antagonist (G120R) was demonstrated to inhibit the growth of breast 
cancer xenografts in nude mice (Roshan et al., 1999). 
 
lit/lit mouse is a mouse strain with extremely low circulating GH and low IGF-I levels 
because of a mutation in the growth hormone-releasing hormone receptor. Tumor growth 
is dramatically reduced after the transplantation of human MCF-7 breast cancer cells into 
this model. In addition, serum from lit/lit mice was less mitogenic to breast cancer cells 
in vitro than control serum (Yang et al., 1996). The growth hormone-deficient 
Spontaneous Dwarf rat (SDR) is resistant to chemically induced mammary 





2.2.3.3. Human studies 
 
Tall stature is associated with an increased incidence of breast cancer (Hunter and 
Willett, 1993). Acromegaly patients suffer from malignant disorders more frequently than 
the normal population (Alexander et al., 1980; Nabarro, 1987; Bengtsson et al., 1988). 
Some investigators have found a general increase in the incidence of malignant tumors 
(Alexander et al., 1980; Bengtsson et al., 1988) whereas other investigators have reported 
an over-representation of tumors in the colon of acromegaly patients (Ituarte et al., 1984). 
Nabarro (Nabarro, 1987) has even reported a small but statistically significant increase in 
the prevalence of breast cancer in a personal series of 256 patients with acromegaly, 
although this has not been substantiated by other (smaller) series. In patients with breast 
cancer, increased serum levels of GH have also been reported (Emerman et al., 1985; 
Peyrat et al., 1993). In addition, in treatment of advanced breast cancer in human it was 
demonstrated that hypohysectomy had beneficial effects in combination with estrogen 
removal, compared to estrogen removal alone (VanGilder and Goldenberg, 1975).  
 
2.2.3.4. Expression of GH and GHR in normal breast and breast cancer 
 
Growth hormone mRNA is detectable in normal and neoplastic mammary glands of dogs 
and cats (Mol et al., 1995a). Similarly, normal, hyperplastic, and neoplastic canine 
mammary tissue have also been demonstrated to express GH mRNA transcripts identical 




neoplastic human mammary glands identical to pituitary hGH has also been observed 
(Mol et al., 1995b). Increased epithelial expression of the hGH gene is associated with 
the acquisition of pathological proliferation, and the highest level of hGH gene 
expression is observed in metastatic mammary carcinoma cells (Raccurt et al., 2002).  
 
Receptors for GH have been identified in the mammary gland in mouse (Ilkbahar et al., 
1995), rat (Lincoln et al., 1990), cow (Hauser et al., 1990), rabbit, sheep, pigs (Jammes et 
al., 1991), monkey (Ng et al., 1997), and human mammary gland as well (Mertani et al., 
1998). Growth hormone receptor (GHR) mRNA expression has been documented in the 
mouse mammary epithelium and stroma with expression higher in the stromal versus the 
epithelial compartment (Ilkbahar et al., 1999). In addition, GH receptor mRNA 
expression in the mouse mammary gland decreases gradually throughout pregnancy 
starting on day 8 of gestation and declines further during lactation (Ilkbahar et al., 1995). 
In human, the expression levels of hGH receptor mRNA and protein were shown to be 
increased in both the epithelial and stromal components of breast tissue, with levels being 
higher in cancer tissue compared with adjacent normal tissue (Mertani et al., 1998).  
 
2.3      Autocrine GH and breast cancer  
 
Growth hormone, identical to pituitary GH, is synthesized locally in different tissues and 
organs, including the mammary gland and mammary tumors (Mol et al., 1995b). 
Receptors for GH have been identified in almost all tissues, including human mammary 




participate in an autocrine stimulatory loop within breast tissues and that there is a 
possible role for autocrine GH in the pathogenesis of breast cancer.  
 
With these data in mind, previous students in our lab have developed an in vitro model 
and investigated a) the role of autocrine hGH production in the proliferation, spreading 
and attachment of human mammary carcinoma cells in vitro; b) the mechanism of action 
of the cellular effects of autocrine hGH production in this in vitro model of human 
mammary carcinoma cells; and c) the role and specificity of the hGH receptor in the 
mediation of these effects of autocrine GH in human mammary carcinoma cells in vitro. 
(Kaulsay et al., 1999; Kaulsay et al., 2000; Kaulsay et al., 2001).  
 
2.3.1      Autocrine GH and human mammary carcinoma cell proliferation  
 
Kaulsay et al. first demonstrated that the hGH receptor is present in MCF-7 cells which 
are human mammary carcinoma cells (Kaulsay et al., 1999). She also examined the 
receptor protein localization within the cell by confocal laser scanning microscopy and 
found that GH receptor immunoreactivity was in a nucleocytoplasmic distribution in 
MCF-7 cells, but with the majority of the immunoreacivity confined to the cytoplasm. 
After that, an in vitro model of autocrine hGH production was established by stable 
transfection of the hGH gene (MCF7-hGH) and also the translation-deficient hGH gene 
as control (MCF7-MUT) into mammary carcinoma cells (MCF-7). The MCF7-hGH cells 
synthesized hGH mRNA and hGH protein within the cell and secreted hGH into the 




like structures in the cytoplasm. The MCF7-MUT cells produced hGH mRNA but did not 
produce hGH protein and no secreted hGH protein was detected in the medium. Confocal 
laser scanning microscopy also did not detect hGH protein in MCF7-MUT cells (Kaulsay 
et al., 1999).  
 
Using these two cell lines, a series of investigations on the cellular function of the 
autocrine hGH was performed. In serum-free medium, the MCF7-hGH cell number 
increased dramatically faster than MCF7-MUT cell number. Ten percent serum increased 
proliferation in both cell lines. However, the proportionate increase in cell number was 
greater in MCF7-hGH compared to MCF7-MUT. In the presence of hGH-G120, an hGH 
receptor antagonist, proliferation of MCF7-hGH cells was suppressed to the level of cell 
proliferation observed with MCF7-MUT cells. When the cells were grown in 10% serum, 
hGH-G120 also abrogated the proliferative effects of autocrine hGH production in 
MCF7-hGH cells (Kaulsay et al., 1999).  
 
It has been demonstrated that exogenous hGH stimulates both the p42/44 mitogen-
activated protein kinase (MAPK) (Moller et al., 1992; Hodge et al., 1998) and the p38 
MAPK pathways (Hodge et al., 1998). Both of these pathways have been demonstrated to 
mediate mitogenesis in response to various cellular stimuli (Dhanasekaran and 
Premkumar, 1998). In serum-free medium with PD98059, which is p42/p44 MAPK 
inhibitor, or with SB203580, which is p38 MAPK inhibitor, there was no increase in cell 
number of MCF7-MUT. PD98059 and SB203580 both prevented the increase in cell 




cell number between MCF7-MUT and MCF7-hGH in the presence of either inhibitor. 
PD98059 or SB203580 completely prevented the synergism between autocrine hGH and 
10% serum (Kaulsay et al., 1999). These results demonstrated that in this in vitro model, 
autocrine GH increased cell proliferation via p42/p44 and p38 MAPK pathway. 
 
The investigators also examined the interaction of autocrine hGH with 17-β-estradiol and 
insulin-like growth factor-1 (IGF-1). The proliferation of both MCF7-MUT and MCF7-
hGH was increased by 17-β-estradiol, and the different proliferation rates between 
MCF7-MUT and MCF7-hGH were maintained. On the other hand, hIGF-1 stimulated the 
proliferation of both MCF7-MUT and MCF7-hGH, but the fold stimulation observed for 
MCF7-hGH was greater than that observed for MCF7-MUT (Kaulsay et al., 1999).  
 
Kaulsay et al. continued to check JAK-STAT expression level in the two cell lines by 
Western blot analysis and found that there were no consistent differences in the 
expressions of JAK2, JAK1, STAT5, and STAT3 in MCF7-MUT and MCF7-hGH grown 
in serum-free medium or in the presence of 10% serum. However, they found that 
autocrine hGH increased the transcriptional response mediated by STAT5 using reporter 
gene assays. Autocrine hGH did not show any effect on the transcriptional response 
mediated by STAT1 and STAT3 (Kaulsay et al., 1999).  
 
In conclusion, the results from these in vitro studies suggest that autocrine hGH in human 






2.3.2      Autocrine GH and human mammary carcinoma cell spreading 
 
The role of autocrine production of human growth hormone (hGH) in the attachment and 
spreading of mammary carcinoma cells in vitro was then investigated (Kaulsay et al., 
2000). The same two cell lines, MCF7-MUT and MCF7-hGH, were used in this study.  
 
MCF7-MUT and MCF7-hGH were cultured in collagen-coated dishes. MCF7-hGH cells 
demonstrated a highly polarized morphology, with locomotor activity initiated by 
formation of long protrusions as early as 5 min after plating. This was continued at 15 
min, resulting in an increased surface area of cellular attachment to the substrate. MCF7-
MUT also demonstrated the formation of protrusions, but beginning at a later time point 
(15 min) compared with MCF7-hGH cells and in fewer numbers compared with MCF7-
hGH cells. In contrast to MCF7-hGH, the development of cellular protrusions over the 
course of 4 h in MCF7-MUT cells did not result in an elongation of the individual cell 
(Kaulsay et al., 2000).  
 
There were no significant differences in the rates of attachment between MCF7-MUT and 
MCF7-hGH cells. However, MCF7-hGH cells spread at a faster rate than MCF7-MUT 
cells. The increase in the rate of spreading of MCF7-hGH compared with MCF7-MUT 
was completely inhibited by an hGH receptor antagonist, hGH-G120R. In addition, the 
rapid formation of filamentous actin-containing complexes was observed in MCF7-hGH 
cells. The complex was accumulated most prominently within filipodia extending from 




were observed and they were distributed in the cytoplasm and at the cell membrane or 
short linear deposits of filamentous actin in the cell margins. MCF7-MUT cells also 
demonstrated a rounded, symmetrical, and characteristically epithelial morphology. 
MCF7-hGH cells displayed numerous microspikes oriented around the ventral margins 
perpendicular to the long axis of the cell. MCF7-MUT cells also demonstrated 
microspike activity. In contrast to the distribution pattern observed in MCF7-hGH cells, 
the microspikes in MCF7-MUT cells were distributed symmetrically around the cell 
periphery (Kaulsay et al., 2000). 
 
Tyrosine phosphorylation plays important role in cell spreading to extracellular matrix 
adhesion (Guan and Shalloway, 1992; Burridge et al., 1992). In MCF7-hGH cells plated 
in collagen-coated substrata, an elevated level of cytoplasmic phosphotyrosine was 
observed as the cells spread while in MCF7-MUT cells plated in the same strata, only 
low levels of phosphotyrosine was observed. Cytoplasmic phosphotyrosine aggregates 
were evident in MCF7-hGH cells while the aggregates were not present in MCF7-MUT 
cells, as localization generally occurred in a diffuse pattern throughout the cell with some 
perinuclear localization. Growth hormone-dependent tyrosine phosphorylation within the 
cell has been shown to be mediated by the receptor-associated JAK2 kinase (Argetsinger 
et al., 1993; Lobie, 1999). Expression of JAK2 was demonstrated to be equivalent 
between MCF7-MUT and MCF7-hGH cells. However, when MCF7-MUT and MCF7-
hGH cells were cultured on collagen substrata, the phosphotyrosine content of JAK2 was 
increased in MCF7-hGH cells. In addition, colocalization of JAK2 with phosphotyrosine 




increment in the rate of cell spreading stimulated by autocrine hGH was abrogated by a 
JAK2 tyrosine kinase-specific inhibitor, AG490. Transient transfection of JAK2 cDNA 
significantly increased the rate of spreading in MCF7-hGH, but not MCF7-MUT cells, 
and this effect was inhibited by AG490 (Kaulsay et al., 2000).  
 
In conclusion, these in vitro studies demonstrated that autocrine production of hGH 
enhanced the rate of mammary carcinoma cell spreading in a JAK2-dependent manner.  
  
2.3.3    The effects of autocrine GH on human mammary carcinoma cell are 
mediated via the hGH receptor 
 
Human growth hormone has been reported to bind to both the hGH receptor and the 
hPRL receptor (Cunningham et al., 1990). To study whether the effects of autocrine hGH 
on human mammary carcinoma cell behavior were mediated via the hGH receptor, 
Kaulsay et al. used a specific human GH antagonist (B2036) which did not bind, activate, 
or antagonize PRL receptors of either rat or human origin (Goffin et al., 1999). They 
found that the enhanced JAK2 tyrosine phosphorylation observed in MCF7-hGH cells 
compared with MCF7-MUT cells was abrogated by B2036 (Kaulsay et al., 2001). B2036 
did not affect MCF7-MUT total cell number in comparison to MCF7-MUT cells cultured 
in the absence of B2036 (i.e. no effect). In contrast, B2036 prevented the autocrine hGH-
stimulated increase in cell number observed in MCF7-hGH cells cultured in serum-free 
media. B2036 also inhibited the increase in cell number due to the synergistic effect of 




in MCF7-hGH compared with MCF7-MUT cells could be due to the increase in cell 
synthesis or the prevention of apoptosis, so they examined the effect of the hGH 
antagonist, B2036 on the number of cells in S-phase and the number of apoptotic cells in 
MCF7-MUT and MCF7-hGH. Treatment of MCF7-hGH cells with B2036 reduced the 
level of the cells in S-phase to that observed in MCF7-MUT cells. In addition, B2036 
inhibited the protection from apoptosis afforded by autocrine hGH.  B2036 was also used 
to check whether autocrine hGH-stimulated transcriptional activation mediated by 
STAT5, CHOP and Elk-1 is via interaction with the hGH receptor. Treatment of MCF7-
hGH cells with 600nM B2036 abrogated the ability of autocrine hGH to stimulate 
STAT5, CHOP and Elk-1 mediated transcription. B2036 also had a dose-dependent 
inhibition of the ability of autocrine hGH to enhance the rate of cell spreading (Kaulsay 
et al., 2001).  
 
In conclusion, these studies using the hGH specific antagonist B2036 demonstrated that 
the effects of autocrine hGH on human mammary carcinoma cells described above are 
mediated specifically via the hGH receptor.  
 
2.3.4      Identification of genes regulated by autocrine production of hGH in human 
mammary carcinoma cells 
 
Autocrine production of hGH by mammary carcinoma cells may direct mammary 
carcinoma cell behavior such as cell proliferation, apoptosis, cell spreading etc (Kaulsay 




GH affects cellular function is by regulating the level of specific mRNA species 
(Isaksson et al., 1985). So it is likely that many of the effects of autocrine hGH on 
mammary carcinoma cell function are mediated by specific regulation of certain genes. 
Continuing the previous work, Mertani et al. used a cDNA microarray to determine the 
effect of autocrine productin of hGH on gene expression in human mammary carcinoma 
cells (Mertani et al., 2001). Of 588 screened genes, 24 exhibited a 2-fold or greater 
increase in their expression in MCF7-hGH cells (Figure 3 and Table 1) (Mertani et al., 
2001). Most of the up-regulated genes were among those in the regulation of DNA 
synthesis/repair/recombination proteins. Of note was the dramatic effects of autocrine 
hGH on the expression of DNA repair helicase (ERCC3), ATP-dependent helicase II, 
DNA repair protein XRCC1, superoxide dismutase, UV excision repair protein RAD23, 
growth arrest, and DNA damage-inducible protein (GADD) 45 and GADD153 (otherwise 
known as CHOP). Other up-regulated genes of particular interest included the ski 
oncogene, homeobox containing transcription factor HOXA1, and β-catenin (Mertani et 
al., 2001). Twenty eight genes exhibited a 2-fold or greater decrease in their expression in 
the presence of autocrine hGH (MCF7-hGH cells) (range 2-20-fold) compared with the 
absence of autocrine hGH (MCF7-MUT cells) (Figure 3 and Table 2) (Mertani et al., 
2001). Most of the down-regulated genes were to be found among those grouped as DNA 
binding/transcription/transcription factors. The relative expression of housekeeping genes 
(ubiquitin, phospholipase A2, glyceraldehyde-3-phosphate dehydrogenase, β-actin, -
tubulin, 23-kDa highly basic protein, ribosomal protein S9) did not differ by more than 






Figure 3   Effect of autocrine production of hGH on relative levels of gene 
expression in mammary carcinoma cells. cDNA microarray analysis of the relative 
levels of gene expression in MCF-7 cells stably transfected with the hGH gene but with 
the start codon mutated to TTG (MCF7-MUT) (A) or in MCF-7 cells stably transfected 
with the hGH gene (MCF7-hGH) (B) cultured in serum-free medium. 32P-Labeled cDNA 
probes generated from poly(A)+ RNA isolated from MCF7-MUT and MCF7-hGH cells 
were hybridized to a cDNA microarray containing 588 known human genes. The left 
upper box and left lower box encase those genes grouped as oncogenes/tumor 
suppressors/cell cycle control proteins and DNA binding/transcription/transcription 
factors, respectively. The right upper box encases those genes grouped as DNA 
synthesis/repair/recombination proteins. The position of CHOP cDNA is indicated by the 
arrow. The relative expression level of specific cDNAs was determined by comparison 
















TABLE 1   Identification by cDNA array of genes positively regulated by the  
autocrine  production of hGH in mammary carcinoma cells.  Genes were considered 
positively regulated when they exhibited a 2-fold or greater increase in the presence of 
autocrine hGH (MCF7-hGH cells) compared to the absence of autocrine hGH (MCF7-
MUT cells) in three independently performed experiments. Fold regulation is calculated 
as the ratio of the level of gene expression in MCF7-hGH cells to that in MCF7-MUT 
cells (Mertani et al., 2001). 
 
 
GeneBank number                                    Name                                       -Fold stimulation  
 
M15024                               Myb proto-oncogene protein                                       3.05 
X15218                                SKI oncogene                                                              4.10 
X03484                                raf proto-oncogene                                                      2.00 
D10924         HM89 (probable G protein-coupled receptor LCR1 homolog)         3.45 
M74816                                Clusterin                                                                     2.25 
M31899                                DNA repair helicase [ERCC3]                                  12.50 
M32865                                ATP-dependent DNA helicase II                               6.10 
M36089                                DNA repair protein XRCC1                                      5.55 
M74524                                Ubiquitin-conjugating enzyme E2                             3.50 
M29971        Methylated DNA protein cysteine methyltransferase                        2.85 
K00065                                 Superoxide dismutase                                                13.45 
U07418                                 DNA mismatch repair protein hMLH1                      2.30 
D21090                                 UV excision repair protein RAD23 (HHR23B)         2.45 
D21235                                 UV excision repair protein RAD23 (HHR23A)         3.75 
M60974        Growth arrest and DNA damage-inducible protein GADD45            3.95 
S40706         Growth arrest and DNA damage-inducible protein GADD153          5.10 
M97287                                 DNA-binding protein SATB1                                    3.20 
U10421                                  Homeobox protein HOXA1                                       8.20 
X67951                                  Proliferation-associated protein PAG                        2.15 
U14722                                  Activin type 1 receptor                                               4.10 
X52425                                  Interleukin-4 receptor α chain                                    2.15 
M21097                                 CD19 B-lymphocyte antigen                                      4.90 
Y00796                                  Integrin α L                                                                3.70 











TABLE 2   Identification by cDNA array of genes negatively regulated by the 
autocrine production of hGH in mammary carcinoma cells. Genes were considered 
negatively regulated when they exhibited a 2-fold or greater decrease in the presence of 
autocrine hGH (MCF7-hGH cells) compared with the absence of autocrine hGH (MCF7-
MUT cells) in three independently performed experiments. Fold regulation is calculated 
as the ratio of the level of gene expression in MCF7-hGH cells to that in MCF7-MUT 
cells (Mertani et al., 2001). 
 
 
GeneBank number                                    Name                                       -Fold stimulation  
 
J04111                         Transcription factor AP-1 (c-jun proto-oncogene)           0.10 
L25080                        Transforming protein RhoA                                              0.20 
X02751                        Transforming protein p21 (n-Ras)                                    0.25 
M26708                       Prothymosin-α                                                                   0.40 
M25753                       Cyclin B1                                                                           0.30 
U10564                        CDK tyrosine 15-kinase; wee1Hu                                     0.30 
U41816                        C-1                                                                                     0.40 
M33294                        Tumor necrosis factor receptor 1                                      0.50 
J03746                          Glutathione S-transferase microsomal                              0.40 
M68891                        Endothelial transcription factor GATA-2                         0.15 
M59079                        CCAAT-binding transcription factor subunit                    0.10 
X69111                         DNA-binding protein inhibitor ID-3                                 0.15 
M95809                        Basic transcription factor (62kDa subunit; BTF-2)           0.30 
M97796                        DNA-binding protein inhibitor ID-2                                 0.05 
X69391                         60 S ribosomal protein L6 (DNA-binding protein TAX)  0.40          
M28372                        Sterol  regulatory element-binding protein                        0.10 
L12579                          CCAAT displacement protein                                           0.20 
D26156                          Transcriptional activator hSNF2b                                     0.30 
D90209                          cAMP-dependent transcription factor ATF-4                   0.10 
L05515                          cAMP-response element-binding protein CRE-BPA        0.05                                
L14922                          Activator 1 140-kDa subunit                                             0.40 
D28118                          DB1 (zinc finger protein 161)                                           0.20 
M36711                         Transcription factor AP-2                                                  0.40 
M76541                         Transcriptional repressor protein YY1                              0.50 
U30504                          Transcription initiation factor TFIID subunit TAFII31    0.20 
M29366                          Protein-tyrosine kinase receptor ERBB-3                        0.45 
S59184                           Related to receptor tyrosine kinase (RTK)                       0.45 









As the work presented in this thesis will be a study involving the homeobox gene, 
HOXA1, the literature review will now concentrate on the homeobox gene and mammary 
gland carcinoma.  
 
2.4     Homeobox genes 
 
 
Homeobox genes are a family of regulatory genes encoding specific nuclear proteins 
(homeoproteins) that act as transcription factors. Homeobox genes share a common 183-
bp DNA sequence motif (the homeobox) encoding the roughly 61 amino acid 
homeodomain (HD). There are different homeobox gene classes based on the sequence 
similarities within the HDs and flanking regions (Duboule, 1994). Among these, the 
Drosophila Antennapedia (Antp) HD defines a consensus sequence referred to as class I 
HD (Hox genes) (Akam, 1987). Other homeobox gene families are Bicoid (Bcd), Caudal 
(Cad), Engrailed (En), Even-skipped (Eve), muscle segment homeobox genes (Msx), 
Paired (Pax), Pit-Oct-Unc (Pou), empty spiracles (Emx), and Orthodenticle (Otx) etc. 
(Duboule, 1994). These families vary in size from the relatively large ones, such as the 
Hox group, that comprises 39 members, to the small families, such as the Msx and En 
groups, which only have two or three members each.  
 
The homeobox was initially identified in genes controlling Drosophila development 
(Lewis, 1978). Later, it was identified in evolutionarily distant animal species (Kappen, 
2000), plants (Parcy et al., 1998) and fungi (Torres-Guzman and Dominguez, 1997). The 
sequence identity between vertebrate and Drosophila homeoboxes was astounding. For 




that of Antp in Drosophila (Gehring, 1993). Novel and divergent homeobox genes are 
being continuously isolated. There are over 100 homeobox genes identified in the human, 
with a comparable number of homologous identified in the mouse (Stein et al., 1996). 
Recent indications suggest that homeobox genes constitute as much as 0.1-0.2% of the 
whole vertebrate genome (Stein et al., 1996).  
 
Class I homeobox genes are structurally and functionally homologous to the homeotic 
complex (HOM-C) of Drosophila (Krumlauf, 1994). Analysis of the mouse and human 
Hox complex is the most detailed and indicates that there are at least 39 genes organized 
in four different chromosomal complexes approximately 100 kb in length, termed Hox 
loci, and that the genes in each cluster are still oriented in the same 5’ to 3’ direction of 
transcription (Kessel and Gruss, 1990; Duboule, 1992; Krumlauf, 1992). Each Hox loci is 
localized on a different chromosome (HOXA at 7p15.3, HOXB at 17p21.3, HOXC at 
12q13.3, and HOXD at 2q31) (Apiou et al., 1996) and comprises from 9 to 11 genes 
arranged in a homologous sequence organization (Scott, 1992) (see Figure 4) (Mark et 
al., 1997). Hox genes in the four clusters can be aligned to any one of 13 homology 
groups on the basis of sequence similarity and position on the locus (Acampora et al., 
1989). A distinguishing characteristic of the Hox complex is the correlation between the 
physical order of genes along the chromosome and their expression/function along the 
anteroposterior axis of the embryo. The 3  Hox genes express early in development and 
control anterior regions, followed by progressively more 5  genes express later in 
development and control more posterior regions (Dekker et al., 1992). In particular, 3  






Figure 4. Genomic organization and collinear expression patterns of Drosophila 
HOM genes and mammalian Hox genes. Schematic representation of the Drosophila 
homeotic complex (HOM-C) and the four human Hox complexes is displayed showing 
their possible phylogenic relationships. Each gene is represented by a colored box. The 
expression domains of HOM/Hox genes are schematized in a fly and in the CNS and 
prevertebrate of a human fetus (extrapolated from data in the mouse). For the sake of 
clarity, the partial overlap between HOM gene transcripts in thoracic and abdominal 
segments of the fly and overlapping expression domains of mammalian Hox genes along 
the body axis are not represented; hence, each color is meant to show the anteriormost 
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3’anterior 
   Early 
cervical thoracic lumbo-sacral 





the rhombencephalon, the embryonic region corresponding to the hindbrain (Lumsden 
and Krumlauf, 1996). Central Hox genes in groups 5 to 8 control the thoracic portion of 
the body, whereas 5  Hox genes in groups 9 to 13 control the lumbo-sacral region.  
 
The nomenclature of clustered vertebrate Hox genes was determined and agreed at a 
meeting in Ascona, Switzerland in 1992. The names are a single letter (A,B,C,or D) 
followed by a number from 1 to 13, starting from the ends where the genes express most 
anteriorly are located. Sequence comparisons permit the assignment of the constituent 
genes of each complex to 1 of 13 groups (Figure 4). “Paralog” is sometimes used to 
indicate corresponding genes in different complex, e.g., A1 and B1. The complete name 
of a gene therefore will be Hoxa1, Hoxc4, etc. in mice, and HOXA1, HOXD2, etc. in 
humans. The name Hox should not be used for homeobox genes outside complex. In 
other words, the divergent homeobox genes are not classified and named as “Hox” genes. 
 
The Hox network, as a decoding system for external signals, allows the activation of 
specific genetic programs (Cillo et al., 2001). The external signals from growth factors 
and signal transduction pathways are collected by some collector genes in the network. 
The decoder genes transfer these signals to key genes in the decoding network. Through 
transmitter genes, a response is sent outside the Hox network. This activates specific 
programs of effector genes, e.g. cell-cycle related proteins to achieve the changes induced 






2.5     Homeodomain (HD) 
 
Homeobox-containing genes were first recognized in the fruitfly Drosophila 
melanogaster where duplication caused homeotic transformation such as a fly with four 
wings instead of two (Lewis EB. 1978). In 1984, the homeobox motif was discovered in 
genes of the Drosophila homeotic (HOM-C) complexes (McGinnis et al., 1984; Scott and 
Weiner, 1984). The term “homeodomain” has evolved to define a class of protein 
domains that have a 61 amino acid motif (encoded by 183 bp homeobox sequences). 
Those homeodomains that have been tested contain sequence-specific DNA binding 
activities and are part of larger proteins that function as transcriptional regulators (Levine 
and Hoey, 1988).  
 
Homeodomains have a high degree of conservation throughout the animal and plant 
kingdom. Homeodomains form parts of much larger proteins, and are usually located 
near the C-terminus of the proteins. Generally, there is little similarity between the 
primary sequences of the proteins outside the homeodomain. 
 
There are three features of homeodomains. a) In primary sequence, all the homeodomains 
exhibit striking similarities, even without the introduction of gaps in any of the domains. 
These structural similarities in large part define the homeodomain. Four amino acid 
residues are conserved in all non-yeast homeodomains and three of the four are also 
conserved in the yeast sequence. The invariant residues are tryptophan, phenylalanine, 
asparagine and arginine at positions 49, 50, 52 and 54, respectively. Another eight 




(arginine/glycine), 13(usually glutamine), 17(leucine/valine), 21(phenylalanine/tyrosine), 
41(leucine/asparagine), 46(isoleucine/valine), 56(lysine/arginine), and 58(lysine/arginie). 
The 12 extreme highly conserved residues, together with the high degree conservation at 
other positions characterize the homeodomains.  b) There is also considerable 
conservation of the secondary structure in homeodomains, even in regions that tend to be 
relatively variable in primary sequence. There are predominant α-helix structures in some 
specific regions of the homeodomains, which has important functional implications. c) 
Another distinguishing characteristic is the nuclear location of the homeodomain-
containing proteins. This nuclear distribution is consistent with their role as 
transcriptional regulators. Thus, the primary sequence and secondary structure, as well as 
the subcellular distribution are three important features in determining whether a 
homeodomain-related sequence is in fact a true homeodomain.  
 
Recent nuclear magnetic resonance and crystallographic studies on two homeodomains 
have shown their structures to be related to the helix-turn-helix motif of prokaryotic 
DNA-binding proteins (Otting et al., 1990; Kissinger et al., 1990). The first helix is eight 
amino acids long and the second helix is nine amino acids long. The critical residues in 
the helix-turn-helix framework are a hydrophobic residue at the fourth and eighth 
positions in helix 2, an alanine in the fifth position in helix 2, a glycine (or sometimes 
cysteine or serine) in the first position of the turn followed by a hydrophobic residue, an 
isoleucine or valine at the fourth position of the recognition helix, and a hydryophobic 




residues in the predicted helical regions of homeodomain sequences. All of these 
characteristics are common to the homeodomain sequences. 
 
Homeodomains are responsible for recognizing and binding specific DNA sequences 
(McGinnis and Krumlauff, 1992). Many of these sequences contain the motif TAAT. The 
specificity of this binding allows homeoproteins to activate or repress the expression of 
batteries of downstream effector target genes (Boersma et al., 1999).  
 
2.6 Homeobox genes and development 
 
Homeobox genes (clustered Hox genes and divergent homeobox genes) play a key role in 
a variety of developmental processes including central nervous system and skeletal 
development, limb and digit specification, and organogenesis (Edelman et al., 1993). In 
mammalian embryos, the earliest expression of Hox genes can be detected at gastrulation. 
Hox genes are expressed in all three germ layers with overlapping domains that extend 
from the caudal end of the embryo to a sharp anterior limit which is specific for each Hox 
gene. Mutations of these genes cause dramatic developmental defects including loss of 
specific structures as well as homeotic transformation in which the anatomy characteristic 
of one segment in a given location is assigned incorrectly to another segment (Edelman et 
al., 1993).  
 





The homeobox genes are the major regulator genes in the specification of the body plan 
along the antero-posterior axis both in invertebrates and in vertebrates.  
 
In Drosophila, ectopic expression of a homeotic gene often results in posterior homeotic 
transformation. For example, gain-of-function mutants of Ubx lead to the transformation 
of the second into the third thoracic segment with the transformation of the wings into a 
second pair of halteres (Gehring, 1994). Similarly, ectopic expression of the 
Antennapedia (Antp) gene leads to the conversion of the antenna into mesothoracic 
(second thoracic) legs (Gehring, 1994).  
  
The sequence homology between Drosophila homeotic genes and vertebrate Hox genes, 
and their ordered gene organization, raised the possibility that these genes may have a 
homeotic function in vertebrates as well. The function of Hox genes in vertebrate 
development was analyzed by constructing both gain- and loss-of-function mutants and 
testing them in transgenic mice, and by insertion of the mammalian genes into 
Drosophila. In 1991, Kessel and Gruss constructed an artificial gain-of-function mutant 
by fusing the Hoxa7 gene to a ubiquitously expressed actin promoter (Kessel and Gruss, 
1991). The resulting transgenic mice had an extra cervical vertebra (a proatlas) which 
arose from conversion of an occipital bone of the skull into an eighth cervical segment 
(Kessel and Gruss, 1991). This conversion represented an anterior to posterior 
transformation. To date, numerous loss-of-function mutations in mammalian Hox genes 
have been reported. The mice with targeted disruption of Hoxd3 exhibit anterior 




and Capecchi, 1993). Hoxb4 mutant mice show homeotic transformation of a cervical 
vertebra and defects in the closure of the sternal rudiments (Ramirez-Solis et al., 1993). 
Hoxc8 inactivation in mice resulted in the conversion of the first lumbar vertebra to a 
thoracic vertebra, thus producing a supernumerary 14th pair of ribs (Le Mouellic, 1992). 
Hoxd11 mutant mice show transformation of the first sacral into a lumbar vertebra 
(Favier et al., 1995; Favier et al., 1996). Null mutant mice for a given Hox gene usually 
show homeotic transformations in the anteriormost region where that Hox gene is 
normally expressed, and not within regions where a more 5’ gene is expressed (Mark et 
al., 1997). Homeobox genes in mammals are thought to specify segmental identity along 
the antero-posterior axis in much the same way as in flies. This interpretation receives 
further support from gene-transfer experiments between mouse and Drosophila. For 
example, the Hoxb6 of the mouse can induce antennal legs when ectopically expressed in 
Drosophila (Malicki et al., 1990). 
 
2.6.2 Hox genes in limb morphogenesis and patterning of reproductive and digestive 
tracts  
 
The mammalian Hox gene family contains 15 genes related to the Drosophila gene, Abd-
B. They are Hoxa9 to Hoxa11, Hoxa13, Hoxb9, Hoxb13, Hoxc9 to Hoxc13, Hoxd9 to 
Hoxd13 (Mark et al., 1997). Most of these genes are expressed with overlapping domains 
in the developing fore and hind limbs consistent with a role in specification of the digit 
pattern (Duboule, 1991). Knock-out experiments of these murine Abd-B-related genes 




elements of both fore-limb (e.g. Hoxa9, Hoxd9, Hoxd11) (Favier et al., 1995; Fromental-
Ramain et al., 1996; Davis and Capecchi, 1994; Davis and Capecchi, 1996) and hind limb 
(e.g. Hoxa10) (Favier et al., 1996). These results indicate that these genes control initially 
the allocation and growth of prechon-drogenic condensations and, subsequently, the 
ossification sequence of the cartilage models (Favier and Dolle, 1997; Mark et al., 1997). 
Compound Hox mutant phenotypes have revealed partial redundant functions in limb 
patterning, as for vertebral specification, between paralogous and nonparalogous genes 
(Fromental-Ramain et al., 1996; Davis et al., 1995; Favier et al., 1996). For instance, 
Hoxa13/Hoxb13 compound mutants displayed alterations of growth and patterning of the 
autopods much more severe than those observed in each single mutant (i.e. almost 
complete lack of chondrogenic patterning) showing that these gene products can also 
partly compensate each other (Fromental-Ramain et al., 1996; Mark et al., 1997).  
 
It was also demonstrated that other Abd-B-related Hox genes play roles in the developing 
genitourinary tract and terminal part of the digestive tract. Both male and female Hoxa10 
null mutant mice were hypofertile. Mutant male subjects exhibited cryptorchidism, 
caused by abnormal formation of the inguinal canal and by a failure of shortening of the 
gubernaculums (Rijli et al., 1995; Satokata et al., 1995). In addition, they displayed a 
malformation of the vas deferens that resembled a partial homeotic transformation to an 
epididymis (Benson et al., 1996). In Hoxa11 null mutant mice, partial homeosis of the 
vas deferens to an epididymis-like morphology was also observed (Hsieh-Li et al., 1995). 
The most posterior murine gene, Hoxd12 and Hoxd13, were also demonstrated to have a 




al., 1997). Hoxd12 and Hoxd13 null mutants display a disorganization of the smooth 
muscles layers forming the internal anal sphincter, resulting in rectal prolapsus in some 
mutants (Kondo et al., 1996). These data clearly indicate an important function of some 
Hox genes in defining regional organ development.  
 
2.6.3 Hox genes in hindbrain patterning and craniofacial development  
 
The hindbrain or rhombencephalon, is transiently divided along its anteroposterior axis 
into a series of segments (seven in mice and man) called rhombomeres (Keynes and 
Lumsden, 1990). Neural crest cells migrate across these segments from the neurectoderm 
to populate and pattern the pharyngeal arches. It was shown that some Hox genes which 
are expressed in a given rhombomere are also expressed in the neural crest cells 
migrating from that rhombomere, suggesting that Hox genes may be important in the 
patterning of the branchial region of the head (Krumlauf, 1993).  
 
Defects of rhombomeres 4 and 5, cranial nerve and inner ear abnormalities were found in 
Hoxa1 null mutant mice (Mark et al., 1993; Carpenter et al., 1993). Hoxa2 mutant mice 
exhibit homeotic transformation of skeletal elements derived from cranial neural crest 
(Gendron-Maguire et al., 1993). Targeted inactivation of Hoxa3 leads to 
hypoparathyroidism and thymic and thyroid hypoplasia (Manley and Capecchi, 1995). In 
Hoxb1 and Hoxb2 knockout mice, selective facial nerve motor nucleus deficiencies were 





2.6.4 Divergent homeobox genes in normal and abnormal head development  
 
Apart from the clustered Hox genes, divergent homeobox genes are also involved in 
development. In Drosophila, the control of head specification is dependent on the 
divergent homeobox genes (genes not present within a cluster) including the 
orthodenticle and empty spiracles genes (Mark et al., 1997). The vertebrate homologues, 
Emx1, Emx2, Otx1 and Otx2 genes, are expressed in discrete, overlapping regions of the 
developing forebrain and midbrain in mice, which often coincide with anatomical 
landmarks. Null mutant mice with these genes inactivated showed that they play an 
important role in the patterning of the forebrain and midbrain (Acampora et al., 1995; 
Ang et al., 1996; Pellegrini et al., 1996).  
 
The Engrailed homeobox genes En1 and En2 are both expressed in a domain spanning 
the first rhombomere and the midbrain. The knockout experiments have demonstrated 
that En1 has a critical role in its entire region of expression, whereas En2 function is 
restricted to cerebellar foliation (Mark et al., 1997). However, insertion of the En2 cDNA 
into the En1 locus rescues the En1 null phenotype, agenesis of the tectum and 
cerebellum, suggesting that the distinct phenotype of the En1 and En2 mutations reflect 
differences in the temporal expressions of the corresponding proteins, rather than 
differences in their biochemical activity (Hanks et al., 1995).  
 
Expression of Msx1 and 2 in the mouse fetus and the phenotype displayed by Msx1 null 




early stages of odontogenesis (Thesleff and Nieminen, 1996). These and other homeobox 
genes such as Distall-less 1 and 2 (Dlx1, Dlx2) and Goosecoid (Gsc), are expressed in 
restricted overlapping fields in the developing mandible. Based on these findings an 
“odontogenic homeobox code” that specifies tooth position and type (incisor, canine, 
premolar, molar) has been proposed (Sharpe, 1995).  
 
2.7  Cellular effects and targets of homeobox genes  
2.7.1 Cell cycle 
In addition to the functions already described and reviewed, several homeobox genes are 
also implicated in the regulation of events in cell cycle progression.  
The product of the divergent homeobox gene Msx1 was shown to upregulate cyclin D1 
expression and Cdk4 activity, so preventing cells from leaving the cell cycle and 
undergoing differentiation (Hu et al., 2001). The homeoprotein, HSIX1, was 
demonstrated to abrogate the DNA-damage-induced G2 cell-cycle checkpoint (Ford et al., 
1998). The divergent homeobox gene HOX11 was demonstrated to cause cell cycle 
aberrations in transgenic mouse models when overexpressed in the thymus (Kawabe et al., 
1997). HOX11 can bind to the catalytic subunit of both protein serine-threonine 
phosphatase 2A and protein phosphatase 1 to promote progression into M-phase in both 
G2 arrested xenpus oocytes and in Jurkat cells arrested in G2 following DNA damage 




In addition, it was shown that the CDX2 homeoprotein transactivated and physically 
interacted with the promoter of p21 in a p53-independent manner. Moreover, 
overexpression of CDX2 increased the mRNA expression of p21 in HT-29 colon 
carcinoma cells (Bai et al., 2003). The GAX homeoprotein induces p21 expression, 
which results in an increased association of p21 with Cdk2, thereby inhibiting cellular 
proliferation (Smith et al., 1997). In addition, the Cdk1 gene was shown to contain a 
homeoprotein binding site in its promoter (Liu and Bird, 1998).  HOXA10 was shown to 
bind directly to the p21 promoter and activated p21 transcription (Bromleigh and 
Freedman, 2000).  
 
2.7.2 Apoptosis 
Several homeobox genes have been associated with apoptosis. Hoxa9, crucial for the 
control of hematopoiesis, induces programmed cell death in primitive thymocytes (Izon 
et al., 1998). Inhibition in the expression of the DLX7 homeobox gene renders 
erythropoietic cells apoptotic (Shimamoto et al., 1997). A block in the expression of 
Cux1, a homeobox gene involved in mammalian kidney development, results in 
increased apoptosis of embryonal kidney cells (Quaggin et al., 1997). The homeoprotein, 
PAX5, is able to bind the 5’ regulatory region of the human p53 gene, at a vital site for 
P53 activity (Stuart et al., 1995). Recently, it was reported that HOXA5 is able to 
regulate p53 transcription in human breast cancer cells through binding at the p53 




expressing wild-type p53, but not in isogenic variants lacking the p53 gene, led to 
apoptotic cell death (Raman et al., 2000).  
 
2.7.3 Adhesion  
Interactions between cytokines and growth factors, homeoproteins, and adhesion 
molecules are crucial for the living cell (Edelman and Jones, 1993). A link was 
demonstrated between the expression of homeobox genes and the expression of cell 
adhesion and substrate adhesion molecules (CAMs and SAMs). CAMs and SAMs have 
been found to modulate cellular primary processes such as proliferation, movement, 
interaction, differentiation and death (Edelman, 1988). The promoter region of the 
cytotactin gene, an extracellular matrix glycoprotein, exhibits many potential 
transcription factor binding motifs including homeodomain binding sites (Jones et al., 
1990). The gene promoter for the mouse neural cell adhesion molecule (N-CAM) has 
also been found to contain potential homeodomain binding sites (Hirsch et al., 1990). 
Later, it was shown that the product of homeobox gene Evx1, activates the cytotactin 
gene and the specific homeodomain binding site was also found in the promoter of the 
gene (Jones et al., 1992). In addition, N-CAM gene expression is controlled by different 
Hox gene products. Expression of Evx1, Hoxb8, and Hoxb9 are able to interact with the 
promoter region of N-CAM genes by mechanisms involving a growth-factor signal 
transduction pathway (Edelman, 1993; Jones et al., 1992). Similarly, a homeoprotein 
encoded by the Hoxc6 gene was bound to a specific TAAT-containing sequence 




homeobox genes, Msx1 and Msx2, are able to regulate cadherin-mediated cell adhesion 
(Lincecum et al., 1998).  
 
2.7.4 Extracellular matrix 
Extracellular matrix (ECM) molecules play an important role in determining cell 
phenotypes through modulation of gene expression (Srebrow et al., 1998). Recent 
findings support an interaction between homeobox genes and ECM. Expression of 
HOXD3 increases 5 3 integrin expression and the matrix-degrading proteinase 
urokinase-type plasminogen activator (uPA) (Boudreau et al., 1997). HOXC10, 11, 13 
are connected with decreased expression of 2 1, 5 1, and 6 1 (Cillo et al., 1996). 
Reduced expression of Hoxb9 has been observed in 5 integrin null mice embryos (Goh 
et al., 1997). 
 
2.7.5 Specific target genes of homeoproteins in Drosophila 
 
The selector homeoproteins are conserved throughout the Eumetazoa and include the 
Hox (or homeotic) proteins, the Engrailed-like proteins, and the Eve-like proteins 
(Burglin, 1994; Raff, 1996; Kuhn et al., 1996). These transcription factors are each 
expressed in unique domains along the anterior/posterior axis of animals, and they 
coordinate the development of most or all cells within these domains (Garcia-Bellido, 




Drosophila genome is under homeobox gene control (Mannervik, 1999). In vivo UV 
crosslinking suggested that the selector homeoproteins bind at significant levels to a 
majority of genes in Drosophila (Walter et al., 1994). Later, it was shown that the 
majority of Drosophila genes, at least 87% of genes, are directly or indirectly regulated 
by the homeoproteins and each downstream gene shows a unique pattern of expression, 
indicating that all are under precise and specific control (Liang et al., 1998).  
 
 
2.7.6 Specific target genes of HOXB7 and Hoxa1 
 
It was demonstrated that HOXB7 directly transactivates the basic fibroblast growth factor 
(bFGF) gene through one out of five putative homeodomain binding sites present in its 
promoter (Care et al., 1996). Treatment of melanoma cell lines with antisense oligomers 
targeting HOXB7 mRNA specifically abolished expression of bFGF mRNA (Care et al., 
1996). In another study, it was shown that vascular endothelial growth factor, melanoma 
growth-stimulatory activity/growth-related oncogene α, interleukin 8, and angiopoietin 2 
were upregulated by HOXB7 transduction (Care et al., 2001). In the same study, several 
enzymes were also analyzed including matrix metalloprotease (MMP)-2 and MMP-9 and 
heparanase, capable of proteolytic degradation of extracellular matrix and basement 
membranes. Results showed an induction of only MMP-9 (Care et al., 2000).  
 
In order to clone and characterize target genes of Hoxa1, Shen et al. utilized differential 




which are differentially expressed in F9-10, a murine F9 teratocarcinoma stem cell line 
which expresses high levels of exogenous Hoxa1, compared to F9 wild-type stem cells, 
which do not express endogenous Hoxa1 mRNA in the absence of retinoid acid (Shen et 
al., 2000). A wide range of genes were isolated, including signaling molecules such as 
BMP-4 and BMP-2, the enzyme superoxide dismutase, the cell-cell adhesion molecule 
cadherin-6, proteins involved in gene transcription such as HMG-1 and SAP18, 
homeodomain-containing proteins Gbx2 and Evx2, and cell cycle regulatory proteins 
such as the retinoblastoma binding protein-2 (Table 3) (Shen et al., 2000).  
 
Eph receptor tyrosine kinases and their membrane-bound ligands, ephrins, form a large 
family of molecules that are involved in diverse developmental and differentiation 
processes (Frisen et al., 1999; Holder and Klein, 1999). There is accumulating evidence 
that homeobox genes can regulate Eph family members function. For example, reduced 
EphA2 expression was observed in Hoxa1 and Hoxb1 double mutant mice. Co-
expression of either Hoxa1 or Hoxb1 with Pbx1 transactivated EphA2 enhancer-
dependent reporter gene expression. These results suggest that expression of EphA2 gene 
in rhombomere 4 is directly regulated by Hoxa1 and Hoxb1 homeobox transcription 
factors (Chen and Ruley, 1998). In addition, Hoxa2 was shown to regulate EphA7 








Table 3 Clones of genes that are differentially expressed in Hoxa1-overexpressing 
F9 cells (F9-10 line) vs F9 wild-type (WT) cells (modified from Shen et al., 2000). 
 
Clone number              Fold of change of expression                   Blast search  
                                             in F9-10 line vs F9 WT                       (from NCBI) 
 
          2                                         + 3.2                                             Novel gene 
          3                                         + 3.0                                             Novel gene  
          5, 26                                   - 9.3                                              SOD1 
          13                                       - 5.6                                              BMP-4 
          21                                       + 3.2                                             BMP-2 
          22                                       + 4.4                        Retinoblastoma binding protein-2 
          27                                       + 4.0                        Lactate dehydrogenase A4 
          29, 102                               + 3.0                        Mitochondrial genome  
          32                                       - 2.1                         IGF binding protein 6 
          42                                       + 4.0                                             HMG-1 
          60                                       - 2.0                                              Novel gene 
          62                                       + 2.0                                             Novel gene 
          63                                       -12.0                                             eEf-1-α 
          64                                       - 4.0                                              Novel gene  
          80                                       - 8.4                                              Novel gene 
          100                                     + 3.2                                             Cadherin-6 
          101                                     + 16.0                      CTD-binding SR-like protein rA8 
          103                                     + 32.0                                           Novel gene 
          104                                     + 36.0                                           Novel gene 
          112                                     - 6.4                         Sin3-associated polypeptide p18 
          127                                     + 4.0                         Proteasome subunit RC6-1  
          131                                     + 27.0                                           Novel gene 
          157                                     + 28.2                                           Novel gene 
          168                                     + 4.0                         Phosphoglycerate kinase Pgk1-ps1  
          172                                     + 11.2                                           Gbx2 











2.8 Homeobox genes and human diseases  
 
Emerging evidence supports a role of HOX genes in human diseases and development 
and growth. In 1996, a human malformation syndrome was first shown to be caused by 
mutations in a HOX gene. This syndrome was synpolydactyly and the gene in question 
was HOXD13 (Muragaki et al., 1996). Synpolydactyly is a rare, dominantly-inherited 
limb malformation in which there is a combination of syndactyly and polydactyly. One to 
four limbs can be involved. Typically, patients have syndactyly between the third and the 
fourth fingers, and between the fourth and fifth toes. There may also be clinodactyly, 
camtodactyly or brachydactyly of the fifth fingers, and variable syndactyly of the second 
to fifth toes, often with middle phalanxhypoplasia. Severely affected males can also have 
hypospadias. Mutation in HOXD13 was found to be responsible for synpolydactyly 
through the expansion of an alanine stretch in the corresponding homeoprotein (Muragaki 
et al., 1996).  
 
In 1997, hand-foot-genital (HFG) syndrome was shown to be caused by a mutation in 
HOXA13 (Mortlock and Innis, 1997). Hand-foot-genital syndrome is another rare, 
dominantly-inherited condition, in which distal limb abnormalities are accompanied by 
malformations of the lower genito-urinary tract. In the limbs, the striking feature is first 
digit hypoplasia, producing short, proximally placed thumbs with hypoplastic thenar 
eminences and short, medially deviated halluces. These abnormalities are fully penetrant, 
bilateral and symmetrical with little variation in severity. In contrast, the genito-urinary 




abnormalities include hypospadias in males and Mulllerian duct fusion defects in 
females. The mutations which cause hand-foot-genital (HFG) syndrome include the 
nonsense mutation in the homeobox and the polyalanine tract expansion (Mortlock and 
Innis, 1997). 
 
De novo mutations in the human homeobox gene EMX2 have been reported in patients 
with schizencephaly, an extremely rare congenital disorder characterized by a full-
thickness cleft within the cerebral cortex; eventually, large portions of the cerebral 
hemispheres may be lacking, resulting in a holohemispheric cleft filled with 
cerebrospinal fluid. The phenotype of these patients suggests a requirement of the EMX2 
protein for the correct formation of the cerebral cortex (Brunelli et al., 1996).   
 
Many PAX homeobox genes are connected with human diseases. PAX2 is connected to 
renal defects (Dressler and Douglass, 1992). In Waardenburg syndrome (WS), a 
dominantly-inherited syndrome associated with sensorineural hearing loss and 
pigmentary disturbances, loss-of-function mutations of the PAX3 have been found in WS 
type I and WS type III (Stuart et al., 1993). Heterozygotic mutations in PAX6 have been 
reported in families with eye defects such as 1) aniridia, a panocular disorder in which the 
development of the iris, cornea lens, and retina are disturbed; 2) Peters’ anomaly, a defect 
of the anterior chamber of the eye with corneal malformations and attachment of the lens 
to the central aspect of the cornea; and 3) isolated foveal hypoplasia (Glaser et al., 1994; 




It was demonstrated that selective tooth agenesis (i.e. lack of all permanent second 
premolars and third molars) in a family with autosomal dominant tooth agenesis was 
caused by a single point mutation in the human MSX1 gene (Davideau et al., 1999). 
Mutation analysis in families with Rieger’s syndrome (an autosomal-dominant disorder 
characterized by hypodontia, abnormalities of the anterior chamber of the eye, and a 
protuberant ombilicus) has led to the identification of a novel homeobox gene, RIEG, 
whose mutations are responsible for the abnormalities observed in the Rieger syndrome 
(Semina et al., 1996).  
One member of the POU family of homeoproteins, Pit1, is synthesized only in the 
anterior pituitary gland. Pit1 regulates expression of growth hormone, prolactin, and β-
glycoprotein subunit of the TSH-β. Pit1 mutations have been identified in patients with 
combined pituitary hormone deficiency characterized by lack of GH, prolactin, and TSH, 
resulting in mental retardation and growth deficiency (Rhodes et al.,1994). The mutant 
Pit1 can still bind to its DNA-binding site in target genes, but unlike the normal 
transcription factor, it does not activate transcription and it prevents the normal protein 
from binding to DNA (Rhodes et al.,1994).  
Mutations in the POU3F4 homeobox gene cause deafness with fixation of the stapes, 
which represents the most frequent X-linked form of hearing impairment (Kok et al., 
1995). 
Homeobox genes are also related to lipid metabolism and metabolic diseases. The Smith-
Lemli-Opitz syndrome, an inborn error of cholesterol metabolism, is related to the sonic 




and Hannekam, 2000). PDX1 homeobox genes can regulate pancreatic development and 
islet specific gene expression (insulin 1 and 2 and prohormone convertase 1/3) (Ferber et 
al., 2000).  
 
2.9 Homeobox genes and cancers 
2.9.1 Homeobox genes and solid tumors 
Following the initial reports that HOX genes are expressed in carcinoma cell lines, the 
deregulated expression of homeobox genes has been described in many tumors and 
derivative cell lines (Table 4) (Abate-Shen, 2002).  
Table 4   Deregulated homeobox genes in solid tumors (modified from Abate-Shen, 
2002). 
Homeobox genes   Deregulation in cancer   Normal expression          Functional insights   
HOX      Gain of expression in           Expression patterns           Overexpression promotes 
               primary tumors and cell       during embryogenesis        cellular transformation  
               lines from brain, breast,       reflect roles in patterning,   in culture 
               colon, lung and kidney         segmentation and fate  
                                                            determination of many  
                                                             tissues 
 
MSX      Gain of expression in            Expression during            Overexpression leads to  
               in mammary, colon,              embryogenesis                 inhibition of  
               stomach, kidney, thyroid       associated with                differentiation, correlated 
               and other carcinomas            epithelial-mesenchymal   with upregulation of  
                                                             interactions and                 cyclin D1 
                                                             inversely correlated with 
                                                             differentiation 
 
HSIX1 Gain of expression in               Limited expression          Overexpression abrogates 
             mammary and other                 analyses available;           the G2 cell-cycle 
             carcinomas                               homologues expressed     checkpoint in  
                                                              in the developing              response to X-ray 




                                                              tissues 
 
GBX2  Gain of expression in               Expressed in the              Downregulation of GBX2 
             Prostate carcinoma                  developing nervous          via antisense correlated  
                                                              system; limited                 with reduced  
                                                              information concerning    tumorigenicity 
                                                              expression in prostate  
 
PAX     Gain of expression in               Expression patterns         Overexpression promotes  
              Wilms’ tumor, brain                during embryogenesis     cellular transformation  
              and breast cancer;                    reflect roles in                  in culture 
              translocation of PAX8             organogenesis of kidney 
              in thyroid carcinoma                and other tissues 
 
CDX2   Loss of protein                          Expressed during           Overexpression promotes 
             expression in colon                    embryogenesis in           differentiation of  
             carcinoma                                   extraembryonic tissues;  intestinal cells, while 
                                                                 expression in older         leading to reduced   
                                                                 embryos and adults         proliferation and  
                                                                 restricted to intestinal     tumorigenicity; 
                                                                 epithelium                       heterozygous mutant 
                                                                                                         mice predisposed to 
                                                                                                         colon cancer 
 
NKX3.1  Loss of protein                         Expressed during             Localized to 8p21,   
                expression in                            embryogenesis in            which is frequently 
                prostate cancer                         somites and other            deleted in prostate 
                and pre-neoplastic                   derivatives;                      cancer; overexpression 
                lesions                                      expression in older          leads to reduced cell 
                                                                 embryos and adults         growth and  
                                                                 is restricted to                  and tumorigenicity; 
                                                                 prostatic epithelium         homozygous and  
                                                                                                          heterozygous mutant 
                                                                                                          mice are predisposed  
                                                                                                           to prostate cancer 
 
BARX2  Loss of expression                     Expressed in normal        Localized to 11q24,   
               in ovary carcinoma                    ovarian surface                 which is frequently 
                                                                  epithelium; limited           deleted in ovarian  
                                                                  expression analyses          cancer; displays  
                                                                  available                            tumor suppression 
                                                                                                            and anti-metastastic  
                                                                                                            activities in cell  





Gain of function of certain classes of homeobox genes has been demonstrated to promote 
the oncogenic phenotype.  
1) It was shown that NIH 3T3 fibroblast cells bearing the activated Hoxb8 gene produced 
fibrosarcomas in nude mice (Aberdam and Sachs, 1991). 
2) Msx1 is involved in the terminal differentiation of myogenic cells (Song et al., 1992). 
Transfection of Msx1 into myoblasts inhibited terminal differentiation and induced cell 
transformation (Song et al., 1992). 
3) The oncogenic potential of several deregulated murine homeobox genes was 
investigated using in vitro and in vivo transformation assays (Maulbecker and Gruss, 
1993). It was shown that the overexpression of the murine homeobox genes, Hoxa7, 
Hoxa5, Hoxa1, Hoxb7, and Hoxc8 as well as the homeobox genes Evx1 and Cdx1 can 
cause transformation and tumorigenesis in mice (Maulbecker and Gruss, 1993). 
4) Retroviral-mediated transduction of the sole Hoxb7 cDNA into SkBr3 breast 
adenocarcinoma cells resulted in transcription of both Hoxb7 and bFGF and in several 
phenotypic changes including increased cell growth rate and independence from serum 
withdrawal (Care et al., 1998). NIH3T3 transfectants bearing an activated Hoxb8 gene 
exhibited a transformed phenotype and produced fibrosarcomas in nude mice (Aberdam 
et al., 1991). 
5) The divergent homeobox gene HOX11 was demonstrated to cause tumorigenicity in 
transgenic mouse models when overexpressed in the thymus (Kawabe et al., 1997). The 




documented by experiments showing that overexpression of HOX11 in NIH3T3 cells led 
to transformation of the cells (Dube et al., 1992). 
6) PAX3 and PAX7 have been involved in some forms of rhabdomyosarcoma 
characterized by t(2;13) (q35;q14) and t(1;13) (p26;q14) chromosomal translocations, 
respectively (Sorensen and Triche, 1996). It was shown that murine Pax genes can 
promote oncogenesis in tissue culture cells and in mice. Pax1, Pax2, Pax3, Pax6, and 
Pax8 homeoproteins were able to induce transformation of cell cultures and tumor 
formation in mice (Maulbecker and Gruss, 1993). The oncogenic potential of the Pax 
homeoproteins is dependent on the DNA binding function of the paired motif, as the Un-
Pax1 protein, which carries a point mutation in this domain that impairs DNA binding, is 
also defective in tumor formation (Maulbecker and Gruss, 1993). 
It is also likely that HOX genes can regulate vasculogenesis and angiogenesis. Indeed, 
HOXD3 has been linked to the mechanism converting endothelial cells from a resting to 
angiogenic/invasive state (Boudreau et al., 1997), whereas HOXB13 is required for the 
subsequent capillary morphogenesis of the new vascular sprouts (Myers et al., 2000). 
Importantly, HOXB7 was demonstrated as a key factor upregulating a variety of 
proangiogenic molecules, including vascular endothelial growth factor, melanoma 
growth-stimulatory activity/growth-related oncogenence α, interleukin 8, and 
angiopoietin 2 (Care et al., 2001). Furthermore, HOXB7 was found to induce growth and 
angiogenesis in vitro and in vivo (Care et al., 2001). 
Normal adult human organs such as the kidney, colon, and lung display expression 




DeVita et al., 1993). The patterns differ greatly from organ to organ with respect to active 
or silent genes. HOX genes active in different organs often display differences in 
transcript size. This indicates that the patterns of HOX gene expression result from the 
whole expressions of the different cell phenotypes characteristic of a specific organ and 
that these organ-specific HOX patterns may be responsible, at the same time, for form, 
structure and correct positioning of the organs along the antero-posterior body axis (Cillo 
et al., 2001). But, major differences in HOX gene expression are detectable in primary 
solid tumors (kidney, colon, small cell lung cancer, etc.) compared with the 
corresponding normal adult organs (Cillo, 1994-1995). These alterations involve HOX 
genes crucial for the organ development as well as HOX genes apparently unrelated to 
the organ. 
 
In renal carcinomas and normal human kidneys, several differences in HOX gene 
expression were detected (Cillo et al., 1992). In primary kidney tumors HOX genes can 
be turned off (HOXB5, HOXB9) or on (HOXC11) or can display different-sized 
transcripts (HOXD4) if compared to the expression of normal kidneys, indicating an 
association between altered HOX gene expression and kidney cancer. In addition, HOX 
and other homeobox genes may play a role in aberrant kidney differentiation that leads to 
Wilm’s tumor (Cillo et al., 1995). The possibility for some HOX genes to act as reliable 
indicators of the histological subtype of kidney cancers and Wilm’s tumors has been 





HOX gene expression was analyzed in normal human colon and in primary and 
metastatic colorectal carcinomas (De Vita et al., 1993). Twenty-nine HOX genes appear 
to be actively expressed in normal colon. The entire HOXA locus, containing 11 genes, is 
expressed and virtually all the genes of HOXB cluster are expressed with the exception of 
HOXB1. In contrast, only some of the genes of HOXC and HOXD locus are expressed. 
The expression of some HOX genes is identical in normal and neoplastic colon including 
genes at 5’ end of the HOXA locus, HOXA9 through HOXA13 and five genes at the 5’ 
end of the HOXC locus, HOXC9 through HOXC13. Virtually all the HOXB genes are 
active and their expression does not vary when normal tissues are compared to colorectal 
cancer specimens. In contrast, other HOX genes exhibit altered expression in primary 
colon cancers and their hepatic metastases. These HOX genes include the 3’ HOXA 
genes, HOXA1 through HOXA4 and the 3’ end of HOXC genes, HOXC4 through 
HOXC8. The HOXD locus is characterized by a marked variable expression of HOX 
genes (De Vita et al., 1993). 
 
The expression of the whole HOX gene network in normal adult human lung was tested. 
The expression of 11 genes of the network was detected. Their expression is restricted to 
5 genes of the 3  end of the HOXA locus (from HOXA2 to HOXA6), the paralogous 
genes of the HOXB locus (from HOXB2 to HOXB6) (corresponding to the boundary of 
the expression of the embryonal lung bud), and the gene HOXD1 (Tiberio et al., 1994). 
In contrast, a strikingly different overall pattern of HOX gene expression was observed in 
human small-cell lung cancer (SCLC). Between 23 and 30 HOX genes were expressed 




loci (Tiberioi et al., 1994). Furthermore, in SCLC, the number of actively expressed HOX 
genes may be lower in metastatic cancer than in primary tumors (Tiberio et al., 1994). 
 
Hox genes were shown to play a role in murine skin morphogenesis (Matthews et al., 
1993; Scott and Goldsmith, 1993). Analysis of cultured fetal melanocytes shows the 
expression of several genes of the A and C Hox clusters (Bieberich et al., 1992; Scott and 
Goldsmith, 1993). On the basis of HOX gene expression, it is possible to group 
melanoma clonal populations derived from the same metastatic cell line (Me 665/2) into 
two types (Cillo et al., 1996). In type one, the HOX gene network is expressed according 
to a very similar pattern of the parental Me 665/2 cell line and in type two, HOX genes 
display a silent block of genes (HOXC10, HOXC11, and HOXC13) localized at the 5’ 
end of the HOXC locus (Cillo et al., 1996). The expression and function of HOXB cluster 
genes in human normal and neoplastic melanocytic cells were investigated (Care et al., 
1996). In this study, HOXB7 was found to be consistently expressed in all the melanoma 
cell lines and patients’ melanoma samples examined. Conversely, HOXB7 was expressed 
in proliferating but not quiescent normal melanocytes (Care et al., 1996). Treatment of 
melanoma cell lines with antisense oligomers targeting HOXB7 mRNA markedly 
inhibited cell proliferation (Care et al., 1996).  
 
All these findings above have indicated an association between altered HOX gene 
expression and primary human tumors (Cillo et al., 1992). Besides the involvement of 
altered homeobox gene expression in primary tumors, major variations in homeobox gene 




HOX genes was detected in metastatic lesions with respect to the primary tumor of origin 
and the corresponding normal tissue (De Vita et al., 1993). Furthermore, in some cases, 
HOX gene expression appears to be specifically linked to stage of tumor progression and 
histological tumor type (Tiberio et al., 1994).  
 
In conclusion, homeobox genes that are normally expressed in developing tissues and are 
downregulated in differentiation are often re-expressed in cancer. Conversely, homeobox 
genes that are expressed in differentiated tissues are often downregulated in cancer 
progression (Abate-Shen, 2002). 
 
2.9.2 Homeobox genes and leukemia  
 
Role of homeobox genes in malignant processes was first documented in leukemia. Many 
homeobox genes play an important role in haemopoiesis, including the specification of 
definitive haemopoietic stem cells and differentiation along the myeloid lineage (Kyba et 
al., 2002; van Oostveen et al., 1999). The first evidence of the involvement of a 
homeobox gene in leukemia was the Hoxb8 gene which is transcriptionally activated in 
the mouse myeloid leukemia cell line WEH1-3B. The constitutive over-expression of this 
homeobox gene is due to the insertion of its first exon of a retrovirus-like intracisternal A 
particle (IAP) (Kongsuwan et al., 1989; Perkins et al., 1990). It was shown that the 
overexpression of HOXB8 inhibited specific pathways of the myeloid differentiation 
program (Perkins et al., 1990). Several indications have been provided by leukemic mice 




targeted destruction of Hoxa9 gene is leukemogenic in mice (Lawrence et al., 1997). The 
overexpression of Hoxa10 induces myeloid leukemia after long periods of latency 
(Thorsteinsdottir et al., 1997). The fusion in frame between the nucleoporin gene NUP98 
and the HOXA9 gene is achieved through the translocation t(7;11) (p15;p15) in human 
AML (Nakamura et al., 1996). The pattern of expression of homeobox genes contained in 
the four human HOX clusters has been studied in different types of human leukemia 
(Celetti et al., 1993). The results suggest that hematopoietic malignant cells express a 
repertoire of HOX genes characteristic of a particular cell lineage at a specific stage of 
differentiation. PBX1 is a divergent homeobox gene that was identified as the 
chromosome 1 partner of the t(1;19) translocation in human pre-B-cell ALL. The t(1;19) 
results in the fusion of a portion of PBX1 including the homeodomain, with a truncated 
EA2 protein. Fusion between PBX1 and E2A proteins alters the sequence-specific 
binding to the HOX genes directing the homeoprotein on a different target and inducing 
leukemogenesis (Knoepfler and Kamps., 1997). In addition, cooperation between 
HOXB3, HOXB4, and PBX1 homeoproteins plays an important role in blood cell 
proliferation and transformation (Krosl et al., 1998). HB24 is another divergent human 
homeobox gene expressed in hematopoietic progenitor cells (Deguchi et al., 1992). High 
expression of HB24 was shown to confer to a human T cell line the ability to form 
metastasis in mouse (Deguchi et al., 1993). HOX11 is a divergent homeobox gene 
originally isolated from a human leukemia. Overexpression of this gene occurs in rare 
cases of human T cell ALL that have the translocations t(10;14)(q24,q11) or t(7;10) 
(q35;q24), in which the HOX11 gene is activated due to juxtaposition with promoter 




Homeobox genes are also involved in lymphomagenesis. The locus HOXC is mainly 
implicated in lymphomas: while HOXC4 and C6 are expressed in non-Hodgkin's 
lymphoma, HOXC5 displays a type- and site-restricted expression pattern in both T- and 
B- cell non-Hodgkin's lymphomas (Bijl et al., 1997). 
 
In conclusion, the consequences of deregulated homeobox genes for carcinogenesis can 
be interpreted as an extension of their normal function. In normal tissues, their 
cumulative activities provide a balance between proliferation and differentiation, whereas 
perturbations of homeobox gene expression promote the transformed phenotype (Abate-
Shen, 2002). 
 
2.10 Homeobox genes and mammary gland 
 
Early immunohistochemical studies and screens based on polymerase chain reaction first 
detected homeobox gene expression in mammary epithelial cell lines and tumors (Wewer 
et al., 1990; Castronovo et al., 1994). This has led to a series of investigations that have 
indicated that homeobox genes may be important for normal mammary gland and 
mammary carcinoma development.  
 
2.10.1 Homeobox genes and mice mammary gland and mice breast cancer 
 
In 1994, Friedmann et al. examined Hox gene expression in normal and neoplastic mouse 




development included Hoxa7, Hoxb6, Hoxc6, and Hoxd12. Further study found that 
Hoxc6 transcripts were detected in mammary glands throughout all stages of 
development from pubescent to mature animals. The transcript levels then declined in 
glands from animals that were in early stages of pregnancy and could not be detected in 
the late stages of pregnancy or during lactation. In contrast, Hoxa1 was not detected in 
any of these stages of development (Friedmann et al., 1994). Hoxc6 showed very low 
levels of expression in the precancerous mouse mammary tissue but showed no 
expression in cancers. In contrast, Hoxa1 showed high levels of expression in mouse 
breast cancer but showed no expression in precacerous tissue (Friedmann et al., 1994). 
Friedmann and coworkers continued their studies and further identified several other Hox 
genes in mouse mammary gland (Friedmann et al., 1995).  In situ hybridization 
demonstrated that many of these genes are expressed either in the mammary epithelium 
or in the periductal stroma, or both (Figure 5). In addition, expression of the normally 
expressed homeobox genes examined (Hoxb6, Hoxb7, Hoxc8, Hoxd4, Hoxd8, Hoxd9, 
and Hoxd10) was lost on neoplastic progression in a selected population of mouse 
hyperplasias and tumors (Friedman, 1995).  
 
Soon after, five Hox genes were identified to be expressed in CID-9 mouse mammary 
epithelial cells (Srebrow et al., 1998). It was found that Hoxa1 and Hoxb7 were 
downregulated by extracellular membrane, suggesting that homeobox gene expression 
may be modulated in vivo by interactions between epithelial cells and components of the 




differentiation and function and that they tend to be altered on neoplastic progression 
(Robinson et al., 1999; Streuli and Gilmore, 1999). 
 
In later studies, Chen and Cappechi examined and analyzed mice with mutant Hoxa9, 
Hoxb9, and Hoxd9 genes (Chen and Cappechi, 1999). The genotype of mutant mice is 
designated by capital and lower-case letters, where A, B, and D denote the wild-type 
alleles and a, b, and d denote the loss-of-function alleles of Hoxa9, Hoxb9, and Hoxd9, 
respectively. Single mutant (monoallellic) of Hoxa9 or Hoxb9 showed only a small 
decease in newborn survival, while the mutant of Hoxd9 reduced survival to below 50%. 
Double mutant (biallellic) showed synergistic effects that reduced newborn survival 
below the survival rate compared with single mutation. The mammary glands of Aabbdd,  
aaBbdd, and aabbdd females showed hypoplasia of the mammary glands during 
pregnancy and post parturition. Measurement of serum-estrogen levels in virgin and 
pregnant aabbdd females showed that concentrations of this hormone do not differ 
significantly from those in age-matched, wild-type female controls, indicating that the 
mammary hypoplasia observed in aabbdd mice is not likely to be caused by a deficit in 
the production of reproductive hormones.  Expression of Hoxa9, Hoxb9, and Hoxd9 was 
found in mammary-gland samples from 8-week-old virgin females, pregnant and 
lactating females, as well as 12.5 days gestational embryos. The expression of Hoxa9, 
Hoxb9, and Hoxd9 in embryonic, pregnant and lactating mammary-gland tissues suggests 







Figure 5. Tissue distribution of homeobox gene expression through mouse 
mammary gland development. Selected stages of mammary gland development are 
depicted with reference to the expression patterns of several homeobox genes as 
demonstrated by in situ hybridization. Expression at a given stage is shown by a bar 
above the stage. Bars are pattern coded to represent a unique tissue compartment or 
epithelial structure. Transition points affected by a given homeobox gene mutation are 
denoted by a hatched box above the arrow representing the transition (modified from 





Msx is a small family of three related homeobox genes. Only Msx1 and Msx2 have been 
examined in the mouse mammary gland (Friedmann and Daniel, 1996; Phippard et al., 
1996). Transgenic mice that express Msx1 under the control of the mouse mammary 
tumor virus long terminal repeat (MMTV LTR) display impaired differentiation of the 
mammary epithelium during pregnancy (Hu et al., 2001). The expression of Msx1 and 




Msx2 was present in mammary glands of virgin mice and in mammary glands of mice in 
early pregnancy, but the expression decreased dramatically during late pregnancy. In 
mammary glands from lactating animals and during the first days of involution, low 
levels of Msx1 transcripts were detected.  But during lactation or early involution, Msx2 
expression was not detected in mammary glands. Expression of both genes increased 
gradually as involution progressed (Friedmann and Daniel, 1996). During embryogenesis, 
both Msx1 and Msx2 were expressed in the epithelium. In contrast, in postnatal mice, 
Msx1 and Msx2 were expressed in reciprocal tissue compartments, with Msx1 expressed 
in the epithelium and Msx2 expressed in the periductal stroma (Friedmann and Daniel, 
1996). Expression studies also suggested a potential role of Msx2 in mediation of 
hormone responses. Msx2 expression was decreased following ovariectomy or following 
exposure to anti-estrogen implanted directly into the gland, and returned to normal levels 
after estrogen was administered to ovariectomized animals (Friedmann and Daniel, 
1996).  
 
Both Engrailed-related (En) homeobox genes, En1 and En2, have also been examined in 
the mouse mammary gland (Friedmann, 1995). En1 was expressed at constant levels 
through early pregnancy but was not detectable during late pregnancy or lactation. En2 
was not detected in any tissue examined (Friedmann, 1995). 
 





Four different human homeobox genes, HOXA1, HOXA10 HOXB6, and HOXC6 were 
identified in the human breast cancer cell line, MCF-7 (Castronovo et al., 1994). In 
another study, it was shown that HOXA1 can be induced by retinoic acid in MCF-7 
breast cancer cells (Chariot et al., 1995). HOXA1 was further demonstrated to be induced 
by progestin in MCF-7 cells (Chariot and Castronovo, 1996). HOXA1 expression was 
also detected in a variety of human beast cancer lesions (Chariot and Castronovo, 1996). 
Later, more and more homeobox genes were examined in human mammary gland. 
 
In 2003, Cantile et al. analyzed whole HOX gene network expression in human normal 
breast tissue and in primary breast cancers by RT-PCR. Seventeen of 39 HOX genes 
were expressed in normal adult human breast (Figure 6) (Cantile et al., 2003). There were 
no quantitative differences in HOX gene expression detected between normal epithelial 
breast tissues. More loci A and C were expressed compared with loci B and D. In locus 
A, HOXA3, HOXA7, HOXA9, HOXA10, and HOXA11 were expressed. In locus B, 
HOXB3, HOXB5, HOXB6, and HOXB7 were expressed. In locus C, HOXC6, HOXC8, 
HOXC10, HOXC11, and HOXC13 were expressed. In locus D, HOXD1, HOXD8 and 
HOXD9 were expressed.  More thoracic (7/11 active genes) and lumbo-sacral (7/16) 
HOX genes were expressed in the normal breast whereas only 3 out of 12 cervical HOX 
genes were expressed. Furthermore, no adjacent HOX genes were expressed in the 
cervical region. In contrast, adjacent 3' or 5' end HOX genes were expressed both in the 





Cantile et al. also compared the whole HOX gene expression pattern in normal breast 
(large squares) and in fourteen breast cancer biopsies (Figure 6) (Cantile et al., 2003). 
The expression of some HOX genes is similar in normal and neoplastic breast tissue 
indicating that these genes may be involved in breast organogenesis. In contrast, other 
HOX genes had altered expression in breast cancers compared with normal breast 
indicating their involvement in breast cancer tumorigenesis.  
 
The cervical part of the HOX gene network displayed the largest difference between 
normal breast and breast cancer. In normal breast HOX gene network, only HOXA3, 
HOXB3 and HOXD1 in cervical region were expressed while in breast cancer, 11 of 12 
cervical HOX genes became alternatively expressed. HOXC4 was constitutively silent in 
normal breast and breast cancers. In contrast, HOXD1 was active in all normal tissue and 
breast cancers. HOXD3 was silent in normal breast and expressed in all the breast cancer 
tissues examined (Cantile et al., 2003). HOXA1, which is silent in normal breast, became 
expressed in some breast cancer tissues. This is consistent with the reports of Chariot and 
Castronovo, who showed that HOXA1 expression was detected in a variety of human 
beast cancer lesions and in human breast cancer cell line MCF-7 (Chariot and 
Castronovo, 1996). Interestingly, the human HOXA1 expression pattern in mammary 







Figure 6. Diagram of HOX gene expression in normal and neoplastic breast. Closed 
or open symbols indicate active or silent HOX genes, respectively. Large squares 
represent normal breast; small ovals represent each individual cancer biopsy tested. Small 
ovals in the same position in the figure refer to the same breast cancer biopsy (modified 
from Cantile et al., 2003). 
 
Thoracic genes of the HOX network displayed only minor difference between normal 
breast and breast cancer. HOXA7 was invariantly expressed in all normal and neoplastic 
tissues. HOXA5 and HOXA6 were silent in the normal breast tissue and became active in 
the breast cancer biopsies. Three out of 4 thoracic HOXB genes were expressed in 
normal breast. HOXB5 became silent in most of the breast cancer tissues while the other 
three HOXB genes did not display any quantitative differences in their expression 
between normal and neoplastic tissues. The thoracic HOXC genes showed slight 
differences in their expression between normal and neoplastic breast tissues. Finally, 




HOXD8 appeared to be constitutively active in both normal and neoplastic breast tissues 
(Cantile et al., 2003). 
 
There are 7 out of 16 lumbo-sacral HOX genes expressed in normal breast tissue 
including three adjacent genes HOXA9, HOXA10 and HOXA11. HOXA9 and HOXA10 
were still active in the cancer biopsies while HOXA11 was silent in all, but one, of the 
breast cancer tissue tested by the authors. HOXA13 and HOXB9 were switched off in the 
normal breast tissue but active in some breast cancer tissues. The locus C HOX genes did 
not display major differences in their expression between normal and neoplastic breast 
tissue. HOXD10 and HOXD13 manifested differences in their expression between 
normal and neoplastic breast tissue (Cantile et al., 2003). 
 
The HOX gene network manifests expression patterns corresponding to specific cell 
phenotypes (Cillo et al., 2001). Thus, it is possible that thoracic paralogous HOX gene 
groups control the thoracic embryonic development and its homeostatic regulation during 
adult life. In contrast, cervical and lumbo-sacral paralogous HOX groups may be 
involved in signaling pathways related to the determination of the breast cell phenotype 
and therefore their expression is altered during breast cancer progression (Cantile et al., 
2003). 
 
In the human mammary gland, a family of Iroquois-class (IRX) homeobox genes was 
identified (Lewis et al., 1999). One gene, IRX2, is expressed in discrete epithelial cell 




gland development, its expression is increased in terminal end buds and terminal lobules 
and is reduced in a subset of epithelial cells during lactation. IRX2 expression is also 
maintained in human mammary neoplasias (Lewis et al., 1999).   
 
At least 4 POU homeobox genes: OCT1, OCT2, OCT3, and OCT11 were identified in 
human breast cancer cell line, MCF-7 (Jin et al., 1999). The expression of OCT1 and 
OCT2 in other human breast epithelial cell lines was further determined. It was found 
that OCT3 is expressed in both human breast cancer cell lines and all human primary 
breast carcinomas examined, but not in normal human breast tissue, indicating its 
important role in mammary gland carcinogenesis (Jin et al., 1999).  
 
Overexpression of homeobox gene HSIX1 in MCF-7 cells abrogated the G2 cell cycle 
checkpoint in response to x-ray irradiation. HSIX1 expression was absent or very low in 
normal mammary tissue, but elevated expression was observed in 44% of primary breast 
cancers and 90% of metastatic lesions. In addition, HSIX1 was expressed in a variety of 
cancer cell lines (Ford et al., 1998).  
 
2.10.3 Summary of homeobox gene expression and function in mammary gland 
development and neoplasia 
 
Thus far, it seems that loss-of-function mutations simply affect developmental 
progression but that gain-of-function mutations impact neoplastic progression (Lewis 




developmental failure, rather than tumor formation (Chen and Capecchi, 1999). In terms 
of gain-of-function mutations, overexpression of murine Hoxb7 in SkBr3 mammary 
cancer cells caused increased proliferation and decreased growth factor dependency (Care 
et al., 1998). Table 5 summarizes homeobox gene expression and function in mammary 
gland development and neoplasia (Lewis, 2000). 
 
Table 5 Summary of homeobox gene expression and function in mammary gland 
development and neoplasia (modified from Lewis, 2000). 
 
Gene      Expression       Expression altered      Possible                    Mammary or  
name      detected in         in neoplasias            regulation?            in vitro phenotype?                                  
   
Hoxa1     MG(UD)           OE (freq.)         Extracellular matrix  
                Scp2, CID-9                               components  
HOXA1   MCF-7                                       Retinoic acid    
Hoxa5      CID-9           
Hoxa7       MG 
HOXA7    MG 
Hoxa9       MG                                                                               KO: lactational defects 
HOXA10  MCF-7                                      Vitamin D                   OE in MCF-7: promotes 
                                                                                                       cell cycle arrest in G1 
Hoxb6       MG                   Lost 
HOXB6    MCF-7              
Hoxb7       MG                   UE                  Extracellular matrix   OE in SkBr3 cells: bFGF 
                                                                   components;               induction; increased  
                                                                   developmental            proliferation; decreased  
                                                                                                      growth factor dependency 
Hoxb8        CID-9  
Hoxb9        CID-9 E12.5                                                               KO: lactational defects 
                   Embryo (MM) 
Hoxc6         MG                  Lost                  Estrogen (-); 
                                                                     developmental    
HOXC6      MCF-7;                                     Variable 
                   MCF-7D    
                   Hs578Bst 
                   MCF-10F 




Hoxc8         MG                   Lost                  Estrogen (-); 
                                                                      Developmental 
HOXC10    MG 
Hoxd3         MG (UD)         OE (rarely)     
Hoxd4         MG (E)             Lost 
Hoxd8         MG                   Lost                   Developmental 
Hoxd9         MG (E+S); 
                    E12.5 Embryo  Lost                   Developmental       KO: lactational defects 
                    (MM) 
Hoxd10       MG (E+S)         Lost                   Developmental       KO: lactational defects 
Hoxd11       MG (UD)           No 
Hoxd12       MG                    OE (myc tumor) 
Msx1          E13.5 Embryo (E);   Maintained    Developmental      KO: none detected  
                   MG (E)                     but variable                                         in embryos  
Msx2          E13.5 Embryo (E);   Lost                Estrogen;  
                   MG (S)                                             developmental      KO: MG fail to form 
IRX1          MG 
IRX2          MG; primary             Maintained.    Developmental 
                   tumors                       expression 
                                                     levels or splice 
                                                     form usage may 
                                                     altered in some 
                                                     tumors 
IRX3           MG 
IRX4           MG 
IRX5           MG 
Alx4            MG (S)                                                Expression          KO: none detected 
                                                                                associated with  
                                                                                actively  
                                                                                condensing  
                                                                                periductal stroma 
 
HSIX1         MCF-7                      OE                    Expressed in S       OE  in MCF-7  
                                                                                phase of cell          abolishes X-ray 
                                                                                cycle                      induced cell cycle 
                                                                                                               arrest in G2 phase 
OCT1          MCF-7;  
                    MCF-10; 
                    SkBr3; 
                    MDA-MB453 
Oct1            MG (lact.) 
OCT2          MCF-7; 
                    MCF-10; 
                    SkBr3 
OCT3          MG (UD);                   OE (freq.)                                       Form with a 5  




                    MCF-10;                                                                            detected in MCF-7 
                    SkBr3;                                                                                cells 
                    primary tumors 
Oct3            MG (lact.) 
OCT11        MG (UD);                   OE (freq.) 
                    MCF-7; 
                    SkBr3; 
                    MDA-MB453; 
                    primary tumors 
Pit-rs1          MG (lact.) 
Pou4f1         MG (lact.) 
Pou4f-rs1     MG (lact.) 
Pou3f4         MG (lact.) 
Pou3f-rs1     MG (lact.) 
En1              MG                               UE (freq.)          Developmental            
En2              MG (UD)                      UD                                                 KO: none detected 
MOX1         MG 
MEIS2a       MG 
MEIS2d       MG 
MRG1a        MG 
 
E, epithelium; freq., frequently; KO, knockout mutation; lact., lactating; M, mammary 
mesenchyme; MG, mammary gland; OE, overexpressed; S, periductal stroma; UD, 























Recently a study in our laboratory demonstrated that autocrine GH effects in MCF-7 cells 
included changes in cell-cell adhesion and E-cadherin localization (Mukhina et al., 
manuscript submitted). Recent developments show that E-cadherin functions not only as 
an adhesion structure to bring cells together, but also may have additional functions as 
active receptors to direct cell signaling and activate downstream molecules (Kovacs et al., 
2002). Initial results showed that HOXA1 was upregulated in MCF-7 at full confluence 
and this upregulation was confirmed to be directed by E-cadherin-activated signaling 
through Rac1 (results detailed in Chapter 4.2).   
 
2.11    E-cadherin 
 
2.11.1 E-cadherin structure 
 
Adjoining epithelial cells are connected by a number of structures between them: (1) tight 
junctions at the topical part of the cell-cell contact, (2) adherens junctions, (3) 
desmosomes, (4) gap junctions, (5) other structures including hemidesmosomes and focal 
adhesion complex (Jiang and Robert, 2000). The appropriate functions of these structures 
maintain the normal physiology, integrity, and function of the epithelial cells.  
 
Cadherins are a major class of cell adhesion molecules responsible for strong cell-cell 
adhesion. The main structure of cadherin complex is composed of the following 
components: cadherin, intracellular components associated with cadherin (such as 




family of transmembrane glycoproteins that mediate cell-cell adhesion. They have a 
single-span transmembranous domain containing a carboxy terminal in the intracellular 
domain, with five tandem repeats in the N-terminal extracellular domain, and anchor to 
the cytoskeleton via other proteins, including catenins (Shapiro et al., 1995; Nagar et al., 
1996). The extracellular repeats allow cadherin to form homotypical interactions in the 
presence of extracellular calcium, thus forming a zip-like structure between two cells. 
However, heterotypic interactions between different cadherin molecules are also possible. 
A-CAM-(N-cadherin) expressing cells and L-CAM-(E-cadherin) expressing cells were 
found to form heterotypic junctions (Jiang, 1996; Volk et al., 1987).  
 
The classification of cadherins is traditionally based on the tissue distribution or the 
origin from which they are discovered (Jiang and Robert, 2000). For example, the 
cadherin distributed in epithelial cells is named as E-cadherin, in heart as H-cadherin, in 
neural tissues as N-cadherin.  
 
E-cadherin is a protein 120 kDa in size and is widely expressed in epithelial cells. Like 
other cadherins, E-cadherin has three domains, the extracellular, transmembrane, and 
intracellular domains. Ca2+ binds to the extracellular domain of E-cadherin, thereby 
inducing a conformational change that promotes homophilic interaction with E-cadherin 
in an adjacent cell (Koch et al., 1997).  The cytoplasmic domains of E-cadherin provide 
attachment to the actin cytoskeleton via catenins and other cytoskeletal proteins 
(Gumbiner, 1996; Takeichi, 1995). β- or γ-catenin binds to E-cadherin and α-catenin and 




Rimm, 1999). Another protein, p120ctn, binds E-cadherin independently of β- and γ-
catenin and is thought to regulate adhesion separately from the other catenins (Provost 
and Rimm, 1999). Furthermore, it has been demonstrated that a homotypical binding 
domain is conferred by the HAV sequence, a domain located in the first cadherin repeat 
of E-cadherin (Overdiun et al., 1995; Pokutta et al., 1994; Noe et al., 1999). Disruption or 
mutation of the HAV domain results in a damage to cell-cell adhesion (Noe et al., 1999). 
Once synthesized, E-cadherin has a short half-life (5-10h). The subsequent assembly and 
turnover of the adhesion structure are regulated by many external and internal signals 
(Jiang and Robert, 2000).  
 
2.11.2 Cellular effects of E-cadherin 
 
The role of E-cadherin in cell-cell adherens junctions is described as above. Continued 
expression and functional activity of E-cadherin are required for cells to remain tightly 
associated in the epithelium, and in its absence the many other cell adhesion and cell 
junction proteins expressed in epithelial cells are not capable of supporting intercellular 
adhesion (Gumbiner, 1996). E-cadherin-mediated cell-cell adhesion is regulated by a 
number of pathways. Activation of Wnt pathways was shown to result in an enhanced 
cell-cell adhesion that is mediated by E-cadherin (Hinck et al., 1994; Bradley and Cowin, 
1992). It was also shown that phosphorylation of E-cadherin, β-, and α-catenins alters E-
cadherin-mediated adhesion (Hiscox and Jiang, 1999). Several lines of evidence suggest 
that members of the Rho family are required for the establishment and maintenance of E-




al., 1997; Zhong et al., 1997; Kuroda et al., 1997). Overexpression of constitutively 
active Rac1 or Cdc42 in epithelial cells increases E-cadherin localization and actin 
accumulation at cell-cell junctions, whereas these events are inhibited by dominant 
negative mutants of Rac1 and Cdc42 (Hordijk et al., 1997; Takaishi et al., 1997; Kuroda 
et al., 1997; Ridley et al., 1995; Jou and Nelson, 1998).  
 
In addition to its effects on adhesion, E-cadherin also has effects on cell growth. In 
normal epithelial cells, when the cells grow to a certain degree, the rate of growth and 
proliferation is reduced. This phenomenon is called contact inhibition. This is one of the 
key mechanisms by which normal epithelial cells control their own fate and is one of the 
fundamental differences between normal epithelial cells and epithelium-derived tumor 
cells. The contact inhibition is lost and the cancer cells undergo uncontrolled growth. It is 
now known that the loss of the contact inhibition in epithelial cell lineage is linked to E-
cadherin and a cell cycle regulator, p27 (Jiang and Robert, 2000). p27 is able to interact 
with cyclins and cyclin-dependent kinases (CDK), resulting in the formation of p27-CDK 
complex and deactivation of CDKs and the blockade of cycle progression (Hengst et al., 
1994; Hengst et al., 1996). It has been demonstrated that when the E-cadherin positive 
cells grow to confluence, the close cell-cell contact is mainly mediated by E-cadherin and 
the p27 level is high in the nucleus (Croix et al., 1998). When the E-cadherin function is 
disturbed, p27 is lost and cell cycle progresses (Croix et al., 1998).  
 
E-cadherin is involved in the expression of Eph receptors and ephrins (Orsulic and 




phosphorylation of EphA2 in mammary epithelial cells are dependent on E-cadherin–
mediated adhesion (Zantek et al., 1999). In epithelial cells, E-cadherin is required for 
EphA2 receptor localization at cell-cell contacts; in the absence of functional E-cadherin, 
EphA2 localizes to the perinuclear region (Orsulic and Kemler, 2000). Constitutive 
ectopic expression of E-cadherin in non-epithelial NIH3T3 cells results in the production 
of the EphA2 receptor (Orsulic and Kemler, 2000). In another study, it was found that E-
cadherin regulates expression of several Eph recettors and ephrins in embryonic stem 
(ES) cells (Orsulic and Kemler, 2000). Rescue of E-cadherin null ES cells with E-
cadherin cDNA restores the wild-type expression patterns of Eph family members 
(Orsulic and Kemler, 2000). Rescue of E-cadherin null ES cells with N-cadherin cDNA 
does not restore the wild-type expression pattern, indicating that the regulation of 
differential expression of Eph family members is specific to E-cadherin (Orsulic and 
Kemler, 2000).  
 
2.11.3 E-cadherin and cancer 
 
E-cadherin has been demonstrated to be involved in cancer invasion and progression. 
There are a number of abnormalities seen in breast cancer cells and breast cancer tissues. 
E-cadherin levels can be reduced or even absent totally, and the level of E-cadherin in 
breast cancer appears to bear no relationship with ER and PR status of the tumor (Perl et 
al., 1998; Palacios et al., 1995; Guriec et al., 1996; Dillon et al., 1998; DeLeeuw et al., 
1997; Bankfalvi et al., 1999; Jacquemier et al., 1999). Loss of E-cadherin is more 




lobular type (Bankfalvi et al., 1999; Jacquemier et al., 1999; Siitonen et al., 1996; 
Zschiesche et al., 1997; Mbalaviele et al., 1996). The reduction of E-cadherin can be in a 
steady progression pattern from pure intra-ductal carcinomas though invasive ductal to 
recurrent carcinomas (Siitonen et al., 1996). Lack of E-cadherin-mediated adhesion in 
human tumors correlates with the loss of epithelial morphology and the acquisition of 
mesenchymal characteristics. Blocking E-cadherin function in vitro with antibodies or 
antisense RNA increases tumor cell motility, invasion and metastatic potential (Behrens 
et al., 1989; Vleminckx et al., 1991). 
 
Mutations of E-cadherin have also been reported in breast cancer. E-cadherin mutation 
appears to be the loss of heterozygosity (LOH) of chromosomal region 16q22.1 
containing the E-cadherin locus (Berx et al., 1996; Berx et al., 1998). It was found that 
the LOH was higher in ductal carcinoma than the lobular carcinoma and LOH was 
associated with the histological grade of the tumors (Huiping et al., 1999). Germline 
mutations of the E-cadherin gene appear to be a prominent feature of inherited cancer 
(Guilford et al., 1999).  
 
The mechanisms of loss of expression of E-cadherin in cancer include DNA 
hypermethylation of promoter, downregulating of E-cadherin by Snail family, and 
shedding of E-cadherin by metalloproteinases (MMPs). It was demonstrated that in breast 
cancer cells which were negative for E-cadherin expression, there was aberrant 
methylation of a 5’ promoter region CpG island. This aberrant methylation was also seen 




can be reversed by demethylation agents (Graff et al., 1995). It was also demonstrated 
that the density of E-cadherin promoter methylation increases (with E-cadherin level 
reduction) when invasion begins to occur (Graff et al., 2000). In addition, E-cadherin 
transcriptional expression was reported to be downregulated by Snail family (Cano et al., 
2000). The Snail family was known to be involved in embryogenesis and some diseases 
(Grau et al., 1984; Boulay et al., 1987). It was found that there was an inverse 
relationship between the level of E-cadherin and Snail in cancer cells (Cano et al., 2000). 
Cancer cells transfected with Snail have reduced expression of E-cadherin and enhanced 
migration and invasiveness in vitro and in vivo (Jiang and Robert, 2000). Certain 
proteolytic enzymes, namely metalloproteinases (MMPs) and adamilysins are able to 
enzymatically degrade the cadherin protein. This degradation destroys E-cadherin 
function and enhances invasiveness of cancer cells (Noe et al., 2000; Jiang and Robert, 
2000).   
  
2.12  Direct signaling from E-cadherin  
 
Classical cadherin molecules are critical morphogenetic determinants in metazoan 
organisms (Takeichi, 1995; Yap et al., 1997). At the cellular level, there is increasing 
evidence that E-cadherin ligation initiates a cascade of molecular and cellular events that 
ultimately determine cellular recognition. Many signaling molecules are reported to 
interact with classical cadherins, albeit under conditions that likely depend on cell type 




heterotrimeric GTPases, adaptor proteins, as well as β-catenin itself (Steinberg and 
McNutt, 1999; Pece et al., 1999; Meigs et al., 2001; Xu et al., 1997).  
 
2.12.1 E-cadherin signaling and Rho family GTPases  
 
The functional relationship between cadherin adhesion and Rho family GTPases was first 
proposed by the observation that several members of this family, including RhoA, Rac1, 
and Cdc42, localized to cadherin-based cell-cell contacts (Braga, 2000). Changes in Rho 
family GTPase activity can accompany the cadherin-dependent formation of cell-cell 
contacts. It was demonstrated that initiation of E-cadherin-mediated cell-cell attachment 
significantly increased in a time-dependent manner the amount of active Cdc42 in MCF-7 
mammary cancer cells (Kim et al., 2000). By contrast, Cdc42 activity was not increased 
under identical conditions in MCF-7 cells incubated with anti-E-cadherin antibodies nor 
in MDA-MB-231 (E-cadherin negative) epithelial cells (Kim et al., 2000). In addition, it 
was shown that induction of cell-cell junctions increased Rac1 activity and this was 
inhibited by E-cadherin function-blocking antibodies (Noren et al., 2001). In another 
study, Rac1 was shown to be colocalized with E-cadherin at sites of cell-cell contact and 
translocate to the cytosol during disruption of E-cadherin-mediated cell-cell adhesion by 
Ca2+ chelation (Nakagawa et al., 2001). The formation of E-cadherin-mediated cell-cell 
adhesion induced Rac1 activation and this activation was inhibited by treatment of cells 
with the E-cadherin functional blocking antibody, or with the inhibitor of PI-3 kinase 
(Nakagawa et al., 2001). In another study, Kovacs et al. reported that homophilic 




Rac signaling (Kovacs et al., 2001). The E-cadherin ligation also recruits PI3-kinase to 
the cadherin complex, leading to the production of phosphatidylinositol 3,4,5-
trisphosphate in nascent cadherin contacts (Kovacs et al., 2001). They also found that Rac 
activation involved an early phase, which was PI3-kinase-independent, and a later 
amplification phase, which was PI3-kinase dependent (Kovacs et al., 2001).  
 
 
2.12.2 Discrimination of E-cadherin-dependent juxtacrine signals and direct E-
cadherin-activated signals  
 
All the studies and results described above could not, however, distinguish between 
signals that arise as direct consequences of E-cadherin ligation (direct E-cadherin 
signaling), and those due to juxtacrine signals that required E-cadherin adhesion to bring 
cell surfaces together but were not themselves direct downstream consequences of E-
cadherin ligation (Yap et al., 1997; Fagotto and Gumbiner, 1996). To overcome this 
problem, the recombinant E- cadherin-specific adhesive ligands were utilized (Kovacs et 
al., 2002; Niessen and Gumbiner, 2002). When presented on planar substrata or coated on 
beads, these ligands support E-cadherin-specific adhesion and recruiting catenins as well 
as regulating the actin cytoskeleton (Brieher et al., 1996; Lambert et al., 2002; Kovacs et 
al., 2002). These reagents therefore present a powerful opportunity to discriminate the 
two cellular effects of E-cadherin. Using this strategy, rapid stimulation of active Rac1 
was observed as E-cadherin-containing cells adhered to substrata coated with ligands for 




to poly-l-lysine, indicating that the rapid change in Rac signaling was a specific 
consequence of E-cadherin ligation, and not due to changes in cell shape concomitant 
upon spreading on planar sustrata (Kovacs et al., 2002). Notably, Rac signaling increased 
within minutes of E-cadherin ligation, a time course comparable to those associated with 
direct pathways activated by growth factors and integrins (Kovacs et al., 2002). 
 
 
2.12.3 How do E-cadherins activate Rho family GTPases? 
 
The mechanism by which E-cadherin activates Rho family GTPases was investigated by 
several studies. The participation of Rho family GTPases in cell signaling depends on 
both their intrinsic capacity to interact with downstream effector molecules and their 
correct subcellular localization (Symons and Settleman, 2000). Emerging evidence 
suggests that classical cadherins can, directly or indirectly, contribute to both these 
processes (Yap and Kovacs, 2003) (Figure 7).  
 
Like other GTPases, Rho proteins cycle between two conformational states, active GTP-
bound and inactive GDP-bound forms. Guanine nucleotide exchange factors (GEFs) are 
major molecules responsible for promoting exchange of GDP for GTP (Schmidt and 
Hall, 2002). Several GEFs might mediate the early activation of Rho family GTPases by 
cadherins. VAV2, which activates Rho, Rac, and Cdc42 (Schmidt and Hall, 2002), can 
interact with p120-ctn, which binds the cytoplasmic tail of classical cadherins (Noren et 




expression and the stability of epithelial adherens junctions (Hordijk et al., 1997). Recent 
evidence suggests that PI3 kinase may act as an upstream activator of Rac in cadherin-
activated signaling. PI3 kinase is capable of activating Rac (Hawkins et al., 1995). 
Cadherin ligation can recruit PI3 kinase to the cadherin complex and stimulate PI3 kinase 
activity (Pece et al., 1999; Kovacs et al., 2002). Moreover, inhibition of PI3 kinase 
activity prevented stimulation of Rac and Cdc42 by E-cadherin (Nakagawa, et al., 2001; 
Kovacs et al., 2002; Kim et al., 2000). However, the process by which PI3 kinase 
activates Rho family proteins remains to be determined. The pleckstrin homology 
domains, which bind phosphatidylinositol lipids and are found in GEFs, have been 
postulated as the link (Reif et al., 1996). In addition, the α-isoform of p21-activated 
kinase-interacting exchange factor, PIX, a GEF for Rac and Cdc42, is activated by PI3-
kinase (Yoshii et al., 1999). 
 
Cadherins may influence the precise sites at the plasma membrane where Rho family 
signaling occurs. Rho family molecules were observed to be localized to adherens 
junctions (Braga, 2000). This may be a consequence of cadherin signaling, especially 
local generation of PIP3 by PI3 kinase (Hansen et al., 2002; Kovacs et al., 2002). In 
addition, it is also possible that proteins of the cadherin-catenin complex can associate 









Figure 7. A model for cadherin-activated Rac signaling participation in early cell–
cell recognition. (A) Productive cadherin ligation in newly forming contacts (1) activates 
Rac signaling at the plasma membrane via a PI3 kinase–dependent intermediary step (2) 
and possibly also a pathway independent of PI3 kinase (3). One key consequence of Rac 
activation is the stimulation of cadherin-directed actin assembly by Arp2/3 (4), thereby 
leading to protrusion of the cell surface (5). (B) Cadherin-directed actin assembly, 
coordinated by Rac activation, is predicted to direct the surface-protrusive activity of the 
actin cytoskeleton toward such nascent contacts, to extend the regions of contact and 
ultimately stabilize cell–cell adhesion (modified from Yap and Kovacs, 2003). 
 
 
Apart from the signaling pathways responsible for cadherin-actin cooperation at the 
plasma membrane, E-cadherin direct signaling pathways may have other effects. For 
example, E-cadherin activated PI3 kinase signaling induced the recruitment to, and 
phosphorylation of Akt (PKB) (Watton and Downward, 1999; Kovacs et al., 2002), an 










Altogether, recent developments firmly establish the principle that E-cadherins function 
both as mediators of cell surface adhesion, and as adhesion-activated cell surface 
receptors.  
 
The increment in HOXA1 expression at full confluence in human mammary carcinoma 
cells (MCF-7) by E-cadherin-activated signaling through Rac1 is detailed in the result 


































Chapter 3  Materials and methods 
 
3.1  Materials 
 
3.1.1  Growth factor, chemicals and reagents 
 
Recombinant human growth hormone (hGH) was a generous gift of Novo-Nordisk 
(Singapore). 17-β-estradiol and bovine serum albumin (BSA) were obtained from Sigma 
Chemical Co. (St. Louis, MO). RPMI 1640 medium and heat-inactivated fetal bovine 
serum were obtained from GIBCO BRL, Life Technologies (Carlsbad, CA). Dulbecco's 
modified Eagle's medium/F-12 medium and horse serum were purchased from Invitrogen 
(Carlsbad, CA). Glutamine, streptomycin, penicillin, ampicillin B, cholera toxin, 
epidermal growth factor were obtained from Upstate Biotechnology (Lake Placid, NY). 
Hydrocortisone was purchased from Calbiochem (La Jolla, CA). Ca2+ - and Mg2+ - free 
phosphate buffered saline solution (PBS) used for cell dissociation were obtained from 
Life Technologies (Grand Is., NY). The EffecteneTM Transfection reagent, RNA isolator 
kit, oligonucleotides, and the One Step RT-PCR kit were obtained from QIAGEN GmbH 
(Hilden, Germany). N-l(2,3-dioleoyloxy) propyl-NNN-trimethylammonium 
methylsulfate (DOTAP) transfection reagent was purchased from Roche Diagnostic 
(Mannheim, Germany). The luciferase assay system was purchased from Promega 
(Madison WI). ECL detection reagents and HybondTM-N Nylon membranes were 
purchased from Amersham Pharmacia Biotech (Little Chalfont, UK) and BrdU staining 




(EGTA), phenylmethylsulfonyl fluoride (PMSF), Hoechst 33528, the E-cadherin function 
blocking antibody, DECMA-1, and 5’-bromo-2´-deoxy-uridine were purchased from 
Sigma Chemical Co (St Louis, MO). Doxorubicin, Bcl-2 inhibitor, and wortmannin (PI-3 
kinase inhibitor) were obtained from Calbiochem (La Jolla, CA).  
 
  
3.1.2  Cell lines 
 
The human mammary gland carcinoma cell line, MCF-7, and the immortalized human 
mammary epithelial cell line, MCF-10A were obtained from the American Type Culture 
Collection (ATCC) (Manassas, VA). MCF-7 cell line was stably transfected with an 
expression plasmid containing the wild-type hGH gene (pMT-hGH) (Liu et al., 1997) 
under the control of the metallothionein 1a promoter (designated MCF7-hGH) (Kaulsay 
et al., 1999). For control purposes the ATG start site in pMT-hGH was disabled via a 
mutation to TTG (stop codon) generated by standard techniques (pMT-MUT) (Liu et al., 
1997), and MCF-7 cells stably transfected with this plasmid were designated MCF7-
MUT (Kaulsay et al., 1999). MCF7-MUT cells therefore transcribe the hGH gene but do 
not translate the mRNA into protein. A detailed description of the characterization of 
these cell lines has been published previously (Kaulsay et al., 1999). MCF-7 and MCF-
10A cell lines were stably transfected with a HOXA1 expression plasmid (pSG5-
HOXA1) (Di Rocco et al., 1997) in a ratio of 5:1 by use of Effectene transfection reagent 
obtained from Qiagen (Hilden, Germany) according to the manufacturer’s instruction. 




for the respective cell lines. Individual colonies were selected to determine the HOXA1 
expression level. Cell lines were established as MCF7-HOXA1 and MCF10A-HOXA1, 
respectively, by pooling five individual colonies.  As controls, the cell lines were also 
stably transfected with the same plasmid which lacks HOXA1 cDNA, named MCF7-
VECTOR and MCF10A-VECTOR respectively. MCF7-HOXA1 and MCF10A-HOXA1 
demonstrated higher levels of HOXA1 mRNA, protein, and transcriptional activity in 
comparison to MCF7-VECTOR and MCF10A-VECTOR (Zhang et al., 2003). A detailed 
description of the characterization of these cell lines has been previously published 
(Zhang et al., 2003).  
 
3.1.3  Antibodies 
 
The anti-β-actin, anti-HOXA1, anti-cyclin D1, anti-α-catenin, anti-β-catenin, and anti-γ-
catenin antibodies used for Western immunoblotting were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA), anti-p27Kip1 and anti- p21waf/cip antibodies from 
Transduction Laboratories (Lexington, KY); and anti-Fas, anti-Fadd, anti-p53, anti-bax, 
anti-bak, anti-bcl-2 and anti-bcl-xl were obtained from Oncogene (San Diego, CA).  
 
 
3.1.4  Plasmids 
 
Plasmids used include a) the expression plasmid containing the hGH gene (pMT-hGH) 




purposes the ATG start site in pMT-hGH was disabled via a mutation to TTG generated 
by standard techniques (pMT-MUT) c) pSG5-HOXA1 was a generous gift of Dr. 
Vincenzo Zappavigna (Milano, Italy) (Di Rocco et al., 1997). d) EphA2-r42B-LUC was a 
generous gift of Dr. Jin Chen (Nashville, TN) (Chen and Ruley, 1998), and e) PBX1 
expression vector is a generous gift of Dr. Vincenzo Zappavigna (Milano, Italy) (Di 
Rocco et al., 1997). f) the Bcl-2 P1 promoter reporter plasmid was a kind gift of Dr. John 
Kurland (Houston, TX) (Kurland et al., 2001). g) the dominantly inhibitory N17 Rac1 
mutant Rac1 (DNRac1) was a gift from Dr. Tom Leong, IMCB, NUS, Singapore. f) 
HOXA1 RNAi was synthesized in IMCB, NUS, Singapore. 
 
3.2  Experiment procedures 
 
3.2.1 Cell culture 
 
MCF-7, MCF7-MUT, MCF7-hGH, MCF7-VECTOR and MCF7-HOXA1 cells were 
cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine at 
37ºC in 5% CO2. MCF-10A, MCF10A-VECTOR, and MCF10A-HOXA1 cells were 
cultured in Dulbecco's modified Eagle's medium/F-12 medium (Invitrogen, Carlsbad, 
CA) supplemented with 5% horse serum (HS) (Invitrogen) plus 2 mM glutamine, 
100 µg/ml streptomycin, 100 IU/ml penicillin, 0.25 µg/ml ampicillin B, 100 ng/ml 
cholera toxin, 20 ng/ml epidermal growth factor, 0.5 µg/ml hydrocortisone, and 10 µg/ml 




carefully for signs of contamination or deterioration. The cell-culture media were 
aspirated completely and cells were washed with PBS. Then 0.10–0.25% trypsin was 
added to trypsinize cells. After the cells were detached from the dish or flask, media 
(containing serum to inactivate the trypsin) were added and cells were dispersed by 
repeated pipetting.  Finally the cells were seeded in new culture dishes or flasks at the 
appropriate concentration.  
 
To freeze and store cells, cells were usually grown to the late log phase and then 
trypsinized as above and counted using a hemocytometer. The freezing media were made 
by diluting dimethyl sulfoxide (DMSO) to 5-10% in growth media. Cells were 
resuspended in freezing media at approximately 1x106-1x107 cells/ml. After the cell 
suspension was dispensed into prelabled ampoules, the ampoules were laid on cotton 
wool in a polystyrene foam box with a wall thickness of ~ 15 mm. (This box, plus the 
cotton wool, provided sufficient insulation such that the ampoules cooled at 1 oC /min 
when the box was placed at -70oC or -90oC in a regular deep freezer.) When the 
ampoules reached -70oC (a minimum of 4-6 h after placing them at -70 oC if starting from 
20 oC ambient temprature), they were transferred to a liquid nitrogen freezer. To thaw 
frozen cells, the ampoules were retrieved from the freezer, and placed in a waterbath at 
37 oC. When the ampoules were thawed, they were swabbed thoroughly with 70% 
alcohol and opened. The contents of the ampoules were transferred to a culture flask with 
media.  
 





Total RNA extraction was performed using Qiagen mini RNA extraction kit. All steps of 
the RNeasy protocol were performed at room temperature. All centrifugation steps were 
performed at 20–25°C in a standard microcentrifuge. 1 x 107 cells were usually used for 
total RNA extraction. Cells grown in a monolayer in cell-culture vessels were either lysed 
directly in the culture vessel (up to 10 cm diameter) or trypsinized and collected as cell 
pellets prior to lysis. For the pelleted cells, 600 µl Buffer RLT (lysis buffer) was added. 
The solution was mixed by vortexing or pipeting. β-Mercaptoethanol (β-ME) was added 
to Buffer RLT before use (10 µl/1ml). For direct lysis of cells grown in a monolayer, 600  
µl Buffer RLT was added to the cell-culture dish. Cell lysates were collected with a 
rubber policeman. Cell lysates were pipeted into a microcentrifuge tube and mixed by 
vortexing or pipeting to ensure that no cell clumps were visible. Three alternative 
methods (a, b, or c) were used to homogenize the sample. a. The lysates were pipeted 
directly onto a QIAshredder spin column placed in a 2 ml collection tube, and centrifuged 
for 2 min at maximum speed. b. Cells were homogenized for 30 s using a rotor–stator 
homogenizer. c. Cell lysates were passed at least 5 times through a 20-gauge needle (0.9 
mm diameter). 70% (600 µl) ethanol was added to the homogenized lysate, and mixed 
well by pipetting. Up to 700 µl of the sample, including any precipitate that may have 
formed, was applied to a RNeasy mini column placed in a 2 ml collection tube. The 
sample was centrifuged for 15 s at ≥8000 x g (≥10,000 rpm). The flowthrough was 
discarded. If the volume exceeded 700 µl, the sample was loaded successively onto the 
RNeasy column, and centrifuged as above. The flow-through was discarded after each 
centrifugation step. Buffer RW1 (700 µl) was added to the RNeasy column, and 




and collection tube were discarded. Then the RNeasy column was transferred into a new 
2 ml collection tube. Buffer RPE (500 µl) was added onto the RNeasy column, and 
centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the column. The flow-through 
was discarded. Another 500 µl Buffer RPE was added to the RNeasy column, and 
centrifuged for 2 min at ≥8000 x g (≥10,000 rpm) to dry the RNeasy silica-gel 
membrane. The RNeasy column was transferred to a new 1.5 ml collection tube.  To 
elute, RNase-free water (30–50 µl) was added to RNeasy silica-gel membrane, and 
centrifuged for 1 min at ≥8000 x g (≥10,000 rpm). DNase digestion was also performed. 
The small residual amounts of DNA remaining were removed using the RNase-Free 
DNase Set (Qiagen) for the optional on-column DNase digestion or by a DNase digestion 
after RNA isolation. 
 
3.2.3 Quantitation, determination of quality, and storage of total RNA 
 
Quantitation of RNA 
 
The concentration of RNA was determined by measuring the absorbance at 260 nm 
(A260) in a spectrophotometer. The cuvettes were washed with 0.1M NaOH, 1 mM 
EDTA, and then washed with RNase-free water. The water was used to zero the 
spectrophotometer. An absorbance of 1 unit at 260 nm corresponds to 40 µg of RNA per 
ml. This relation is valid only for measurements in water. Therefore, dilution of the RNA 
sample was done in water.  
 





The ratio of the readings at 260 nm and 280 nm (A260/A280) provides an estimate of the 
purity of RNA with respect to contaminants that absorb in the UV, such as protein. Pure 
RNA has an A260/A280 ratio of 1.9–2.1. RNA quality was assessed by denaturing 
formaldyhyde agarose (FA) gel electrophoresis and ethidium bromide staining.  
 
Formaldehyde agarose (FA) gel electrophoresis 
 
FA gels (1.2% agarose) of size 10 x 14 x 0.7 cm were prepared by mixing 1.2 g agarose, 
10 ml 10x FA gel buffer (see composition below), and adding RNase-free water to 100 
ml. The mixture was heated to melt the agarose, and cooled to 65°C in a water bath. Then 
the mixture was mixed with 1.8 ml of 37% (12.3 M) formaldehyde and 1 µl of a 10 
mg/ml ethidium bromide stock solution. The agarose was mixed thoroughly and poured 
onto the gel support. Prior to running the gel, the gel was equilibrated in 1x FA gel 
running buffer (see composition below) for at least 30 min. One volume of 5x loading 
buffer (see composition below) was added per 4 volumes of RNA sample (for example 
10 µl of loading buffer and 40 µl of RNA). The RNA sample was incubated for 3–5 min 
at 65°C, chilled on ice, and loaded onto the equilibrated FA gel. Gel was run at 5–7 V/cm 
in 1x FA gel running buffer. The respective ribosomal bands should appear as sharp 
bands on the stained gel. Twenty-eight S ribosomal RNA bands should be present with an 
intensity approximately twice that of the 18S RNA band. If the ribosomal bands in a 
given lane were not sharp, but appeared as a smear of smaller sized RNAs, it was likely 




Composition of FA gel buffers 
10x FA Gel buffer 
200 mM 3-[N-morpholino]propanesulfonic acid (MOPS) (free acid) 
50 mM sodium acetate 
10 mM EDTA 
pH to 7.0 with NaOH 
 
1x FA Gel Running Buffer 
100 ml 10x FA gel buffer 
20 ml 37% (12.3 M) formaldehyde 
880 ml RNase-free water 
 
5x RNA Loading Buffer 
16 µl saturated aqueous bromophenol blue solution 
80 µl 500 mM EDTA, pH 8.0 
720 µl 37% (12.3 M) formaldehyde 
2 ml 100% glycerol 
3084 µl formamide 
4 ml 10 x FA gel buffer 








Storage of total RNA 
RNA samples with high quality were stored at -80 °C for further analysis.  
 
3.2.4 Reverse transcriptase-polymerase chain reaction (RT-PCR) 
 
Reverse transcription and PCR were carried out sequentially in the same tube by use of 
the Qiagen OneStep RT-PCR Kit. All components required for both reactions were added 
during setup. RT-PCR was performed in a final volume of 50 µl containing 0.2 µg of 
tRNA template, 0.6 µM gene-specific primers, 2 µl of enzyme mix, 400 µM of each 
dNTP, 1× reaction buffer, and 1× Q-Solution. All reactions were set up on ice. An 
RNase-free environment was maintained during reaction setup. Briefly, RNA template 
was reverse-transcribed into cDNA for 30 min at 50 °C; Hotstart Taq DNA polymerase 
was activated by heating for 15 min at 95 °C; the denatured cDNA templates were 
amplified by the following cycles: 95 °C/30 s, 60 °C/30 s, and 72 °C/60 s. A final 
extension was performed for 8 min at 72 °C. Fifteen to 40 cycles of PCR were 
performed, and the amplified β-actin cDNA served as an internal control for cDNA 
quantity and quality. All RNA samples were treated with DNaseI to avoid genomic DNA 
contaminations. 
 
Sequences of the oligonucleotide primers used for RT-PCR are as follows: 
 





Sense       5'-GGGAAAGTTGGAGAGTACGGC-3'; 
Antisense 5'-CCTCAGTGGGAGGTAGTCAG-3';  
Amplification yielded a 359 bp cDNA product.  
 
 b) β-actin sequences:   
 
Sense         5'-ATGATATCGCCGCGCTCG-3'; 
Antisense   5'-CGCTCGGTGAGGATCTTCA-3'.  
Amplification yielded a 564bp cDNA product.  
 
 
c) Bcl-2 sequences: 
 
Sense         5'-TGCACCTGAC GCCCT TCAC-3'; 
Antisense   5'-TAGCTGATTCGACGTTTTGCCTGA-3'. 
Amplification yielded a 484bp cDNA product. 
 
Amplified PCR products were visualized on a 1% agarose gel.  
 
3.2.5 Agarose gel electrophoresis   
 
The gel (1%, 50mL volume) was made by mixing 0.5g agarose and 50mL 0.5xTBE  into 




heated solution was left to cool on the bench for 5 minutes down to about 60°C. While 
the agarose was cooling, gel tank was prepared on a level surface. Ethidium bromide (1 
µl of 10mg/mL) was added to the agarose and swirled to mix. Then the gel was poured 
slowly into the tank. The bubbles were pushed away to the side by using a disposable tip. 
The comb was inserted. The gel was left to set for at least 30 minutes, preferably 1 hour. 
Usually 0.5 x TBE buffer (running buffer, see composition below) poured into the gel 
tank to submerge the gel to 2–5mm depth. The DNA samples were mixed with loading 
buffer (see composition below) and then loaded to the gel. The first well of the gel was 
loaded with marker. The gel was stopped when the bromophenol blue (in the loading 
buffer) ran 3/4 the length of the gel. The gel was carried to the dark-room to look at on 
the UV light-box, and photographs were taken properly.  
Recipe for 2L of 10xTBE  
218g Tris base  
110g Boric acid  
 9.3g EDTA  
Loading buffer 
25mg bromophenol blue or xylene cyanol  
4g sucrose  







3.2.6 Transient transfection and luciferase reporter assay for EphaZ-r42B and Bcl-2  
          promoter constructs 
 
MCF-7, MCF7-MUT, MCF7-hGH, MCF7-VECTOR, MCF7-HOXA1, MCF10A-
VECTOR, and MCF10A-HOXA1 cells were cultured in 6-well plates the day before 
transfection. The cells were incubated at 37ºC in 5% CO2, and grew to 50% or 80% 
confluence on the day of transfection. Transient transfection was performed in serum-free 
media with EffecteneTM according to the manufacturer's instructions. Firstly, 0.2 µg of 
the respective luciferase construct was dissolved in TE buffer, pH 7 to pH 8. Then 8 µl 
Enhancer was addedand and mixed by vortexing for 1 s. After incubating at room 
temperature (15–25°C) for 2–5 min, the mixture was spun down for a few seconds to 
remove drops from the top of the tube. Effectene Transfection Reagent (25 µl) was added 
to the DNA-Enhancer mixture and mixed by pipetting up and down 5 times, or by 
vortexing for 10 s. The samples were incubated for 5–10 min at room temperature (15–
25°C) to allow transfection-complex formation. Growth medium (1 ml) was added to the 
tube containing the transfection complexes, and mixed by pipetting up and down twice. 
The transfection complexes were added onto the cells in 6-well plates. Transfected cells 
were incubated in serum-free media for 12 h before the media were changed to fresh 
serum-free media with or without 50 nM hGH and 10% FBS or 5% HS. After a further 
24 h, cells were washed with PBS and scraped into lysis buffer (25 mM Tris phosphate, 
pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N’,N’,-tetraacetic acid, 10% 
glycerol, and 1% Triton X-100). Luciferase assays were performed using a luminometer 




mg/ml D-luciferin, 10 mM DTT, 1 mg/ml bovine serum albumin (BSA), 10 mM 
magnesium acetate, 0.1 M Tris acetate, pH 7.75, and 2 mM EDTA. Luciferase 
measurements were initiated by injecting 30 µl of 5 mM ATP, 0.5 mM sodium 
pyrophosphate and continued for 30 s. The integrated signal was taken as representative 
of luciferase activity. The protein contents of the samples were normalized and luciferase 
assays were performed. Results were normalized to the level of β-galactosidase activity 
to control for transfection efficiency (Wood et al., 1995). 
 
3.2.7 Western Blot analysis 
 
MCF-7, MCF7-MUT, MCF7-hGH, MCF7-VECTOR, MCF7-HOXA1, MCF10A-
VECTOR, and MCF10A-HOXA1 cells were grown to 60% or 100% confluence and 
serum-deprived for 12 h and then cultured in serum-free media or in serum-free media 
supplemented with 50 nM hGH, 10% FBS, 5% HS, Doxorubicin, Bcl-2 inhibitor, EGTA, 
wortmannin or DECMA-1. After 24 hours cells were washed once in ice-cold 1x PBS 
and lysed at 4°C in lysis buffer (50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 150 mM 
NaCl, 1 mM EGTA, 1 mM EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 
0.2% phenylmethylsulfonyl fluoride) for 30 min with regular vortexing. Cell lysates were 
then centrifuged at 4°C at 14000 x g for 15 min, the resulting supernatants were 
collected, and protein concentration determined in triplicate by the Lowry protein assay 
method, using BSA as a standard. Equal amounts of proteins were used in each 
experiment. Remaining protein samples could be stored at -80 °C for further analysis. 5x 




bromphenol blue) was added to 20 µg of total protein, boiled for 10 min, and centrifuged 
at 14000 x g for 5 min. Proteins were separated by 10% SDS-PAGE (1.5 M Tris-HCL, 
pH 8.8, 20% (w/v) SDS, acrylamide/bis-acrylamide (30%/0.8% w/v), 10% (w/v) 
ammonium persulfate, 0.05% TEMED) in 1x Laemlli running buffer (5x Laemllu 
running buffer: 120 mM tris[hydroxymethyl]methylamine, 960 mM glycine, 17 mM 
sodium dodecyl sulphate [SDS]). Proteins were then transferred to nitrocellulose 
membrane using a standard semidry electroblotting apparatus in Laemlli buffer (23 mM 
Tris[hydroxymethyl]methylamine, 19 mM glycine, 0.64 mM SDS) containing 10% 
methanol. Subsequently, nitrocellulose membranes were blocked with 5% non-fat dry 
milk in phosphate buffered saline with 0.1% Tween 20 (PBST) for 2 h at 22 °C and then 
washed twice for 5 min each in PBST. The blots were then treated for 1 h at 22 °C with 
the primary antibodies (HOXA1 at 1:500 and β-actin, cyclin D1, p27Kip1, p21waf/cip,  Fas, 
Fadd, p53, bax, bak, bcl-2, bcl-xl, α-catenin, β-catenin, γ-catenin at 1:1000) in PBST 
containing 1% non-fat dry milk. After 3 washes for 15 min each in PBST, membranes 
were incubated in goat anti-mouse (1:1000), goat anti-rabbit IgG (1:1000) or donkey anti-
goat (1:1000) horseradish peroxidase-conjugated second antibodies in PBST containing 
1% non-fat dry milk for 1 h at 22 °C. Membranes were further washed 3 times for 15 min 
each in PBST before immunolabeling was detected using the enhanced 
chemiluminescence (ECL) system according to the manufacturer’s instruction. Reprobing 
of the membranes was performed after stripping in buffer containg 20 mM Tris-HCL, pH 
6.8, 2% SDS, and 100mM β-mercaptoethanol and incubated at 70°C for 30 min.  
 





Mitogenesis was directly assayed by measuring the incorporation of BrdU (Kaulsay et al., 
2001). For incorporation of BrdU, subconfluent or confluent MCF-7, MCF7-MUT, 
MCF7-hGH, MCF7-VECTOR, MCF7-HOXA1, MCF10A-VECTOR, and MCF10A-
HOXA1 cells were washed twice with PBS and seeded to glass coverslips in either 
serum-free medium or serum-free medium supplemented with 50 nM hGH, 10% FBS, or 
5% HS for 24 h. The cells were pulse-labeled with 20 mM BrdU for 30 min, washed 
twice with PBS, and fixed in cold 70% ethanol for 30 min. After that, the cells were 
washed in 3 changes of distilled water, and BrdU detection was performed by using the 
BrdU staining kit (Zymed, South San Francisco, CA) according to the manufacturer's 
instructions. Briefly, the cells were firstly incubated with denaturing solution for 30 min 
and rinsed in PBS (2 min, 3 times). Then blocking solution was added to the cells (30 
min, room temperature) and blotted off. The cells were incubated with biotinylated 
mouse anti-Brdu (30-60 min, room temperature), and streptavidin-peroxidase (10 min, 
room temperature) successively, and rinsed with PBS (2 min, 3 times). Sufficient 
quantity of the DAB mixture was added to cover the cells (4 min), and rinsed well with 
distilled water. The specimen was counterstained with hematoxylin, and washed in tap 
water, and then put into PBS until sections turn blue (approx. 30 seconds). Finally, the 
slides were dehydrated in a graded series of alcohol, and cleared with xylene. The slides 
were examined after adding 2 drops of histomount and coverslip. A total population of 
over 3 times 300 cells was analyzed in several arbitrarily chosen microscopic fields to 





3.2.9  Use of Bcl-2 antisense oligonucleotide to deplete cellular Bcl-2 
 
The Bcl-2 sense and antisense oligonucleotides utilized were obtained from Calbiochem. 
Bcl-2 (Sense) 5’-TACCGCGTGCGACCCTCT-3’;  
(antisense) 5’-TCTCCCAGCGTGCGCCAT-3’;  
 
Cells were cultured for 24 hours in serum free medium and then transfected with 800 nM 
Bcl-2 sense and antisense oligonucleotides in DOTAP (10 µl/ml medium). Briefly, the 
oligonucleotides were mixed with DOTAP gently by carefully pipetting several times. 
The mixtures were incubated at room temperature for 15-20 min, and added onto the cells 
in 6-well plates. The cells were incubated with the complex for 8 hours at 37°C in a CO2 
incubator. Cells were either lysed and processed as described above for Western blot 
analysis or processed for measurement of apoptosis. 
 
3.2.10 Measurement of apoptosis 
 
Apoptotic cell death was measured by fluorescent microscopic analysis of cell DNA 
staining patterns with Hoechst 33258. MCF-7, MCF7-MUT, MCF7-hGH, MCF7-
VECTOR, MCF7-HOXA1, MCF10A-VECTOR, and MCF10A-HOXA1 cells were 
trypsinized with 0.5% trypsin and washed twice with serum-free medium. The cells were 
then seeded to glass cover slips in 6-well plates and incubated in serum-free medium with 
or without 50 nM hGH, 10% FBS, doxorubicin, Bcl-2 inhibitor, Bcl-2 antisense, 




min in 4% paraformaldehyde in 1X PBS, pH 7.4, at room temperature. The cells were 
then rinsed twice in PBS and stained with the karyophilic dye Hoechst 33258 (20 µg/ml) 
for 5 min at room temperature. Following washing with 1X PBS, nuclear morphology 
was examined under an ultrraviolet-visible fluorescence microscope (Zeiss Axioplan). 
Apoptotic cells were distinguished from viable cells by their nuclear morphology 
characterized by nuclear condensation and fragmentation as well as the higher intensity 
of the blue fluorescence of the nuclei. For statistical analysis, 3 times 300 cells were 
counted in eight random microscopic fields at 400× magnification.  
 
3.2.11 Determination of anchorage-dependent and -independent growth of  
           transfected cells  
 
MCF7-VECTOR, MCF7-HOXA1, MCF10A-VECTOR, and MCF10A-HOXA1 cells (5 
x 104) were seeded into 6-well plates in monolayers in serum-free media or in serum-free 
media supplemented with either 50 nM hGH or 10% FBS. After 48 h, media were 
aspirated, and cells were washed with PBS. Then the cells were trypsinized by adding 
0.10–0.25% trypsin in PBS. After cells detached from the dish or flask, media 
(containing serum) were added to inactivate the trypsin. Cell numbers were determined 
using a hemocytometer. MCF7-VECTOR and MCF7-HOXA1 cells (5 x 104) in 
suspension culture were grown in 30-mm plastic bacteriological dishes (Sterilin, 
Teddington, United Kingdom). On the days indicated, cells were harvested and counted 
as for monolayers. For soft agar colony formation assay, three layers were prepared. 1. 




waterbath. 2X RPMI with 20% FBS was warm to 40oC in waterbath. At least 30 minutes 
were needed for temperature to equilibrate. Equal volumes of the two solutions were 
mixed to give 0.5% agar + 1X RPMI + 10% FBS. 1.5 ml base agar was added to each 
well (6-well plate) and allowed to set. The plates can be stored at 4oC for up to 1 week. 2. 
Top agar layer. 0.7% agar (DNA grade agarose) was melted in microwave, and cooled to 
40oC in a waterbath. (It is important not to exceed 40oC, otherwise cells can be killed). 
2X RPMI with 20% FBS was also warmed to the same temperature. Equal volumes of 
the two solutions were mixed to give 0.35% agar + 1X RPMI + 10% FBS. MCF7-
VECTOR and MCF7-HOXA1 cells were trypsinized, counted, and seeded with 1.5 ml 
top agar onto the base agar (5 x 103 cells/well). 3. Top layer.  Medium was added to 
prevent drying of the agarose gels. The MCF10A-VECTOR and MCF10A-HOXA1 cells 
in soft agar colony assay were same with the process above except that the medium 
changed to DMEM-F12 containing appropriate components described in cell culture 
above, and 1 x 104 cells were seeded to the top agar layer of the soft agar. The plates 
were incubated at 37oC in humidified incubator for 9 days for MCF7-VECTOR and 
MCF7-HOXA1 cells and 14 days for MCF10A-VECTOR and MCF10A-HOXA1, after 
which the cultures were stained (1.5ml of 0.005% crystal violet for >1 hour), counted, 
and photographed. 
 
3.2.12 Xenograft studies 
 





Nude mice and severe combined immunodeficient (SCID) mice models were used as host 
animals for xenograft studies. The two species were used because the significant 
differences in their recipient to tumor cells. Although nude mice have been used for many 
years to grow various human tumors, nude mice and thymectomized mice can regain 
immune competence and ultimately reject the tumor after some time (Gerald et al., 1991).  
SCID mice are characterized both by T- and B-cell deficiency (Bosma et al., 1983). SCID 
mice have enhanced take rates for tumors compared to genetically athymic nude mice, 
which are T-cell deficient (Giovanella et al., 1974), and also compared to neonatally 
thymectomized mice (Gerald et al., 1991).  
 
Four- to 6-week-old pathogen-free nude mice and SCID mice were purchased from the 
animal holding facility of the National University of Singapore. The mice were 
acclimated for 7–10 days after purchase. All the mice were housed and bred in specific 
pathogen-free conditions at constant temperature (24-26oC) and humidity (30-50%). 
Autoclaved standard chow and water were given ad libitum. On the day of implantation, 
the mice were anaesthetised in the animal laboratory.  
 
3.2.12.2 Cells preparation and implantation 
 
MCF10A-VECTOR, and MCF10A-HOXA1 were cultured in Dulbecco's modified 
Eagle's medium/F-12 medium supplemented with 5% horse serum plus 2 mM glutamine, 
100 µg/ml streptomycin, 100 IU/ml penicillin, 0.25 µg/ml ampicillin B, 100 ng/ml 




insulin at 37ºC in 5% CO2. After the cells were grown to the log phase, they were 
trypsinized as detailed in the cell culture section above and counted using a 
hemocytometer. Cells were then re-suspended in cold PBS or matrigel (5 x 107 cells per 
ml), and the suspension was dispensed into prelabled ampoules and placed on ice. After 
implantation, the viability of the remaining cells in excess ampoules was examined by 
trypan blue exclusion. One drop of cell suspension was mixed with one drop of trypan 
blue and loaded to the counting chamber of the hemocytometer. After 1-2 min, the cell 
viability was examined under a microscope (10 x objective) to ensure that the time lag 
from sequential implantation did not significantly affect cell viability and cell number.  
 
In the first series of s.c. implantation, 0.1 ml (5 x 106) vector- or HOXA1-transfected 
MCF-10A cells were injected into the first mammary (axillary) fat pad of nude mice 
using a 100 µl syringe and a 23-gauge needle. In the second series of implantation, 0.1 ml 
(5 x 106) vector- or HOXA1-transfected MCF-10A cells were injected into the first 
mammary (axillary) fat pad of SCID mice using a 100 µl syringe and a 23-gauge needle. 
The SCID mice simultaneously received a 60-day release pellet containing 0.72 mg of E2 
(Sigma) as previous investigators have shown that without estrogen involvement, breast 
tumors fail to grow in immunodeficient mice (Brunner et al., 1987; Lippman et al., 1987; 
Phillips et al., 1989). Ten mice were used for each group. The positive controls (nude 
mice and SCID mice implanted with human mammary carcinoma cells, MCF-7) and 
negative controls (nude mice and SCID mice implanted with untransfected MCF-10A 





3.2.12.3  Tumor growth and autopsy 
 
The presence of tumours was checked every second day by tactile inspection of the axilla 
of every mouse. At about 2 or 3 weeks after implantation, the animals were killed by 
cervical dislocation. Immediately afterwards, an autopsy of the mice was performed. 
Primary tumors and all organs were evaluated macroscopically for the presence of 
tumors. Tumor volume was calculated using the formula, volume = (d1 x d2 x d3) x 
0.5236, in which dn represents the three orthogonal diameter measurements, measured 
with callipers.  
 
3.2.12.4  Histology 
 
Tissue samples of the primary tumor and organs were dissected, fixed in phosphate-
buffered 4% paraformaldehyde, dehydrated, embedded in paraffin casts, cut in 6-µm-
thick sections and stained with haematoxylin and eosin (H-E) for histopathological 
examination. Haematoxylin and eosin (H-E) staining followed standard procedures 
Solutions were prepared for the staining including 95% ethanol, 100% ethanol, xylene, 
0.1% ammonium hydroxide, H2O, hematoxylin, and eosin. The developed slides were 
stained for 20 to 30 sec in hematoxylin, and rinsed two times in water. After quickly 
incubated with 0.1% ammonium hydroxide and washed in water, the slides were stained 
for 20 to 30 sec in eosin. The slides were then progressively dehydrated in 95% ethanol, 






To freeze the biopsies, the tumors were chopped into about 3-4 mm pieces, and placed in 
ampoules. The ampoules with the tumors were then transferred to -70 oC freezer or 
liquid-nitrogen freezer.   
 
3.2.13 Calcium switch 
 
For calcium switch experiments, MCF-7 cells were seeded into dishes, cultured for 24 
hours, and then the cells were serum starved. After 24 hours incubation, E-cadherin-
mediated cell-cell contacts were disrupted by treatment with 4 mM EGTA at 37oC for 30 
minutes. Thereafter, intercellular contacts were allowed to reform in the presence of 
normal Ca2+ containing medium (CaCl2~ 1.8 mM) at 37 oC at various time points with or 
without E-cadherin function-blocking antibodies (DECMA clone-1 at 1:100 dilution) 
(Sigma-Aldrich). 
 
3.2.14 E-cadherin cell adhesion assays (hE/Fc experiments) 
 
The recombinant protein (hE/Fc) consisting of the complete ectodomain of human E-
cadherin fused to the Fc region of IgG was the generous gift of Dr. Alpha Yap (Brisbane, 
Australia) (Kovacs et al., 2002). Substrata adsorbed with hE/Fc supported E-cadherin-
specific adhesion and contact formation (Kovacs et al., 2002). Using this model, E-
cadherin engagement is induced without cell-cell contact (Kovacs et al., 2002). For hE/Fc 




(50µg/ml) for 2 h at room temperature.  Blocking of non-specific binding sites was 
performed with 1% BSA in Hanks Balanced Salt solution supplemented with 5 mM 
CaCl2 for 1h and 30min at room temperature.  Dishes were washed 5 times before 
addition of cells. MCF-7 cells were washed once with 10mM EDTA in Hanks/ CaCl2 for 
1 min and directly trypsinized in 0.01% crystalline trypsin in Hanks/CaCl2 for 15 min at 
37 oC. MCF-7 cells were then washed with Hanks/CaCl2 and resuspended in 
Hanks/CaCl2 supplemented with 0.05% FCS, seeded onto the 10 cm dishes and incubated 
at 37 oC. Thirty minutes after seeding, non-adhered cells were carefully removed by 
exchange of media. Five hours after seeding the cells onto the dishes, RNA and protein 





All experiments were repeated at least three to five times. All numerical data are 





















4.1                       Human growth hormone-regulated HOXA1 is a human mammary    
                            epithelial oncogene 
 
The upregulation of HOXA1 gene by autocrine production of hGH was addressed in this 
series of studies. The studies also investigated the role of HOXA1 in human mammary 
carcinoma cells (MCF-7) and the immortalized but not transformed human mammary 
epithelial cells (MCF-10A). Increased epithelial expression of the hGH gene is associated 
with the acquisition of pathological proliferation, and the highest level of hGH gene 
expression is observed in metastatic mammary carcinoma cells (Raccurt et al., 2002). 
One major mechanism by which GH affects cellular and somatic function is by regulating 
the level of specific mRNA species (Isakasson et al., 1985). cDNA microarray analyses 
have previously been utilized to identify genes regulated by autocrine production of hGH 
in human mammary carcinoma cells (MCF-7) (Mertani et al., 2001). One gene 
demonstrated to be upregulated by autocrine hGH in MCF-7 cells was the homeobox 
containing transcription factor HOXA1 (Mertani et al., 2001). Alterations of HOX 
expression have been detected in a variety of human tumours (Cillo et al., 1992; Celetti et 
al., 1993), including those of the mammary gland (Care et al., 1998; Raman et al., 2000). 
Hoxa1 was expressed only in cancerous but not in normal or precancerous mouse 
mammary tissue (Friedmann et al., 1994), suggesting that it may play a role in 





Autocrine hGH production by human mammary carcinoma cells increased the expression 
and transcriptional activity of HOXA1. Forced expression of HOXA1 in human 
mammary carcinoma cells resulted in increased total cell number primarily by the 
promotion of cell survival mediated by the transcriptional upregulation of Bcl-2. HOXA1 
also abrogated the apoptotic response of mammary carcinoma cells to doxorubicin. 
Forced expression of HOXA1 in mammary carcinoma cells, in a Bcl-2-dependent manner, 
resulted in dramatic enhancement of anchorage-independent proliferation and colony 
formation in soft agar. Finally, forced expression of HOXA1 was sufficient to result in 
the oncogenic transformation of immortalized human mammary epithelial cells with 
aggressive in vivo tumor formation in severe combined immunodeficient mice (SCID 


















4.1.1                  Autocrine hGH stimulation of mammary carcinoma cells increases  
                          HOXA1 mRNA, protein, and transcriptional activity 
 
HOXA1 had previously been identified by cDNA microarray analysis as an autocrine 
hGH-regulated gene in human mammary carcinoma cells (Mertani et al., 2001). To verify 
the autocrine hGH-dependent upregulation of HOXA1 mRNA observed by cDNA array 
screening in mammary carcinoma cells, the level of HOXA1 mRNA in MCF7-MUT and 
MCF7-hGH cells was examined by semi-quantitative RT-PCR.  
 
Figure 4.1.1 A shows the RT-PCR products on an agarose gel. One amplified fragment 
of the predicted size (359 bp) appropriate for HOXA1 mRNA was detected in MCF7-
MUT and MCF7-hGH cells. Autocrine production of hGH by MCF7-hGH cells resulted 
in an increased level of HOXA1 mRNA in comparison to MCF7-MUT cells. Exogenous 
hGH and FBS also increased HOXA1 mRNA in MCF7-MUT cells and potentiated the 
increased level of HOXA1 mRNA observed in MCF7-hGH cells due to autocrine 
production of hGH. The level of β-actin mRNA did not differ between the two cell lines 
under the different treatment conditions and was used as a control for RNA quality 
(Figure 4.1.1 A). 
 
To determine if the autocrine hGH-stimulated increase in HOXA1 mRNA also resulted in 




from MCF7-MUT and MCF7-hGH cells by Western blot analysis. Figure 4.1.1 B shows 
that both the 33-kDa and the 35-kDa forms of HOXA1 were detected in lysates from 
MCF7-MUT and MCF7-hGH cells with increased HOXA1 protein observed in MCF7-
hGH cells. FBS also increased the level of HOXA1 in MCF7-MUT cells and potentiated 
the level of HOXA1 in MCF7-hGH cells. Exogenous hGH did not stimulate an increase 
in HOXA1 protein in MCF7-MUT cells and only minimally enhanced the level in 
MCF7-hGH cells (Figure 4.1.1 B). 
 
To determine if the autocrine hGH-stimulated increase in HOXA1 protein also resulted in 
increased HOXA1-mediated transcription, we examined luciferase reporter activity from 
the EphA2-r42B enhancer which contains four HOX-PBX binding sites (Chen and Ruley, 
1998). Figure 4.1.1C shows that autocrine production of hGH by MCF7-hGH cells 
resulted in increased luciferase activity from the EphA2-r42B enhancer compared with 
MCF7-MUT cells indicative of increased HOXA1 transcriptional activity. Transient 
transfection of HOXA1 cDNA increased HOXA1 transcriptional activity in MCF7-MUT 
cells and dramatically enhanced the already greater HOXA1 transcriptional response in 
MCF7-hGH cells. Transient transfection of MCF7-MUT cells with cDNA for the HOX 
binding partner PBX1 was without effect, whereas transient transfection of PBX1 cDNA 
dramatically increased HOXA1-mediated transcription in MCF7-hGH cells. Transient 
transfection of MCF7-MUT cells with both HOXA1 and PBX1 cDNAs resulted in a 
robust transcriptional response through the EphA2-r42B enhancer. Transient transfection 
of MCF7-hGH cells with both PBX1 and HOXA1 cDNAs synergistically increased 




PBX1 alone (Figure 4.1.1 C). Thus, autocrine hGH production by mammary carcinoma 
cells result in increased HOXA1-mediated transcriptional activity.  
A                                      
 
Figure 4.1.1 (A)    Effect of autocrine hGH on HOXA1 mRNA in mammary 
carcinoma cells. MCF7-MUT and MCF7-hGH cells were cultured in serum-free 
media or in serum-free media supplemented with either 50 nM hGH or 10% FBS. 
Experiments were performed as described under “Experimental Procedures.” The 
level of HOXA1 mRNA was determined by RT-PCR as indicated. β-Actin was used 
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Figure 4.1.1 (B)    Effect of autocrine hGH on HOXA1 protein in mammary 
carcinoma cells. MCF7-MUT and MCF7-hGH cells were cultured in serum-free 
media or in serum-free media supplemented with either 50 nM hGH or 10% FBS. 
Experiments were performed as described under “Experimental Procedures.” The 
level of HOXA1 protein was determined by Western blot analysis as indicated. β-
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Figure 4.1.1 (C)      Effect of autocrine hGH on HOXA1 transcriptional activity 
in mammary carcinoma cells. MCF7-MUT and MCF7-hGH cells were cultured in 
serum-free media or in serum-free media supplemented with either 50 nM hGH or 
10% FBS. Experiments were performed as described under “Experimental 
Procedures.” The level of HOXA1 transcriptional activity was determined by 














































4.1.2          Forced expression of HOXA1 in human mammary carcinoma cells  
                  results in increased total cell number 
 
To determine the functional consequences of the autocrine hGH-stimulated increased 
HOXA1 expression in mammary carcinoma cells we generated a mammary carcinoma 
cell line (MCF-7) with increased expression of HOXA1 by stable transfection of HOXA1 
cDNA (termed MCF7-HOXA1). Figure 4.1.2 A shows the RT-PCR results which 
demonstrated clearly the increased expression of HOXA1 mRNA in MCF7-HOXA1 cells 
compared with vector-transfected (MCF7-VECTOR) cells. Figure 4.1.2 B shows the 
Western blot results of the same cells and demonstrated higher levels of HOXA1 protein 
in MCF7-HOXA1 compared with MCF7-VECTOR cells.  
 
Analysis of HOXA1 transcriptional activity by use of the EphA2-r42B enhancer 
demonstrated increased HOXA1-mediated transcriptional activity in MCF7-HOXA1 
cells compared with MCF7-VECTOR cells under serum-free conditions or when 
stimulated with exogenous hGH or FBS (Figure 4.1.2C). Transient transfection of cDNA 
for the HOXA1 binding partner PBX1 in MCF7-VECTOR cells did not alter the level of 
HOXA1-mediated transcriptional activity under serum free conditions or exogenous hGH 
stimulation and only slightly enhanced HOXA1-mediated transcriptional activity of 
MCF7-VECTOR cells in serum. In contrast, transient transfection of PBX1 cDNA in 




HOXA1-mediated transcription as a result of forced expression of HOXA1 (Figure 
4.1.2C). 
We therefore examined the effect of forced expression of HOXA1 in mammary 
carcinoma cells on total cell number. MCF7-VECTOR and MCF7-HOXA1 cells were 
plated in identical number under serum-free conditions and with either 50 nM exogenous 
hGH or 10% FBS, and the cell number was determined after 48 hours. Exogenous hGH 
stimulated an increase in MCF7-VECTOR cell number as did FBS (although to a greater 
extent). MCF7-HOXA1 cells cultured in serum-free media increased in number 
dramatically more than MCF7-VECTOR cells (Figure 4.1.2 D). Exogenous hGH and 
FBS also increased cell number in MCF7-HOXA1 above that observed in serum free 
conditions but similar to the percentage increases observed with hGH and FBS 
stimulation of MCF7-VECTOR cells. In any case, forced expression of HOXA1 in 
mammary carcinoma cells resulted in a significant increase in cell number.  
 
Increased cell number is achieved by either increased proliferation or decreased apoptotic 
cell death, and we therefore proceeded to determine the relative contribution of these 
processes to the observed increase in cell number as a consequence of forced expression 
of HOXA1. 
  
The D family of cyclins is pivotal to initiate progression through the G1 phase of the cell 
cycle (Sherr, 1995). Cyclin D1 is the predominant member of this family expressed in 
mammary gland (Musgrove et al., 1996) and it was also demonstrated that cyclin D1 is 




(Graichen et al., 2002). Therefore the level of cyclin D1 protein was examined in MCF7-
VECTOR compared with MCF7-HOXA1 cells. The level of cyclin D1 protein was 
increased in MCF7-HOXA1 compared with MCF7-VECTOR cells (Figure 4.1.2 E) 
under serum-free conditions. Both exogenous hGH and FBS increased cyclinD1 protein 
in MCF7-VECTOR cells and accentuated the increase in cyclinD1 observed upon forced 
expression of HOXA1 in MCF7-HOXA1 cells (Figure 4.1.2 E). We consequently also 
examined the expression of the cyclin-dependent kinase (cdk) inhibitor p21waf1/cip1 in 
MCF7-VECTOR and MCF7-HOXA1 cells. MCF7-HOXA1 cells exhibited a marked 
decrease in p21waf1/cip1 protein in comparison to MCF7-VECTOR cells (Figure 4.1.2 E). 
We next examined the protein level of the cdk inhibitor p27Kip1. Decreased expression of 
p27Kip1 is associated with G1/S phase transition (Sgambato et al., 2000). The level of 
p27Kip1 was not altered between MCF7-VECTOR and MCF7-HOXA1 cells (Figure 4.1.2 
E) under the conditions studied. Equal loading of the cell extracts was verified by 
reprobing the stripped membrane for β-actin (Figure 4.1.2 E). To determine the effects of 
forced expression of HOXA1 on cell cycle progression in MCF7-VECTOR and MCF7-
HOXA1 cells, we examined the nuclear incorporation of 5’-bromo-2’-deoxyuridine 
(Brdu) in these cells. Although MCF7-HOXA1 cells exhibited a significantly higher 
percentage of nuclear BrdU incorporation compared with MCF7-VECTOR cells (Figure 
4.1.2 F) the differences were small and could not account for the observed differences in 
total cell number between MCF7-VECTOR and MCF7-HOXA1 cells.  
 
We therefore examined the effect of forced expression of HOXA1 on a variety of 




did not differ between MCF7-VECTOR and MCF7-HOXA1 cells under serum-free 
conditions nor with stimulation by either exogenous hGH or FBS (Figure 4.1.2 G). The 
level of p53 did not differ between MCF7-VECTOR and MCF7-HOXA1 cells in serum- 
free media nor by stimulation with exogenous hGH but was dramatically reduced in both 
cell lines in the presence of FBS. Interestingly however, the level of Bcl-2 was 
dramatically increased in MCF7-HOXA1 cells compared with MCF7-VECTOR cells in 
serum-free media, and the level of Bcl-2 was even further increased in MCF7-HOXA1 
cells in the presence of FBS. Apoptotic cell death was also dramatically reduced in 
MCF7-HOXA1 cells compared with MCF7-VECTOR cells in serum-free conditions 
(Figure 4.1.2 H). Exogenous hGH slightly reduced apoptotic cell death in both cell lines. 
FBS functioned as a powerful survival stimulus for both cell lines, although apoptosis 

















        
                            
Figure 4.1.2 (A)     Demonstration of overexpression of HOXA1 mRNA upon 
stable transfection of MCF-7 cells with HOXA1 cDNA. MCF-7 cells were   stably 
transfected with either the empty vector (MCF7-VECTOR) or the vector containing 
HOXA1 cDNA (MCF7-HOXA1). The level of HOXA1 mRNA was determined by 






































Figure 4.1.2 (B)     Demonstration of overexpression of HOXA1 protein   upon 
stable transfection of MCF-7 cells with HOXA1 cDNA. MCF-7 cells were   stably 
transfected with either the empty vector (MCF7-VECTOR) or the vector containing 
HOXA1 cDNA (MCF7-HOXA1). The level of HOXA1 protein was determined by 















Figure 4.1.2 (C)      Demonstration of functional overexpression of HOXA1 
protein upon stable transfection of MCF-7 cells with HOXA1 cDNA. MCF-7 cells 
were stably transfected with either the empty vector (MCF7-VECTOR) or the 
vector containing HOXA1 cDNA (MCF7-HOXA1). HOXA1 transcriptional 
activity (in the presence and absence of its binding partner PBX1) was determined 
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Figure 4.1.2 (D)     Effect of forced expression of HOXA1 in mammary carcinoma 
cells on cell number. MCF7-VECTOR and MCF7-HOXA1 cells were cultured in 
serum-free media or in serum-free media supplemented with either 50 nM hGH or 
10% FBS as indicated. Total cell number was determined in both cell lines under 
the indicated conditions as detailed under “Experimental Procedures.” Results 














































Figure 4.1.2 (E)     Effect of forced expression of HOXA1 in mammary carcinoma 
cells on cell cycle progression. MCF7-VECTOR and MCF7-HOXA1 cells were 
cultured in serum-free media or in serum-free media supplemented with either 50 
nM hGH or 10% FBS as indicated. Western blot analysis was utilized to determine 
the level of proteins involved in cell cycle progression (cyclinD1, p21waf1/cip1, and 
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Figure 4.1.2 (F)      Effect of forced expression of HOXA1 in mammary carcinoma 
cells on cell cycle progression. MCF7-VECTOR and MCF7-HOXA1 cells were 
cultured in serum-free media or in serum-free media supplemented with either 50 
nM hGH or 10% FBS as indicated. Cell cycle progression (BrdU incorporation) was 
determined in both cell lines under the indicated conditions as detailed under 
“Experimental Procedures.” Results represent means ± S.D. of triplicate 















































     
 
Figure 4.1.2 (G)     Effect of forced expression of HOXA1 in mammary carcinoma 
cells on apoptosis. MCF7-VECTOR and MCF7-HOXA1 cells were cultured in 
serum-free media or in serum-free media supplemented with either 50 nM hGH or 
10% FBS as indicated. Western blot analysis was utilized to determine the level of 
proteins involved in apoptosis (Fas, Fadd, p53, Bax, Bak, Bcl-xL, and Bcl-2). β-Actin 
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Figure 4.1.2 (H)      Effect of forced expression of HOXA1 in mammary 
carcinoma cells on apoptosis. MCF7-VECTOR and MCF7-HOXA1 cells were 
cultured in serum-free media or in serum-free media supplemented with either 50 
nM hGH or 10% FBS as indicated. Apoptotic cell death was determined in both cell 
lines under the indicated conditions as detailed under “Experimental Procedures.” 











































4.1.3                 HOXA1 expression in human mammary carcinoma cells prevents  
                         apoptotic cell death in a Bcl-2-dependent manner 
 
The previous studies showed that forced expression of HOXA1 in mammary carcinoma 
cells resulted in decreased apoptotic cell death associated with a specific increase in Bcl-
2 protein. To determine if HOXA1 regulated Bcl-2 at the transcriptional level, we 
examined the effect of forced expression of HOXA1 in mammary carcinoma cells on the 
level of Bcl-2 mRNA. Increased Bcl-2 mRNA was observed in MCF7-HOXA1 in 
comparison to MCF7-VECTOR cells in serum-free media (Figure 4.1.3 A). FBS 
stimulation of MCF7-VECTOR cells also increased Bcl-2 mRNA in comparison to the 
serum-free state, and FBS enhanced the level of Bcl-2 mRNA in MCF7-HOXA1 cells. 
Examination of Bcl-2 promoter activity demonstrated that the effect of forced expression 
of HOXA1 on Bcl-2 mRNA expression was mediated at the transcriptional level. Thus, 
Bcl-2 promoter activity was significantly higher in MCF7-HOXA1 cells in comparison to 
MCF7-VECTOR cells in serum-free conditions (Figure 4.1.3 B). Exogenous hGH was 
without effect on Bcl-2 promoter activity, but FBS stimulated Bcl-2 gene transcription in 
MCF7-VECTOR cells and dramatically enhanced Bcl-2 promoter activity in MCF7-
HOXA1 cells. Thus HOXA1 regulates Bcl-2 at the transcriptional level. 
 
To determine if Bcl-2 was responsible for the dramatic decrease in apoptosis as a 
consequence of forced expression of HOXA1, we prevented expression of Bcl-2 by use 
of antisense oligonucletides (Chi et al., 2000) as observed in Figure 4.1.3 C. Transfection 




Bcl-2 in MCF7-HOXA1 cells, whereas sense control oligonucleotides did not 
significantly affect the level of Bcl-2 (Figure 4.1.3 C). Transfection of Bcl-2 antisense 
oligonucleotides in MCF7-HOXA1 increased apoptotic cell death above that in control or 
sense oligonucleotide-transfected MCF7-VECTOR cells (Figure 4.1.3 D), and Bcl-2 
antisense also increased apoptotic cell death in MCF7-VECTOR cells. To further verify 
the Bcl-2 dependence of the survival effect of forced expression of HOXA1 in mammary 
carcinoma cells, we utilized a novel Bcl-2 inhibitor which antagonizes Bcl-2 function by 
blocking the BH3 binding pocket in Bcl-2 (Enyedy et al., 2001). Bcl-2 expression was 
not altered by cellular treatment with the Bcl-2 inhibitor (Figure 4.1.3 E). Use of the Bcl-
2 inhibitor also abrogated the protection from apoptotic cell death as a consequence of 
forced expression of HOXA1 (Figure 4.1.3 F) similar to the effect observed with Bcl-2 
antisense oligonucleotides. The anti-apoptotic effects of forced expression of HOXA1 in 
















Figure 4.1.3 (A)       HOXA1 expression in human mammary carcinoma cells 
increases Bcl-2 mRNA. Bcl-2 mRNA levels in MCF7-VECTOR and MCF7-HOXA1 
cells were determined by RT-PCR under the conditions indicated (serum-free, 50 
nM hGH, and 10% FBS) and β-actin was used as loading control. The experiment 












  FBS           -             -          +           -            -           + 
β-Actin 
  hGH          -            +           -           -           +           -














Figure 4.1.3 (B)     HOXA1 expression in human mammary carcinoma cells 
increases Bcl-2 promoter activity. Bcl-2 promoter activities in MCF7-VECTOR and 
MCF7-HOXA1 cells were determined by reporter assay using the Bcl-2 promoter 
under the conditions indicated (serum-free, 50 nM hGH, and 10% FBS). The 
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Figure 4.1.3 (C)   Bcl-2 antisense oligonucleotides prevent the HOXA1-stimulated 
expression of Bcl-2. Bcl-2 protein levels in MCF7-VECTOR and MCF7-HOXA1 
cells were determined by Western blot analysis under the conditions indicated 
(serum-free, serum free with Bcl-2 sense and antisense oligonucleotide (800nM)). β-
Actin was used as loading control. The experiment was performed as described 
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Figure 4.1.3 (D)     HOXA1 expression in human mammary carcinoma cells 
prevents apoptotic cell death in a Bcl-2-dependent manner. Apoptotic cell death was 
determined in MCF7-VECTOR and MCF7-HOXA1 cells under the conditions 
indicated (serum-free, serum free with Bcl-2 sense and antisense oligonucleotide 
(800nM)). Bcl-2 antisense oligonucleotide abrogated protection from apoptotic cell 
death as a consequence of forced expression of HOXA1 as indicated. The 
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Figure 4.1.3 (E)     Bcl-2 inhibitor does not alter Bcl-2 expression. Bcl-2 protein 
levels in MCF7-VECTOR and MCF7-HOXA1 cells were determined by Western 
blot analysis under the conditions indicated (serum-free, serum free with Bcl-2). β-
actin was used as loading control. The experiment was performed as described 
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Figure 4.1.3 (F)    HOXA1 expression in human mammary carcinoma cells 
prevents apoptotic cell death in a Bcl-2-dependent manner. Apoptotic cell death was 
determined in MCF7-VECTOR and MCF7-HOXA1 cells under the conditions 
indicated (serum-free, serum free with Bcl-2 inhibitor). Bcl-2 inhibitor abrogated 
protection from apoptotic cell death as a consequence of forced expression of 
HOXA1 as indicated. The experiment was performed as described under 
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4.1.4                     HOXA1 expression in mammary carcinoma cells protects against  
                             doxorubicin-induced apoptosis 
 
Since forced expression of HOXA1 in mammary carcinoma cells offered dramatic 
protection from apoptosis, we reasoned that increased HOXA1 expression would also 
result in decreased sensitivity to cell death as a result of exposure to anti-neoplastic 
agents. We therefore examined the effect of forced expression of HOXA1 on the 
apoptotic response of mammary carcinoma cells to doxorubicin. Doxorubicin decreased 
Bcl-2 promoter activity in MCF7-VECTOR cells and also decreased the HOXA1-
enhanced promoter activity in MCF7-HOXA1 cells, although Bcl-2 promoter activity in 
MCF7-HOXA1 cells treated with doxorubicin remained higher than in vehicle-treated 
MCF7-VECTOR cells (Figure 4.1.4 A). The level of Bcl-2 mRNA as determined by RT-
PCR demonstrated concordance with Bcl-2 promoter activity (Figure 4.1.4 B). 
Furthermore, Western blot analysis for Bcl-2 demonstrated an equivalent decrease in Bcl-
2 protein upon treatment of MCF7-VECTOR cells and relative maintenance of Bcl-2 
protein in doxorubicin-treated MCF7-HOXA1 cells. Bcl-xL protein was also slightly 
decreased after doxorubicin treatment but to equivalent levels in both cell lines. The level 
of Bak and Bax did not differ between the two cell lines, and no effect of doxorubicin 
was observed. A dramatic increase in p53 in both MCF7-VECTOR and MCF7-HOXA1 
demonstrated the efficacy of doxorubicin treatment (Figure 4.1.4 C). Doxorubicin 
dramatically increased apoptosis in MCF7-VECTOR cells, and in comparison MCF7-




4.1.4 D). Therefore, increased expression of HOXA1 in human mammary carcinoma 



























Figure 4.1.4 (A)     Forced expression of HOXA1 in mammary carcinoma cells 
(MCF7-HOXA1) maintains Bcl-2 promoter activity above that observed in vector-
transfected control cells upon treatment of both cell lines with doxorubicin. Bcl-2 
promoter activities in MCF7-VECTOR and MCF7-HOXA1 cells were determined 
by reporter assay using the Bcl-2 promoter under the conditions indicated (1 µg/ml 
doxorubicin). The experiment was performed as described under “Experimental 




































Figure 4.1.4 (B)    Forced expression of HOXA1 in mammary carcinoma cells 
(MCF7-HOXA1) maintains Bcl-2 mRNA levels above that observed in vector-
transfected control cells upon treatment of both cell lines with doxorubicin. Bcl-2 
mRNA levels in MCF7-VECTOR and MCF7-HOXA1 cells were determined by RT-
PCR under the conditions indicated (1 µg/ml doxorubicin) and β-actin was used as 







































Figure 4.1.4 (C)     Western blot analysis demonstrates dramatic doxorubicin-
induced expression of p53 in both MCF7-VECTOR and MCF7-HOXA1 cells and 
maintenance of Bcl-2 expression in MCF7-HOXA1 cells compared with MCF7-
VECTOR cells. p53, Bak, Bax, Bcl-xL, and Bcl-2 protein levels in MCF7-VECTOR 
and MCF7-HOXA1 cells were determined by Western blot under the conditions 
indicated (1 µg/ml doxorubicin) and β-actin was used as loading control. The 
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Figure 4.1.4 (D)    Forced expression of HOXA1 in mammary carcinoma cells 
protects against doxorubicin-induced apoptosis. Doxorubicin-induced apoptotic cell 
death was abrogated by forced expression of HOXA1 in mammary carcinoma cells 
as indicated. The experiment was preformed as described under “Experimental 
































   
   
   
   
   
   












4.1.5                   Forced expression of HOXA1 in human mammary carcinoma cells  
                           results in increased anchorage-independent growth in a Bcl-2-  
                           dependent manner 
 
Anchorage-independent growth is one pivotal characteristic of malignant transformation 
(Hanahan and Weinberg, 2000). To determine if forced expression of HOXA1 would 
alter the oncogenicity of mammary carcinoma cells, we examined the anchorage- 
independent growth of MCF7-VECTOR and MCF7-HOXA1 in both soft agar and 
suspension culture. MCF7-VECTOR cells formed colonies in soft agar as expected. 
However, forced expression of HOXA1 in MCF7-HOXA1 cells dramatically enhanced 
colony formation in soft agar (Figure 4.1.5A). The size of the individual colonies formed 
by MCF7-HOXA1 was also significantly larger than the small cell aggregates observed 
with MCF7-VECTOR cells (Figure 4.1.5D). Similarly, when cultured in suspension 
condition, MCF7-HOXA1 cells also increased in number significantly greater than 
MCF7-VECTOR cells and after 10 days were approximately tripled in number compared 
with MCF7-VECTOR cells (Figure 4.1.5B).  
 
To determine if Bcl-2 expression was also required for the observed enhancement of 
anchorage-independent growth as a result of forced expression of HOXA1, we examined 
soft agar colony formation of MCF7-VECTOR and MCF7-HOXA1 cells in the presence 
of the Bcl-2 inhibitor. As is observed in Figure 4.1.5C, use of the Bcl-2 inhibitor 




carcinoma cells (Figure 4.1.5D). Thus, forced expression of HOXA1 enhances 




























Figure 4.1.5 (A)    Forced expression of HOXA1 enhances anchorage-independent 
growth of mammary carcinoma. Soft agar colony formation by MCF7-VECTOR 
and MCF7-HOXA1 cells was performed as described under “Experimental 
Procedures.” The results are given as means ±S.D. of triplicate determinations. *, p 
< 0.001. 
































Figure 4.1.5 (B)    Forced expression of HOXA1 enhances anchorage-independent 
growth of mammary carcinoma cells. Anchorage-independent growth of MCF7-
VECTOR and MCF7-HOXA1 in bacteriological dishes was performed as described 
under “Experimental Procedures.” The results are given as means ± S.D. of 
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Figure 4.1.5 (C)    Forced expression of HOXA1 enhances anchorage-independent 
growth of mammary carcinoma cells in a Bcl-2-dependent manner. Soft agar colony 
formation by MCF7-VECTOR and MCF7-HOXA1 cells was performed as 
described under “Experimental Procedures.” Bcl-2 inhibitor was used at a 
concentration of 1 µM to demonstrate Bcl-2 dependence of HOXA1-stimulated 
enhancement of soft agar colony formation. The results are given as means ± S.D. of 































Figure 4.1.5 (D)    Forced expression of HOXA1 enhances anchorage-independent 
growth of mammary carcinoma cells in a Bcl-2-dependent manner. Soft agar colony 
formation by MCF7-VECTOR and MCF7-HOXA1 cells was performed as 
described under “Experimental Procedures.” Bcl-2 inhibitor was used at a 
concentration of 1 µM to demonstrate Bcl-2 dependence of HOXA1-stimulated 




















4.1.6                       Forced expression of HOXA1 results in oncogenic transformation   
                               of immortalized human mammary epithelial cells in vitro 
 
To further determine if forced expression of HOXA1 would result in oncogenic 
transformation of human mammary epithelial cells, we utilized the immortalized but not 
transformed human mammary epithelial cell line MCF-10A (Soule et al., 1990). When 
grown attached to a plastic substrate these cells display a typical epithelial morphology, 
do not form colonies in soft agar. They also are not capable of growth in 
immunocompromised mice (Soule et al., 1990).  
 
To examine the potential oncogenic capacity of HOXA1, we therefore stably transfected 
HOXA1 cDNA in MCF-10A cells (MCF10A-HOXA1). These cells expressed higher 
levels of both HOXA1 mRNA (Figure 4.1.6A) and protein (Figure 4.1.6B) compared 
with vector-transfected controls (MCF10A-VECTOR). Forced expression of HOXA1 in 
MCF10A-HOXA1 cells also resulted in enhanced HOXA1 transcriptional activity as 
evidenced by reporter activity from the EphA2-r42B enhancer (Figure 4.1.6C). Transient 
transfection of the cDNA for HOXA1 binding partner PBX1 further dramatically 
enhanced HOXA1 transcriptional activity in MCF10A-HOXA1 cells as expected (Figure 
4.1.6C).  
 
We therefore proceeded to examine the growth characteristics of both MCF10A-
VECTOR and MCF10A-HOXA1 cells. MCF10A-HOXA1 total cell number was 




than MCF10A-VECTOR cell number (Figure 4.1.6D). Comparison of nuclear BrdU 
incorporation between the two cell lines under serum-free conditions, 50 nM exogenous 
hGH, or FBS demonstrated that forced expression of HOXA1 significantly increased cell 
cycle progression of mammary carcinoma cells (Figure 4.1.6E). Apoptotic cell death was 
also dramatically reduced in MCF10A-HOXA1 cells compared with MCF10A-VECTOR 
cells in serum-free conditions (Figure 4.1.6F) as previously described for forced 
expression of HOXA1 in MCF-7 cells. Exogenous hGH slightly reduced apoptotic cell 
death in both MCF10A-VECTOR and MCF10A-HOXA1 cells but proportionate to the 
serum-free condition for each cell. FBS functioned as a powerful survival stimulus for 
both cell lines, although apoptosis was still less in MCF10A-HOXA1 cells compared 
with MCF10A-VECTOR cells (Figure 4.1.6F). 
 
MCF10A-HOXA1 cells formed large numerous colonies in soft agar, whereas MCF10A-
VECTOR cells were largely ineffective in colonization of soft agar (Figure 4.1.6G and 
4.1.6H). Thus forced expression of HOXA1 conferred tumorigenic potential upon human 
mammary epithelial cells. This result was also verified with a second independently 
generated pool of HOXA1 cDNA-transfected cell clones (Figure 4.1.6I). MCF10A-
HOXA1 colonization of soft agar was also Bcl-2-dependent since it was entirely 

























Figure 4.1.6 (A)     Demonstration of overexpression of HOXA1 mRNA upon 
stable transfection of MCF-10A cells with HOXA1 cDNA. MCF-10A cells were 
stably transfected with either the empty vector (MCF10A-VECTOR) or the vector 
containing HOXA1 cDNA (MCF10A-HOXA1). The level of HOXA1 mRNA was 











































Figure 4.1.6 (B)   Demonstration of overexpression of HOXA1 protein upon 
stable transfection of MCF-10A cells with HOXA1 cDNA. MCF-10A cells were 
stably transfected with either the empty vector (MCF10A-VECTOR) or the vector 
containing HOXA1 cDNA (MCF10A-HOXA1). The level of HOXA1 protein was 
determined by Western blot analysis under serum-free conditions. β-Actin was 



































Figure 4.1.6 (C)   Demonstration of functional overexpression of HOXA1 
protein upon stable transfection of MCF-10A cells with HOXA1 cDNA. MCF-10A 
cells were stably transfected with either the empty vector (MCF10A-VECTOR) or 
the vector containing HOXA1 cDNA (MCF10A-HOXA1). HOXA1 transcriptional 
activity (in the presence and absence of its binding partner PBX1) was determined 























































Figure 4.1.6 (D)   Effect of forced expression of HOXA1 in immortalized 
mammary epithelial cells (MCF-10A) on cell number. MCF10A-VECTOR and 
MCF10A-HOXA1 cells were cultured in serum-free media or in serum-free media 
supplemented with either 50 nM hGH or 10% FBS as indicated. Total cell number 
was determined in both cell lines under the indicated conditions as detailed under 
“Experimental Procedures.” Results represent means ± S.D. of triplicate 


















































Figure 4.1.6 (E)   Effect of forced expression of HOXA1 in immortalized 
mammary epithelial cells (MCF-10A) on cell cycle progression. MCF10A-VECTOR 
and MCF10A-HOXA1 cells were cultured in serum-free media or in serum-free 
media supplemented with either 50 nM hGH or 10% FBS as indicated. Cell cycle 
progression (BrdU incorporation) was determined in both cell lines under the 
indicated conditions as detailed under “Experimental Procedures.” Results 


































   
   
   
   
   




































Figure 4.1.6 (F)    Effect of forced expression of HOXA1 in immortalized 
mammary epithelial cells (MCF-10A) on apoptosis. MCF10A-VECTOR and 
MCF10A-HOXA1 cells were cultured in serum-free media or in serum-free media 
supplemented with either 50 nM hGH or 10% FBS as indicated. Apoptotic cell 
death was determined in both cell lines under the indicated conditions as detailed 
under “Experimental Procedures.” Results represent means ± S.D. of triplicate 



















































Figure 4.1.6 (G)    Forced expression of HOXA1 in immortalized mammary 
epithelial cells results in oncogenic transformation in vitro. Forced expression of 
HOXA1 in immortalized mammary epithelial cells permits soft agar colony 
formation. Assays were performed as described under “Experimental Procedures.” 
Bcl-2 inhibitor (0.5µg/ml) was utilized to demonstrate Bcl-2 dependence of 


































Figure 4.1.6 (H)    Forced expression of HOXA1 in immortalized mammary 
epithelial cells results in oncogenic transformation in vitro. Forced expression of 
HOXA1 in immortalized mammary epithelial cells permits soft agar colony 
formation. Assays were performed as described under “Experimental Procedures”. 















































Figure 4.1.6 (I)    Forced expression of HOXA1 in immortalized mammary 
epithelial cells (a second independently generated pool of HOXA1 cDNA-transfected 
cell clones) results in oncogenic transformation in vitro. Forced expression of 
HOXA1 in immortalized mammary epithelial cells permits soft agar colony 
formation Assays were performed as described under “Experimental Procedures”. *, 











































4.1.7                      Forced expression of HOXA1 results in oncogenic transformation   
                              of immortalized human mammary epithelial cells in vivo 
 
In vitro analyses of oncogenic transformation are not always concordant with 
tumorigenic potential in vivo. Results from in vitro assays may oversimplify many 
factors. For example, in vitro models lack the interaction between cancer cells, 
nonmalignant cells of the tumor supporting stroma, cells of the endocrine system, and the 
extracellular matrix. The ability to grow human tumors in immune-deficient mice offers 
research opportunities to investigate tumorigenicity in vivo (Sharkey and Fogh, 1984).  
 
We therefore implanted both MCF10A-VECTOR and MCF10A-HOXA1 cells into the 
first mammary (axillary) fat pad of female nude mice with use of either PBS or matrigel 
as vehicle. Both cells failed to grow and develop tumors in the nude mice (Table I, A). 
Interestingly, the positive controls, nude mice implanted with human mammary 
carcinoma cells, MCF-7, also failed to grow and develop tumors (Table I, A).  
 
In the next series of experiments, severe combined immunodeficient (SCID) mice were 
used instead of nude mice and the SCID mice simultaneously received a 60-day release 
pellet containing 0.72 mg of E2 (Sigma) as previous investigators have shown that without 
estrogen involvement, breast tumors fail to grow in immunodeficient mice (Brunner et 
al., 1987; Lippman et al., 1987; Phillips et al., 1989). Although nude mice have been used 




growth of human tumors because of their additional B-cell deficiency compared with the 
single T-cell deficiency of nude mice (Bosma et al., 1983; Topley et al., 1993).   
 
We therefore implanted both MCF10A-VECTOR and MCF10A-HOXA1 cells into the 
first mammary (axillary) fat pad of female SCID mice with use of either PBS or matrigel 
as vehicle. The mice simultaneously received a 60-day release pellet containing 0.72 mg 
of E2 (Sigma). MCF10A-HOXA1 cells formed large palpable and visible tumors in SCID 
mice injected with the cells, whereas MCF10A-VECTOR cells did not (Figure 4.1.7A, 
4.1.7B, and Table I, B). The tumor volume is got as follows: tumor volume = (d1 x d2 x 
d3) x 0.5236, in which dn represents the three orthogonal diameter measurements, 
measured with callipers (Figure 4.1.7C and 4.1.7D). The average volume of the tumors 
formed by MCF10A-HOXA1 cells was related to the injection vehicle with matrigel 
resulting in larger tumor volume (Table I, B). This is consistent with the previous studies 
which showed that matrigel, when co-injected with human tumor cells, can improve the 
growth of subcutaneous xenografts in immunodeficient mice (Fridman et al., 1990; 
Pretlow et al., 1991; Noel et al., 1992). 
 
Necropsy revealed that the tumors were attached to the underlying axillary muscle and 
surrounded by a vascular fibrous capsule. Histologically the neoplastic cells were locally 
invasive and associated with fibrous connective tissue (Figure 4.1.7E and 4.1.7F). The 
cells exhibited moderate cytoplasmic and nuclear pleomorphism and formed a solid mass 
often with areas of central necrosis. Necropsy of SCID mice injected with MCF10A-




of lung and liver of SCID mice injected with MCF10A-HOXA1 cells failed to identify 




















































Figure 4.1.7 (A,B)   Forced expression of HOXA1 in immortalized mammary 
epithelial cells results in oncogenic transformation and tumor formation in vivo. 
MCF10A-HOXA1 cells implanted into the first mammary (axillary) fat pad of 
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Figure 4.1.7 (C,D)   Forced expression of HOXA1 in immortalized mammary 
epithelial cells results in oncogenic transformation and tumor formation in vivo. 
MCF10A-HOXA1 cells implanted into the first mammary (axillary) fat pad of 
female severe combined immunodeficient mice formed a large visible tumor mass. 
Tumor volume = (d1 x d2 x d3) x 0.5236, in which dn represents the three 
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Figure 4.1.7 (E,F)    Forced expression of HOXA1 in immortalized mammary 
epithelial cells results in oncogenic transformation and tumor formation in vivo. 
MCF10A-HOXA1 cells implanted into the first mammary (axillary) fat pad of 
female severe combined immunodeficient mice formed a large visible tumor mass 
and histological appearance of the tumor visualized with hematoxylin and eosin (E), 
and local invasion of MCF10A-HOXA1 tumor cells into surrounding skeletal 























Table I  
 
                         HOXA1 overexpression induces in vivo tumor formation 
 
A,   5 x 106 exponentially growing MCF-7, MCF10A-HOXA1, and vector-
transfected control cells were implanted in the absence of estrogen into the 




B,     5 x 106 exponentially growing MCF10A-HOXA1, and vector-transfected 
control cells were implanted in the presence of estrogen into the mammary fat pad 
of SCID mice, and tumors were harvested 3 weeks after inoculation. 
 
 
          
αNA, not applicable 
Incidence of tumorigenicity 








  NAα NA 
(mm3) 
  NA NA
     PBS            Matrigel 
Mean tumor volume
MCF-7 0/10 0/10   NA NA








  NA 
734 ± 55 
NA
903 ± 286 
(mm3) 





4.2 E-cadherin-directed signaling upregulates HOXA1 through Rac1 
 
The confluence-dependent expression of HOXA1 was examined in this study. This study 
also investigated the upregulation of HOXA1 by E-cadherin-directed signaling. When 
cells grow to confluence, they are connected by forming cell-cell adhesion. In E-cadherin 
positive cells, this close cell-cell contact at confluence is mainly mediated by E-cadherin 
(Croix et al., 1998). Recent developments show that E-cadherin functions not only as 
mediator of cell surface adhesion, but also as adhesion-activated cell surface receptor, i.e. 
E-cadherin itself can direct cell signaling when it is activated as cell-cell adhesion forms. 
For example, it was demonstrated that Rac1 was activated as direct downstream 
consequence of E-cadherin ligation (Kovacs et al., 2002). However, the downstream 
targets of E-cadherin-activated signaling are far from identified.   
 
HOXA1 was found to have increased expression at full confluence in human mammary 
carcinoma cells MCF-7. Using a calcium switch method to manipulate junction 
assembly, we found that induction of cell-cell junctions increased HOXA1 expression, 
and this was inhibited by E-cadherin function-blocking antibodies. To distinguish the E-
cadherin-dependent regulation from the E-cadherin-activated signaling regulation of 
HOXA1 expression, a functional E-cadherin ligand (hE/Fc) was utilized and this 
confluence-dependent expression of HOXA1 was confirmed to be direct downstream 
consequence of E-cadherin ligation. Furthermore, E-cadherin-activated increment of 
HOXA1 was through a Rac1 mechanism. Increased HOXA1 expression by E-cadherin-




cells. Taken together, these results indicated that a cross link may exist between E-

























4.2.1             HOXA1 mRNA, protein, and transcriptional activity are increased in   
                     mammary carcinoma cells at full confluence 
 
The level of HOXA1 mRNA in mammary carcinoma cells MCF-7 at full confluence and 
at subconfluence was first examined by semi-quantitative RT-PCR. Figure 4.2.1 A 
demonstrated an amplified fragment of the predicted size (359 bp) appropriate for 
HOXA1 mRNA in MCF-7 cells. HOXA1 mRNA was increased in MCF-7 cells at full 
confluence (100% confluence) in comparison to subconfluences (20%, 40%, 60%, and 
80% confluences). The level of β-actin mRNA did not differ in MCF-7 cells under the 
different conditions and was used as a control for RNA quality (Figure 4.2.1 A).  
 
To determine if the increased HOXA1 protein was also observed in MCF-7 cells at full 
confluence, we examined the level of HOXA1 protein in lysates collected from MCF-7 
cells under the different confluence conditions by Western blot analysis. Both the 33 kDa 
and the 35 kDa form of HOXA1 were detectable (Figure 4.2.1 B) with increased 
HOXA1 protein observed at 100% confluence.  
 
To determine if HOXA1-mediated transcription was also increased in MCF-7 cells at full 
confluence, we examined luciferase reporter activity from the EphA2 r42B enhancer 
which contains four HOX-PBX binding sites (Chen and Ruley, 1998). MCF-7 cells at full 
confluence (100% confluence) had increased luciferase activity from the EphA2-r42B 
enhancer compared with MCF-7 cells at subconfluences (20%, 40%, 60%, 80% 




Thus, confluent MCF-7 cells had elevated HOXA1-mediated transcriptional activity 



























Figure 4.2.1 (A)    HOXA1 mRNA is increased in mammary carcinoma cells at 
full confluence. MCF-7 cells were cultured at different confluences (20%-100% 
confluences). The level of HOXA1 mRNA was determined by RT-PCR. β-Actin was 





































Figure 4.2.1 (B)    HOXA1 protein is increased in mammary carcinoma cells at 
full confluence. MCF-7 cells were cultured at different confluences (20%-100% 
confluences). The level of HOXA1 protein was determined by Western blot analysis. 
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Figure 4.2.1 (C)    HOXA1 transcriptional activity is increased in mammary 
carcinoma cells at full confluence. MCF-7 cells were cultured at different 
confluences (20%-100% confluences). The level of HOXA1 transcriptional activity 







































4.2.2          The increment in HOXA1 expression in mammary carcinoma cells at full       
                  confluence is cell-cell adhesion dependent  
 
The marked elevation in HOXA1 expression in confluent cultures of MCF-7 cells 
prompted us to examine the role of E-cadherin-mediated cell-cell junctions in the 
increment in HOXA1 expression that occurs with high cell density. To achieve this, we 
used EGTA which can chelate Ca2+, thereby disrupting E-cadherin-mediated cell-cell 
contact (Kim et al., 2000). As shown in Figure 4.2.2 A, use of EGTA in MCF-7 cells 
completely abrogated the increased expression of HOXA1 mRNA at full confluence. 
Similarly, analysis of HOXA1 transcriptional activity by use of the EphA2-r42B 
enhancer demonstrated the abrogation of increased HOXA1-mediated transcriptional 
activity in MCF-7 cells at full confluence by EGTA (Figure 4.2.2 B).  
 
Using the calcium switch model in MCF-7 cells (Nakagawa et al., 2001), we examined 
the dynamics of HOXA1 expression by time-lapse analysis (Figure 4.2.2 C). E-cadherin-
mediated cell-cell adhesion was abrogated by chelating Ca2+ and then re-initiated by re-
introducing Ca2+ (Volberg et al., 1986). This approach induced a time-dependent 
accumulation of E-cadherin and formation of adherens junctions in MCF-7 cells (Kim et 
al., 2000).  Induction of E-cadherin homophilic adhesion by Ca2+ significantly increased 
the expression of HOXA1 mRNA and protein in MCF-7 cells (Figure 4.2.2 C and D). 
The increment in HOXA1 mRNA and protein expression was time-dependent. Increased 
HOXA1 expression was detected at 15 min (HOXA1 mRNA) and 30 min (HOXA1 




C and D). Thus, the increment in HOXA1 expression in mammary carcinoma cells at full 










































Figure 4.2.2 (A)  The increment in HOXA1 mRNA in mammary carcinoma cells 
at full confluence is cell-cell adhesion dependent. MCF-7 cells were cultured at 
subconfluence (60% confluence) and full confluence (100% confluence) in the 
presence and absence of EGTA. The level of HOXA1 mRNA was determined by 
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Figure 4.2.2 (B)   The increment in HOXA1 transcriptional activity in mammary 
carcinoma cells at full confluence is cell-cell adhesion dependent. MCF-7 cells were 
cultured at subconfluence (60% confluence) and full confluence (100% confluence) 
in the presence and absence of EGTA. The level of HOXA1 transcriptional activity 
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Figure 4.2.2 (C)  The increment in HOXA1 mRNA in mammary carcinoma cells 
at full confluence is cell-cell adhesion dependent. Confluent MCF-7 cells were 
incubated with 4mM EGTA. After 30 min, the medium was replaced with RPMI 
containing Ca2+ for the indicated time periods (in min). At the indicated times, cells 
were lysed and the level of HOXA1 mRNA was determined by RT-PCR. β-Actin 





































Figure 4.2.2 (D)  The increment in HOXA1 protein in mammary carcinoma cells 
at full confluence is cell-cell adhesion dependent. Confluent MCF-7 cells were 
incubated with 4mM EGTA. After 30 min, the medium was replaced with RPMI 
containing Ca2+ for the indicated time periods (in min). At the indicated times, cells 
were lysed and the level of HOXA1 protein was determined by Western blot 
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4.2.3         The increment in HOXA1 expression in mammary carcinoma cells at full  
                  confluence is E-cadherin-dependent  
 
 
The results above are, however, not sufficient to conclude that E-cadherin-mediated cell-
cell adhesion induced the increased HOXA1 expression at full confluence. Because 
MCF-7 cells adhere to each other through not only E-cadherin but also other adhesion 
molecules, it is possible that cell adhesion molecules besides E-cadherin increased 
HOXA1. Moreover, influx of Ca2+ into cells might induce the increment of HOXA1. To 
exclude the possibility that increased HOXA1 in mammary carcinoma cells at full 
confluence was due to factors other than E-cadherin, we tested the effect of DECMA-1, a 
function-blocking antibody against E-cadherin (Vestweber and Kemler, 1985). As is 
observed in Figure 4.2.3 A and B, use of DECMA-1 in MCF-7 cells completely 
abrogated the increased expression of HOXA1 mRNA and protein at full confluence. In 
addition, use of DECMA-1 in MCF-7 cells also abrogated the increased HOXA1-
mediated transcriptional activity at full confluence (Figure 4.2.3 C).  
 
Calcium switch was performed with DECMA-1. MCF-7 cells were incubated with 
EGTA, and then Ca2+ was restored to the medium in the presence of DECMA-1. The 
increase in HOXA1 expression induced by calcium restoration was blocked by DECMA-
1 (Figure 4.2.2 C and D and Figure 4.2.3 D and E), suggesting that E-cadherin is 





Altogether, the results demonstrated that the increment in HOXA1 expression in 



























Figure 4.2.3 (A)  The increment in HOXA1 mRNA in mammary carcinoma cells 
at full confluence is E-cadherin-dependent. MCF-7 cells were cultured at 
subconfluence (60% confluence) and full confluence (100% confluence) in the 
presence and absence of DECMA-1, a function-blocking antibody against E-
cadherin. The level of HOXA1 mRNA was determined by RT-PCR. β-Actin was 
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Figure 4.2.3 (B)  The increment in HOXA1 protein in mammary carcinoma cells 
at full confluence is E-cadherin-dependent. MCF-7 cells were cultured at 
subconfluence (60% confluence) and full confluence (100% confluence) in the 
presence and absence of DECMA-1, a function-blocking antibody against E-
cadherin. The level of HOXA1 protein was determined by Western blot analysis. β-




































Figure 4.2.3 (C)  The increment in HOXA1 transcriptional activity in mammary 
carcinoma cells at full confluence is E-cadherin-dependent. MCF-7 cells were 
cultured at subconfluence (60% confluence) and full confluence (100% confluence) 
in the presence and absence of DECMA-1, a function-blocking antibody against E-
cadherin. The level of HOXA1 transcriptional activity was determined by reporter 
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Figure 4.2.3 (D)  The increment in HOXA1 mRNA in mammary carcinoma cells 
at full confluence is E-cadherin-dependent. Confluent MCF-7 cells were incubated 
with 4mM EGTA. After 30 min, the medium was replaced with RPMI containing 
Ca2+ in the presence of  DECMA-1, a function-blocking antibody against E-
cadherin,    for the indicated time periods (in min). At the indicated times, cells were 
lysed and the level of HOXA1 mRNA was determined by RT-PCR. β-Actin was used 
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Figure 4.2.3 (E)  The increment in HOXA1 protein in mammary carcinoma cells 
at full confluence is E-cadherin-dependent. Confluent MCF-7 cells were incubated 
with 4mM EGTA. After 30 min, the medium was replaced with RPMI containing 
Ca2+ in the presence of DECMA-1, a function-blocking antibody against E-cadherin, 
for the indicated time periods (in min). At the indicated times, cells were lysed and 
the level of HOXA1 protein was determined by Western blot analysis. β-Actin was 
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4.2.4      The increment in HOXA1 expression in mammary carcinoma cells at full  
              confluence is regulated by E-cadherin-activation and not just E-cadherin- 
              dependent signaling 
 
The results detailed above do not distinguish whether the increment in HOXA1 is direct 
downstream consequence of E-cadheirn ligation or just a result of juxtacrine signals that 
required E-cadherin adhesion to bring cell surfaces together. In other words, it should be 
determined whether HOXA1 increment results from direct E-cadherin-activated signals 
or E-cadherin-dependent juxtacrine signals. To achieve this, we utilized a recombinant 
protein (hE/Fc) consisting of the complete ectodomain of human E-cadherin fused to the 
Fc region of IgG. Substrata adsorbed with hE/Fc supported E-cadherin-specific adhesion 
and contact formation (Kovacs et al., 2002). Thus, using this model, E-cadherin 
engagement is induced without cell-cell contact.  
 
HOXA1 mRNA was increased in MCF-7 cells adhered to hE/Fc-coated substrata in 
comparison to MCF-7 cells adhered to poly-L-lysine (PLL) which is used as control to 
hE/Fc. The level of β-actin mRNA did not differ under the different conditions and was 
used as a control for RNA quality (Figure 4.2.4 A). We further examined the level of 
HOXA1 protein in MCF-7 cells adhered to hE/Fc-coated substrata and poly-L-lysine 
(PLL). As is observed in Figure 4.2.4 B, both the 33- and the 35-kDa forms of HOXA1 
were detected with increased HOXA1 protein observed in MCF-7 cells adhered to hE/Fc-
coated substrata. All these experiments were performed in MCF-7 cells at subconfluence 




carcinoma cells results from direct E-cadherin-activated signals and not E-cadherin-



























Figure 4.2.4 (A)    The increment in HOXA1 mRNA in mammary carcinoma cells 
at full confluence is regulated by E-cadherin-activated signaling. Subconfluent 
MCF-7 cells were plated onto poly-L-lysine-coated substrate (PLL) or hE/Fc-coated 
substrata. The level of HOXA1 mRNA was determined by RT-PCR. β-Actin was 











































Figure 4.2.4 (B)    The increment in HOXA1 protein in mammary carcinoma cells 
at full confluence is regulated by E-cadherin-activated signaling. Subconfluent 
MCF-7 cells were plated onto poly-L-lysine-coated substrate (PLL) or hE/Fc-coated 
substrata. The level of HOXA1 protein was determined by Western blot analysis. β-






















4.2.5           Rac1, but not PI-3 kinase, α-, β-, and γ-catenins is involved in the E- 
                   cadherin-activated increment in HOXA1 expression in mammary  
                   carcinoma cells  
 
α-, β-, and γ-catenins are the key molecules involved in E-cadherin signaling (Provost 
and Rimm, 1999; Jiang and Robert, 2000). To determine whether these molecules are 
involved in the E-cadherin-activated increment in HOXA1 expression, we examined their 
protein levels in MCF-7 cells at subconfluence and confluence. The levels of α-, β-, and 
γ-catenins were not altered in the cells at suconfluence (60% confluence) and full 
confluence (100% confluence) (Figure 4.2.5 A). Equal loading of the cell extracts was 
verified by reprobing the stripped membrane for β-actin (Figure 4.2.5 A).  
 
Apart from the catenins, PI-3 kinase as well as Rac1 has been demonstrated to be 
involved in E-cadherin signaling (Pece et al., 1999; Kovacs et al., 2002; Nakagawa et al., 
2001). To determine if PI-3 kinase or Rac1 was responsible for the E-cadherin-increased 
HOXA1 expression, we prevented function of PI-3 kinase and Rac1 in MCF-7 cells by 
use of wortmannin (Vanhaesebroeck et al., 2001) and a dominantly inhibitory N17 Rac1 
mutant (Kovacs et al., 2002)  respectively. Transient expression of the dominant negative 
N17 Rac1 (DNRac1) mutant significantly inhibited the E-cadherin-increased HOXA1 
mRNA expression and HOXA1-mediated transcriptional activity at full confluence 
(Figure 4.2.5 B and C), whereas wortmannin (60 nM) did not significantly affect the 
level of HOXA1 expression (Figure 4.2.5 B and C). To further verify the involvement of 




and protein levels in MCF-7 cells adhered to hE/Fc-coated substrata and PLL in the 
presence of DNRac1. As observed in Figure 4.2.5 D and E, use of DNRac1 completely 
prevented the increased HOXA1 expression observed in MCF-7 cells adhered to hE/Fc-
coated substrata. Thus, Rac1, but not PI-3 kinase, α-, β-, and γ-catenins is involved in the 
























Figure 4.2.5 (A)  α-, β-, and γ-catenin are not involved in the E-cadherin-
activated increment in HOXA1 expression in mammary carcinoma cells. MCF-7 
cells were cultured at subconfluence (60% confluence) and full confluence (100% 
confluence). The protein levels of α-, β-, and γ-catenin were determined by Western 
































Figure 4.2.5 (B)   Rac1, but not PI-3 kinase is involved in the E-cadherin-
activated increment in HOXA1 mRNA expression in mammary carcinoma cells. 
MCF-7 cells were cultured at subconfluence (60% confluence) and full confluence 
(100% confluence) in the presence and absence of wortmannin (PI-3 kinase 
inhibitor) or DNRac1 (dominantly inhibitory N17 Rac1 mutant). The level of 
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Figure 4.2.5 (C)   Rac1, but not PI-3 kinase is involved in the E-cadherin-
activated increment in HOXA1 transcriptional activity in mammary carcinoma 
cells. MCF-7 cells were cultured at subconfluence (60% confluence) and full 
confluence (100% confluence) in the presence and absence of wortmannin (PI-3 
kinase inhibitor) or DNRac1 (dominantly inhibitory N17 Rac1 mutant). The level of 
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Figure 4.2.5 (D)  Rac1 is involved in the E-cadherin-activated increment in 
HOXA1 mRNA expression in mammary carcinoma cells. Subconfluent MCF-7 cells 
were plated onto poly-L-lysine-coated substrate (PLL) or hE/Fc-coated substrata in 
the presence and absence of DNRac1 (dominantly inhibitory N17 Rac1 mutant). The 
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Figure 4.2.5 (E)  Rac1 is involved in the E-cadherin-activated increment in 
HOXA1 protein expression in mammary carcinoma cells. Subconfluent MCF-7 cells 
were plated onto poly-L-lysine-coated substrate (PLL) or hE/Fc-coated substrata in 
the presence and absence of DNRac1 (dominantly inhibitory N17 Rac1 mutant). The 
level of HOXA1 protein was determined by Western blot analysis. β-Actin was used 
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4.2.6      Increased HOXA1 expression by E-cadherin-activated signaling has  
              increased anti-apoptotic effect in human mammary carcinoma cells 
 
HOXA1 has been demonstrated to offer dramatic protection from apoptosis in human 
mammary carcinoma cells MCF-7 (Zhang et al., 2003). We therefore examined whether 
the increased HOXA1 expression by the E-cadherin-activated signaling would offer 
protection from apoptosis in MCF-7 cells. MCF-7 cells were incubated in the presence of 
the HOXA1 inhibitor, HOXA1 RNAi and DECMA-1, and the level of apoptotic cell 
death was determined. As expected, MCF-7 cells at full confluence had reduced 
apoptosis compared with MCF-7 cells at subconfluence (Figure 4.2.6 A). Transient 
transfection of HOXA1 RNAi completely prevented the reduced apoptosis at full 
confluence (Figure 4.2.6 A), indicating that increased HOXA1 at full confluence is 
responsible for this anti-apoptotic effect. If E-cadherin-activated increment in HOXA1 
offered this anti-apoptotic effect at full confluence, we then reasoned that blocking of E-
cadherin function would abrogate the anti-apoptotic effect and that expression of HOXA1 
should rescue this abrogation. Indeed, MCF-7 cells at subconfluence and full confluence 
had the same apoptotic level in the presence of DECMA-1 (Figure 4.2.6 B). Transfection 
of HOXA1 expression plasmid (Di Rocco et al., 1997) completely rescued the anti-
apoptosis prevention offered by DECMA-1 (Figure 4.2.6 B). Transfection of HOXA1 
expression plasmid also offered anti-apoptosis in MCF-7 cells at subconflunce (Figure 
4.2.6 B). Altogether, the above results demonstrated that increased HOXA1 expression 






To determine the effect of increased HOXA1 expression by E-cadherin-activated 
signaling on cell cycle progression in MCF-7 cells, we examined the nuclear 
incorporation of 5’-bromo-2’-deoxyuridine (BrdU) in the cells. MCF-7 cells at full 
confluence did not exhibit significant higher percentage of nuclear BrdU incorporation 
compared with MCF-7 cells at subconfluence in the presence or without the presence of 






















Figure 4.2.6 (A)  Increased HOXA1 expression by E-cadherin-activated signaling 
has increased anti-apoptotic effect in human mammary carcinoma cells. MCF-7 
cells were cultured at subconfluence (60% confluence) and full confluence (100% 
confluence) in the presence and absence of HOXA1 RNAi and apoptotic cell death 
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Figure 4.2.6 (B)   Increased HOXA1 expression by E-cadherin-activated signaling 
has increased anti-apoptotic effect in human mammary carcinoma cells. MCF-7 
cells were cultured at subconfluence (60% confluence) and full confluence (100% 
confluence) in the presence and absence of HOXA1 expression plasmid or DECMA-
1 (E-cadherin function-blocking antibody) and apoptotic cell death was determined 
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Figure 4.2.6 (C)   Effect of increased HOXA1 expression by E-cadherin-activated 
signaling on cell cycle progression in human mammary carcinoma cells. MCF-7 cells 
were cultured at subconfluence (60% confluence) and full confluence (100% 
confluence) in the presence and absence of HOXA1 RNAi and cell cycle progression 












































   
   
   











   
   















Chapter 5     General discussion  
 
 
The present work has investigated the various properties, and their mechanisms, of the 
autocrine human growth hormone (hGH)-regulated homeobox gene product, HOXA1, in 
human mammary carcinoma cells. Forced expression of HOXA1 in mammary carcinoma 
cells resulted in increased total cell number. This was primarily by the promotion of cell 
survival mediated by the transcriptional upregulation of Bcl-2. HOXA1 also abrogated 
the apoptotic response of mammary carcinoma cells to the chemotherapy drug, 
doxorubicin. HOXA1 was also identified as a powerful oncogene for human mammary 
epithelial cells in vitro and in vivo. It was further demonstrated that HOXA1 expression 
in mammary carcinoma cells was increased by cell to cell contact at full confluence.  This 




5.1              Human growth hormone-regulated HOXA1 is a human mammary  
                   epithelial oncogene 
 
Forced expression of HOXA1 was sufficient to result in the oncogenic transformation of 
immortalized human mammary epithelial cells with aggressive in vivo tumor formation. 
Primary rodent cells may be transformed by two concomitantly introduced oncogenes 
(Land et al., 1983; Ruley, 1983). Only recently have human cells been transformed by a 
combination of the genomic version of the SV40 Large T antigen, the hTERT gene that 




RasV12 (Hahn et al., 1999). hTERT allows mammary epithelial cells to bypass both 
senescence (M1) and crisis (M2) with resultant immortalization of cells. However, 
immortalization of cells is not sufficient to create an oncogenically transformed cell 
(Hahn et al., 1999; Jiang et al., 1999). In the present study, oncogenic transformation in 
vitro and in vivo was demonstrated in immortalized human mammary epithelial cells by 
introduction of only the HOXA1 cDNA. Other members of the homeobox gene family 
have also been reported to be oncogenic (Kroon et al., 1998; Maulbecker and Gruss, 
1993). Such examples include Hoxb8, which was shown to transform NIH3T3 cells 
(Aberdam et al., 1991), and Cdx1, which caused transformation and tumorigenesis of 
intestinal epithelial cells (Soubeyran et al., 2001). Interestingly, certain homeobox family 
members have also been demonstrated to result in cellular immortalization (Schnabel et 
al., 2000). This raises the intriguing possibility that HOXA1 may both immortalize human 
mammary epithelial cells and result in their oncogenic transformation (shown here). 
Indeed, in preliminary experiments from the same laboratory (Chen et al., manuscript in 
preparation), it was shown that forced expression of HOXA1 does increase transcription 
of the hTERT gene with a resultant increase in telomerase activity in primary human 
mammary epithelial cells. It is possible that HOXA1 may therefore both immortalize and 
oncogenically transform human mammary epithelial and potentially constitute a 
"complete oncogene" for human mammary epithelial cells. This exciting possibility will 
require further investigation. 
The early portion of this study demonstrated that HOXA1 gene expression and 
transcriptional activity is regulated by hGH. Since forced expression of HOXA1 resulted 




that hGH itself is oncogenic. However, other studies in our laboratory have shown that 
exogenous hGH does not support the anchorage-independent growth of immortalized 
human mammary epithelial cells (Zhu et al., unpublished data), despite the requirement of 
endocrine GH for optimal growth of mammary tumor xenografts (Yang et al., 1996). This 
is concordant with the fact that, although exogenous hGH increased HOXA1 mRNA, it 
did not result in an increase in HOXA1 protein nor transcriptional activity (chapter 4.1.1). 
Interestingly, however, and consistent with the previous studies (Raccurt et al., 2002), 
autocrine-produced hGH does indeed confer immortalized mammary epithelial cells with 
the capacity for anchorage-independent growth and tumor formation in vivo (Zhu et al., 
manuscript submitted). It is a likely possibility that autocrine hGH may therefore utilize 
HOXA1 to execute its oncogenic program. The observation that exogenous hGH 
regulates HOXA1 mRNA but not protein nor transcriptional activity is suggestive that 
autocrine hGH production in human mammary epithelial cells also regulates HOXA1 at 
the translational or post-translational level. Such potential regulation of HOXA1 other 
than at the transcriptional level may be required for its transforming activity.  
By use of a functional Bcl-2 inhibitor, we have demonstrated that HOXA1-dependent 
transformation is dependent on Bcl-2 (Enyedy et al., 2001) (chapter 4.1.6). It is unlikely 
that this pathway constitutes the sole mechanism by which HOXA1 confers oncogenic 
transformation of human mammary epithelial cells and further pathways presumably will 
be delineated by microarray and promoter mining experiments in progress. It may be that 
Bcl-2 is simply required for human mammary epithelial cell survival, and functional 
inhibition of Bcl-2 would consequently drive the cell to apoptosis. Indeed, high 




MCF7-VECTOR and MCF7-HOXA1 cells (see chapter 4.1.5). However, titration of the 
Bcl-2 inhibitor allowed selective inhibition of the enhanced colony formation as a 
consequence of forced expression of HOXA1 with no alteration in colony formation by 
MCF7-VECTOR cells. Thus, it is apparent that Bcl-2 is required specifically for HOXA1 
enhancement of mammary carcinoma cell colony formation in soft agar.  
 
5.2             HOXA1 abrogated the apoptotic response of mammary carcinoma cells    
                   to the chemotherapy drug, doxorubicin 
 
Chemotherapeutic agents such as doxorubicin result in the induction of p53 to execute an 
apoptotic program (Hayakawa et al., 2000; Fuchs et al., 1998). Bcl-2 functions to prevent 
mitochondrial cytochrome c release and subsequent cell death (Reed, 1998; Gross et al., 
1999), and therefore, increased Bcl-2 expression could be expected to result in 
chemoresistance (Gutierrez-Puente et al., 2002). Indeed, Bcl-2 has been observed to be 
overexpressed in a large percentage of human neoplasias (Gutierrez-Puente et al., 2002), 
and Bcl-2 expression is associated with resistance to chemotherapy in many cancers, 
including mammary carcinoma (Bonetti et al., 1998; Decaudin et al., 1997). In the present 
study, it was demonstrated that forced expression of HOXA1 resulted in resistance to 
doxorubicin-induced cell death as a consequence of increased Bcl-2 expression (chapter 
4.1.4). Inhibition of HOXA1 transactivation may therefore constitute a novel therapeutic 
target to abrogate resistance to chemotherapeutic agents. However, as Bcl-2 (and 




death of mammary carcinoma cells, simple antagonism of hGH signal transduction may 
represent a more efficacious approach to enhance the response of mammary carcinoma 
cells to chemotherapy. Previous studies from this laboratory have previously described 
that autocrine hGH production promotes mammary carcinoma cell survival by at least 
two other mechanisms (Mertani et al., 2001; Graichen et al., 2002). First, autocrine hGH 
increases transcription of the CHOP gene, and increased p38 mitogen-activated protein 
kinase-dependent CHOP-mediated transcription results in mammary carcinoma cell 
survival (Mertani et al., 2001). Autocrine hGH production in mammary carcinoma cells 
also conversely results in transcriptional repression of the p53-regulated placental 
transforming growth factor-β gene with subsequent decreases in its protein product, 
Smad-mediated transcription, and its cellular effects, which include cell cycle arrest and 
apoptosis (Graichen et al., 2002). Several avenues exist for antagonism of the 
somatotropic axis. Non-dimerizing hGH receptor antagonists have been used clinically to 
treat acromegaly (Sesmilo et al., 2002) and constitute one potential therapeutic approach. 
Indeed, previous studies from this laboratory have utilized this antagonist in vitro to 
demonstrate that the effects of autocrine hGH on mammary carcinoma cell proliferation 
(both mitogenesis and apoptosis) are mediated via the hGH receptor (Kaulsay et al., 
2001). Growth hormone-releasing hormone antagonists have also been utilized to 
decrease mammary GH production and, consequently, decrease the growth of mouse 
mammary carcinoma xenografts (Schally et al., 2001). It is therefore conceivable that 
antagonism of hGH, utilized as adjuvant therapy, will increase the efficacy of 






5.3   E-cadherin-directed signaling upregulates HOXA1 through Rac1 in human     
        mammary carcinoma cells 
 
E-cadherin is a well-known cell-cell adhesion molecule that mediates cell-cell adhesion 
by Ca2+-dependent homophilic interactions. It has been demonstrated that when the E-
cadherin positive cells grow to confluence, the close cell-cell contact is mainly mediated 
by E-cadherin (Croix et al., 1998). Recently, E-cadheirn-mediated cell-cell adhesion is 
postulated to initiate a cascade of cellular signals. Indeed, signaling by PI-3 kinase as 
well as Rho family GTPases has been observed to be activated as E-cadherin-mediated 
cell-cell adhesion forms (Kim et al., 2000; Noren et al., 2001; Nakagawa et al., 2001). 
However, the downstream targets of the signaling pathways activated by E-cadherin 
binding are far from identified. In this study (chapter 4.2), the data presented 
demonstrated that HOXA1 is one of the downstream molecules that was regulated by E-
cadherin-mediated cell-cell adhesion. The increased HOXA1 expression observed in 
confluent MCF-7 cells was lost during disruption of E-cadherin-mediated cell-cell 
adhesion by Ca2+ chelation. Using a calcium switch method to manipulate junction 
assembly, it was shown that induction of cell-cell junctions increased HOXA1 
expression, and this was inhibited by E-cadherin function-blocking antibodies. In 
addition, using a functional recombinant E-cadherin adhesive ligand (hE/Fc), it was 
demonstrated that E-cadheirn homophilic ligation to hE/Fc increased HOXA1 expression. 
Adhesion to Poly-L-Lysine did not increase HOXA1, indicating that signaling was a 
specific response to E-cadherin homophilic ligation and not a nonspecific consequence of 




activated as cultured cells form E-cadherin-dependent contacts with one another could 
not exclude the possibility that they were activated by juxtacrine signals that required E-
cadherin adhesion to bring cell surfaces together but were not themselves direct 
downstream consequences of E-cadheirn ligation (Kim et al., 2000; Noren et al., 2001; 
Nakagawa et al., 2001; Yap et al., 1997; Fagotto and Gumbiner, 1996). The present work 
in this thesis now clearly demonstrates that HOXA1 is increased as a direct downstream 
consequence of E-cadherin ligation. The present work in this thesis also showed that 
Rac1 is responsible for the E-cadherin-increased HOXA1 expression. Since Xenopus C-
cadheirn has also recently been shown to directly activate Rac (Noren et al., 2001), it will 
now be important to assess whether HOXA1 is a downstream molecule upregulated by 
all classical cadherins.  
 
 
5.4       Increased HOXA1 expression by E-cadherin-activated signaling  
            increases anti-apoptotic effect in human mammary carcinoma cells 
 
Although E-cadherin is central to the cell adhesion, it has also been implicated in 
physiologic roles beyond the mere mechanical interconnection of cells. More recent 
evidence suggests that E-cadherin may also be associated with regulatory pathways 
involved in various aspects of cell fate including developmental decisions, cellular 
differentiation, and apoptosis (Miller and Moon, 1996; Peifer, 1997). It is now believed 
that just as integrins function to mediate cell-extracellular matrix interactions in 
anchorage-dependent survival, cadherins may also act in such a capacity, possessing a 
functional role in the regulation of intercellular adhesion-dependent survival. Several 




of gut and ovarian epithelium (Hermiston and Gordon, 1995; Peluso et al., 1996), and 
that E-cadherin-mediated intercellular adhesions suppress apoptosis and promote 
anchorage-independent growth of oral squamous carcinoma cells (Kantak and Kramer, 
1998). These studies suggested that homophilic binding of cadherin molecules on 
adjacent cells could transduce anti-apoptotic signals.  
 
Interestingly, several studies showed that the apoptotic cell death increases if the cells are 
unable to form aggregation and cell-cell adhesion by E-cadehrin (Kantak and Kramer, 
1998; Day et al., 1999). For example, Day et al. (1999) found that activation of protein 
kinase C resulted in 60% apoptosis of mammary and prostate epithelial cells. The 
surviving cells had undergone dramatic aggregation concurrent with increased E-cadherin 
expression. When aggregation was inhibited by the addition of an E-cadherin-blocking 
antibody, apoptosis increased synergistically (Day et al., 1999). The above results that the 
formed cell aggregation and E-cadheirn-mediated cell-cell adhesion are able to protect 
cells against apoptosis are very similar to the results in the present study. In the present 
study, it was also shown that the confluent MCF-7 cells (cell aggregation) and the cell 
adhesion mediated by E-cadherin signaling have decreased apoptotic cell death. 
However, the previous studies and ours identified different molecular mechanisms 
responsible for E-cadherin signaling-mediated cell survival. In the study of Day et al. 
(1999), they indicated E-cadherin-mediated aggregation results in Rb activation and G1 
arrest that is critical for the survival of prostate and mammary epithelial cells. In the 
study of Kantak and Kramer (1998), Bcl-2 may be involved in the E-cadherin-mediated 




demonstrated to be the executor of the anti-apoptosis effect mediated by E-cadehrin-
activated signaling. However, different cell lines were utilized. Day et al. (1999) used 
non-transformed cells, Kantak and Kramer (1998) used oral squamous carcinoma cells, 
while in this thesis’s study, human mammary gland carcinoma cells were used. So it is 
possible that the differences between the cell lines may account for the different 
mechanisms. In addition, Day et al. (1999) used protein kinase C to treat the cells and 
Kantak and Kramer cultured the cells in suspension. These different cell conditions may 
also be a reason for the difference in mechanism seen. Collectively, these studies lead to 
the conclusion that E-cadherin signaling-mediated cell-cell adhesion is an important and 
novel mechanism by which epithelial cells can regulate apoptosis. 
 
 
5.5              Conclusions 
 
 
1.     Autocrine human growth hormone (hGH) production by human mammary 
carcinoma cells increased the expression and transcriptional activity of HOXA1. Growth 
hormone has been demonstrated to be involved in breast cancer. For example, transgenic 
mice that overexpress gene encoding GH agonist exhibit both mammary gland epithelial 
cell hyperplasia and an increased frequency of mammary tumors (Tornell et al., 1992). 
Previous researchers in my supervisor’s laboratory have investigated the role of autocrine 
hGH in mammary carcinoma cells and provided evidence that autocrine production of 
hGH by mammary carcinoma cells may direct the cell behavior to impact on the final 
clinical prognosis (Kaulsay et al., 1999; Kaulsay et al., 2000; Kaulsay et al., 2001), and 




cellular effects is required. One major mechanism by which GH affects cellular function 
is by regulating the level of specific mRNA species (Isaksson et al., 1985). The previous 
investigators in our lab utilized cDNA microarray analyses to identify genes regulated by 
autocrine hGH in mammary carcinoma cells (MCF-7) (Mertani et al., 2001). One gene 
demonstrated to be upregulated by autocrine hGH in MCF-7 cells was HOXA1. The 
present work demonstrated that autocrine production of hGH in MCF-7 cells increases 
HOXA1 mRNA protein, and transcriptional activity and thus verified the hGH-dependent 
upregulation of HOXA1 observed by cDNA array screening. Thus, autocrine hGH may 
therefore utilize HOXA1 to execute its cellular effects in mammary carcinoma cells. For 
example, autocrine GH affords dramatic protection from apoptosis (Kaulsay et al., 2001). 
HOXA1 was also demonstrated to have marked anti-apoptosis effect in the present work 
and thus HOXA1 may be directly involved in autocrine GH anti-apoptosis effect. 
Interestingly, autocrine production of hGH in immortalized human mammary epithelial 
cells was shown to result in oncogenic transformation and tumor formation in vivo (Zhu 
et al., manuscript submitted). So it is possible that HOXA1, acting as the downstream 
target of autocrine hGH, is responsible for the oncogenic program of autocrine hGH.     
 
2.            Forced expression of HOXA1 in an immortalized human mammary epithelial 
cell line (MCF-10A) resulted in oncogenic transformation and the development of a 
rapidly growing carcinoma in vivo. This was quite remarkable, given that forced 
expression of other known oncogenes (e.g. Ras, Her2/neu, and TC21) have been reported 
in several laboratories to be insufficient to convey tumorigenic potential on MCF-10A 




(overexpressed in over 50% of human mammary carcinomas (McIntosh et al., 1995)), 
although able to support anchorage-independent growth of MCF-10A cells, did not prove 
sufficient to induce tumor formation in vivo (Zhou et al., 2000). However, one gene 
(EphA2), which interestingly is directly regulated by HOXA1, has also been reported to 
transform MCF-10A cells with consequent in vivo tumor formation (Zelinski et al., 2001). 
In the present study, we utilized the HOX binding region of the EphA2 promoter (EphA2-
r42B) to measure HOXA1 transactivation, and therefore, EphA2 may also constitute a 
pivotal component of the oncogenic program of HOXA1. The aberrant expression of 
homeobox-containing genes has been reported in a variety of neoplasias (see review by 
Abate-Shen, 2002), including those of the mammary gland (Care et al., 1998; Raman et 
al., 2000). In addition, Hoxa1 has been detected in carcinoma of the mammary gland in 
the mouse but not in normal mammary tissue (Friedmann et al., 1994), and HOXA1 
expression has also been detected in neoplastic lesions of the human mammary gland 
(Chariot and Castronovo, 1996). However, it is debated whether homeobox-containing 
genes should be classified as oncogene/tumor suppressor genes per se or only as "tumor 
modulators" that tip the balance of tumor progression (Abate-Shen, 2002; Celetti et al., 
1993). In the present work, the results therefore provide the first direct and novel 
evidence that a homeobox-containing gene is a bona fide mammary gland oncogene, the 
enhanced expression of which is sufficient for tumorigenesis of human mammary 
epithelial cells.               
 
 
3.         HOXA1 is upregulated by E-cadherin-activated signaling in human mammary 




and pattern formation during development (McGinnis and Krumlauf, 1992). Although the 
coordinated spatial and temporal expression of HOX genes is critical to their regulatory 
function, the vast majority of HOX genes upstream regulators have yet to be elucidated. 
It has been reported that in the mouse mammary gland, Hoxc6, Msx1, and Msx2 
expression are regulated by mammogenic hormones (Friedmann et al., 1994, 1996). 
Hoxa1 and Hoxb7 were showed to be regulated by extracellular matrix-dependent signals 
in mammary epithelial cells (Srebrow et al., 1998). In this present study, we found that 
HOXA1 expression is increased in human mammary carcinoma cells MCF-7 at full 
confluence. The increment of HOXA1 expression at full confluence in MCF-7 cells is 
directed by E-cadherin signaling through Rac1. Thus, E-cadherin, as well as Rac1, is the 
novel upstream regulators of HOXA1. To the best of our knowledge, E-cadheirn has not 
been shown to regulate HOX genes. Herein, the present study provides the first evidence 
that E-cadherin is a regulator of one of the HOX genes, HOXA1. The study is thus the 
first to demonstrate the cross link between E-cadherin and HOX signaling pathways.  It is 
likely that E-cadherin also regulates other homeobox genes and future study is needed to 
address this point.  
 
4.        Increased HOXA1 expression by E-cadherin-activated signaling offers protection 
from apoptosis in human mammary carcinoma cells. The E-cadherin-activated signals 
have been shown to mediate adhesive stabilization and determine cellular recognition 
(Kovacs et al., 2002; Yap and Kovacs, 2003). But the other functions of E-cadherin-
activated signals are largely remained unknown. In the present studies, our data identify 




cells MCF-7 from apoptotic cell death. 1) MCF-7 cells at full confluence had reduced 
apoptosis compared with cells at subconfluence. Transient transfection of the HOXA1 
inhibitor, HOXA1 RNAi, completely prevented the reduced apoptosis at full confluence, 
indicating that increased HOXA1 at full confluence is responsible for this anti-apoptotic 
effect. 2) MCF-7 cells at subconfluence and full confluence had the same apoptotic level 
in the presence of E-cadherin function-blocking antibody, DECMA-1.  3) Transfection of 
HOXA1 expression plasmid ( a gift from Di Rocco et al., 1997) completely rescued the 
anti-apoptosis prevention offered by DECMA-1. Taken together, the above results 
demonstrated that increased HOXA1 expression by E-cadherin-activated signaling had 
increased anti-apoptotic effect in human mammary carcinoma cells. 
 
5.6 Future work  
 
1.        In this project, we demonstrated that HOXA1 is a gene which is regulated by 
autocrine hGH by use of this in vitro cell model. But the downstream genes of autocrine 
hGH are far from identified. Recently, it was demonstrated that autocrine production of 
hGH in immortalized human mammary epithelial cells enhances proliferation, offers 
protection from apoptosis, and results in oncogenic transformation and tumor formation 
in vivo (Zhu et al., manuscript submitted). Therefore, systematic analysis of the 
downstream genes of autocrine hGH and the relevant mechanistic features by which it 
exerts its cellular effects is required. It is likely that autocrine production of hGH also 
transcriptionally regulates other homeodomain-containing proteins. To identify them, 





In deed, another homeobox family member, EMX1, was also identified to be an autocrine 
hGH-regulated gene by microarray analysis in the laboratory of my supervisors. Emx1 
gene is expressed in discrete, overlapping regions of the developing forebrain and 
midbrain in mice. Null mutant mice with this gene inactivation showed that it plays an 
important role in the patterning of the forebrain and midbrain (Acampora et al., 1995; 
Ang et al., 1996; Pellegrini et al., 1996). The regulation and the role of EMX1 in 
mammary carcinoma cells may therefore be a useful direction for further studies. 
 
2.          In the present study, it was shown that HOXA1 increased the protein level of 
Bcl-2, an important molecule involved in cell apoptosis. The mechanism of upregulation 
of Bcl-2 by HOXA1 may be at the transcriptional or the translational level or both. As 
long as HOXA1 is a transcriptional factor, we are more interested in the transcriptional 
regulation. Indeed, we demonstrate that HOXA1 increases Bcl-2 gene transcription. 
Interestingly, another homeobox gene, HOXA5, has been shown recently to regulate p53 
transcription in human breast cancer cells through direct binding at the HOX-core 
binding sequences (ATTA) in the promoter of p53, another important molecule involved 
in cell apoptosis (Raman et al., 2000).  
 
This raises the question that whether HOXA1 can direct bind at the Bcl-2 promoter to 
regulate its transcription. Interestingly, there are also several ATTA sequences in the 
promoter of Bcl-2. To examine the direct binding of HOXA1 to the ATTA-containing 




may need to be performed. Therefore, whether HOXA1 direct binds Bcl-2 promoter can 
be examined by EMSA and supershift assay using HOXA1 protein, HOXA1 antibody, 
and the DNA fragment which contains the ATTA sequence in Bcl-2 promoter.  
 
3.     Chemotherapy is an important option in the treatment of breast cancer. Signal 
transduction pathways that regulate mammary epithelial cell proliferation, differentiation, 
apoptosis, and transformation have been delineated and utilized as therapeutic targets for 
the treatment of mammary gland neoplasia (Pavelic and Gall-Troselj, 2001; Hanahan and 
Weinberg, 2000). Examples of such include selective estrogen modulators (Osborne et 
al., 2000) and herceptin (Pegram and Slamon, 2000) targeting estrogen receptor and 
HER-2 pathways, respectively. However, a significant proportion of carcinomas of the 
mammary gland neither express the estrogen receptor (Osborne, 1998) nor overexpress 
HER-2 (Slamon et al., 1987) and are, therefore, not responsive to these specific 
therapeutic strategies. Clinical data for the treatment of cancer has clearly demonstrated 
the superiority of combinatorial therapy over a single-agent approach (Frei and Antman, 
2000). Delineation, characterization, and development of therapeutic regimes targeting 
novel signaling pathways involved in oncogenic transformation of mammary epithelial 
cells are therefore required.   
 
In this project, we identified a novel pathway which may be used for development of the 
chemotherapy program. Resistance to chemotherapy in many cancers, including 
mammary carcinoma, has been associated with increased expression of Bcl-2 (Bonetti et 




MCF7-HOXA1 cells, resulted in resistance to doxorubicin-induced cell death. Therefore, 
inhibition of HOXA1 transactivation may be a novel therapeutic target to overcome the 
development of resistance to chemotherapeutic drugs. 
 
Both in vitro and in vivo models can be used for testing therapeutic approaches. Usually 
in vivo models are better than in vitro models. Results from in vitro assays have to be 
interpreted cautiously when attempting to predict an in vivo response, since many factors 
may not be directly transferable. Immunodeficient mice have become a very important 
model for the development of new therapeutic approaches (Povlsen and Jacobson, 1975; 
Braakhuis et al., 1984). The main condition for an in vivo chemosensitivity test is the 
possibility of transplanting human tumors into animals. In the present study, we 
successfully transplanted human mammary carcinoma cells, MCF-7, and MCF10A-
HOXA1 cells into an in vivo model (SCID mice), resulting in tumor formation. In further 
studies, this same in vivo model can be used to test the effects of  chemotherapeutic 
agents for breast cancer in the presence of HOXA1 inhibitor such as the antisense to 
HOXA1, checking whether the signaling pathways involved in HOXA1 oncogenic 
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